A study of cellular calcium dynamics in culture using fluorescence microscopy – A statistical and mathematical approach by Idowu, Richard Adekola
Louisiana Tech University
Louisiana Tech Digital Commons
Doctoral Dissertations Graduate School
Fall 2012
A study of cellular calcium dynamics in culture
using fluorescence microscopy – A statistical and
mathematical approach
Richard Adekola Idowu
Follow this and additional works at: https://digitalcommons.latech.edu/dissertations
Part of the Bioinformatics Commons, and the Biostatistics Commons
A STUDY OF CELLULAR CALCIUM DYNAMICS 
IN CULTURE USING FLUORESCENCE 
MICROSCOPY -  A STATISTICAL 
AND MATHEMATICAL 
APPROACH 
by
Richard Adekola Idowu, B.Sc., M.Sc.
A Dissertation Presented in Partial Fulfillment 
Of the Requirements for the Degree 
Doctor of Philosophy
COLLEGE OF ENGINEERING AND SCIENCE 
LOUISIANA TECH UNIVERSITY
November 2012
UMI Number: 3536677
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
UMI 3536677
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
LOUISIANA TECH UNIVERSITY
THE GRADUATE SCHOOL
10/02/2012
Date
We hereby recommend that the dissertation prepared under our supervision
Richard Adekola Idowu
by__________________________________________ :_________________ :_____________ :________________
entitled_________________________________________:______________ _^_____________________________
A Study of Cellular Calcium Dynamics in Culture Using Fluorescence
Microscopy - A Statistical and Mathematical Approach
be accepted in partial fulfillment o f  the requirements for the Degree o f
Doctor of Philosophy
isor o f Dissertation Research
Head o f Department
C o M p u T A ? l 0 f t ) / k t -  A / j M - j S t i  A * ) b
Department
Recommendation concurred in:
Approved:
Director o f Graduate Studies
Dean o f the College
A
Advisory Committee
Approved:
Dean o f the Graduate School
GS Form 13a 
(6/07)
ABSTRACT
Calcium in its ionic form is very dynamic, especially in excitable cells such as 
muscle and brain cells, moving from the high concentration exterior of the cell to much 
lower concentrations inside the cell, where calcium is used as a second messenger. In 
brain cells, and neurons especially, calcium is a key signaling ion involved in memory 
and learning with excitatory neurotransmitters such as glutamate turning neurons “on.” 
Glutamate excites the neurons in part by causing large and dynamic changes in the 
intracellular calcium concentration. While these dynamics are essential for normal 
signaling in the brain, excessive and sustained elevations in neuronal intracellular 
calcium are related to neuronal injury including long- term neurodegenerative processes. 
Helping to regulate these dynamics in the brain are the glial cells known as astrocytes. 
Astrocytes aids glutamate transporters, and in this way, diminish the time that neurons 
are exposed to glutamate, thus also shaping the calcium dynamics in neurons.
Here we describe an in vitro cell culture system composed of rat brain cortical 
neurons with different densities of astrocytes which we have used to statistically and 
mathematically analyze the intracellular calcium dynamics in individual neurons. With 
the proposed applied statistical and mathematical tools we now provide a system for 
predicting: 1) whether the order of repeated glutamate stimulation alters neuronal 
intracellular calcium dynamics and 2) how the presence of different densities of 
astrocyte modulates neuronal brain dynamics. We anticipate that this combined
iv
experimental/analytical approach will also have utility in understanding various brain 
diseases such as brain tumors.
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CHAPTER 1
INTRODUCTION
Calcium is a chemical element that is characterized as a soft gray alkaline earth 
metal. Calcium is essential in cell physiology. When this element is in its ionic state, it 
is very active in excitable cells such as the brain and muscle cells. Calcium is one of 
the most important secondary messengers in the body moving from outside the cells at 
a very high concentration to inside the cells at a much lower concentration. Calcium 
ions are responsible for signal transduction inside living cells and take part in 
intracellular coordination. Berridge, Bootman and Lipp open their review in Nature 
[3] with “Almost everything we do is controlled by calcium ions -  how we move, how 
our heart beats, and how our brain processes information and stores memories [sic].” 
They refer to calcium as a life and death signal because the death of cell in apoptosis is 
also regulated by calcium. Calcium ions have the potential to contribute to a variety of 
pathological and psychological functions, not limited to learning and memory.
2_j_
Intracellular calcium ([Ca ]j) possess a very complex nature. When cytoplasmic 
[Ca2+]j is elevated, many cellular responses occur. The responses range from muscle 
contraction to cellular division. Calcium signaling results from a multifaceted 
relationship between intracellular and extracellular calcium penetrable passages. 
More specifically, when the cytoplasm is stimulated by from the exterior, calcium 
oscillations result [6]. Calcium oscillations are frequency encoded signals that allow
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a cell to use [Ca ]j as a second messenger while avoiding the toxic effects of 
prolonged high calcium concentration [13].
In brain cells, and neurons especially, calcium plays the role of a signaling ion 
concerned with learning and memory by way of excitatory neurotransmitters such as 
glutamate. Glutamate excites, or turns neurons “on,” by causing great and dynamic 
changes as there is an increase in intracellular calcium concentrations ([C a 2+]j). 
Although these [C a2+]j dynamics are vital for normal signaling in the brain, extreme and 
constant elevations in neuronal [C a24], are related to neuronal damage [14], including 
long- standing neurodegenerative processes [5]. Astrocytes, a type of glia cell, help 
regulate these dynamics in the brain. Astrocytes aid glutamate transporters [1], and in 
this approach, reduce the time that neurons are exposed to glutamate, thus also shaping 
the [C a24], dynamics in neurons.
1.1 Brain cells
Two types of brain cells are defined in this work namely: neurons and astrocytes.
1.2 Neuronal structure and function
Figure 1.1 shows a depiction of a neuron, which is one of the most significant 
cell types in the human body. They are characterized as nerve cells that are the basic 
building blocks of the nervous system. Similar to other cells in the body, neurons consist 
of a nucleus that contains its genetic information, a membrane that shields the cell, and 
organelles that help in supporting the life of the cell. Neurons differ from other cells in 
the body in that they are responsible for receiving and transmitting information 
throughout the body. These nerve cells communicate information in chemical and 
electrical forms. Another difference between these specialized cells and other cells in the
body is that the reproduction of neurons is terminated shortly after birth. As a result, 
some parts of the brain have more neurons at birth than later on in life. Although neurons 
do not reproduce, they reconnect throughout our life span [5].
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Figure 1.1: Image of a Neuron [8]
The structure of a neuron contains dendrites, the cell body and the axon. The 
size, shape and characteristic of a neuron vary in the sense that it depends on the 
function of the neurons. Some dendrites have few branches, while others are 
increasingly branched, allowing them to receive an enormous amount of information. 
Neurons transmit information from within the neuron and to one another. The 
dendrites of neurons receive information from sensory receptors or other neurons, and 
the information is then passed to the cell body and onto the axon. After the axon 
obtains the information, it is transcribed into an electrical signal known as an action 
potential, which travels down the axon. After the electrical signal reaches the end of
the axon, the information is transmitted across the synaptic gap to the dendrites of the 
neighboring neuron [5].
In some instances, the electrical signal by itself can bridge the gap between 
the neurons, but other instances require neurotransmitters to send information from 
one neuron to the other. A neurotransmitter is a chemical messenger that is released 
from the axon terminal to cross the synaptic gap in order to reach receptor sites of 
other neurons. Then, through the process of re-uptake, the neurotransmitter attaches 
to the receptor site, and the neurotransmitter is then reabsorbed by the neuron [5].
Figure 1.2 shows an image of a neurotransmitter, a chemical which plays a 
vital role in the everyday human function. They aid in the transport of signals from 
the neurons to target cells across a synapse [26]. Although scientists estimate that 
over a hundred of these chemical messengers, which exist in the body, have been 
identified, they do not know exactly how many more exist. When disease or drugs 
affect neurotransmitters, severe problems arise in the body like Alzheimer’s and 
Parkinson’s disease.
Figure 1.2: Diagram depicting cells involved in Neuronal Transmission [27]
1.3 Glia Cell
The central nervous system consists of two major types of cells namely: nerve 
cells (neurons) and glial cells (glia). Although there are many more glial cells in the 
brain when compared to the number of neurons, at a ratio 50:1, glial cells in the past did 
not get as much attention as the neurons. Researchers were of the opinion that glia only 
supported the activities of neurons, but recent research has shown that astrocytes (type of 
glial cells named for the star- like appearance, see Figure 1.3) support the formation of 
networks on which neurons grow and they occupy the space between neurons [21], Glia 
take part in the uptake of neurotransmitters released by neurons and assist in maintaining 
balance in chemical concentrations around neurons.
6Figure 1.3: Astrocytes Image [28]
1.4 Glutamate
Glutamate is a profuse neurotransmitter in the brain. It attaches to NMD A 
receptors on glia and neuron membranes, thus aiding its rapid removal from the 
extracellular space. Glutamate also brings about the influx of calcium ions into the cell 
via the NMD A receptor channel.
Figure 1.4 is a representation of an NMDA receptor displaying glutamate 
attachment and calcium influx into the cell. The calcium influx into the cell is 
represented by increased fluorescence intensity, which is the basis of the data obtained 
through experiments for this research [18], Excess calcium entry into the cell and 
prolonged elevation can lead to excitotoxicity [17], causing mitochondrial damage and 
in the long run leading to cell .death. Cell death by excitotoxicity is a viscous cycle that 
releases more glutamate into the extracellular fluid and also impacts surrounding cells to 
undergo excitotoxicity. Excitotoxicity in cells can be visually identified using
fluorescence microscopy. In such case the fluorescence intensity representing the 
cellular calcium level would not return to baseline. Sub- threshold exogenous glutamate 
will compel neurons and glia to respond with calcium transient responses or oscillations 
and can be interpreted in the data by the fluorescence intensity returning to baseline.
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Figure 1.4: NMD A receptor displaying glutamate attachment and calcium influx into the
cell.
1.5 Calcium Imaging Technology -  Center for Biomedical Engineering and
Rehabilitation Science
Calcium data and imaging technology has improved remarkably and fluorescence 
data acquisition is now available at the Center for Biomedical Engineering and 
Rehabilitation Science (CBERS) here at Louisiana Tech University. The imaging of the 
cells are visualized by utilizing an Olympus CKX41 inverted microscope with a 488 
excitation wavelength filter over real time at a 4 s frame rate with Intracellular Imaging 
software. Intracellular Imaging software (InCytlml™, Version 5.26, Intracellular 
Imaging Inc., Cincinnati, OH) is used to generate regions of interest (ROIs) around 
every single cell in the image after the experiment. Then the ROIs are used to measure
fluorescence strength over time, and the data transcribed into Microsoft Excel is 
analyzed by taking the ROIs starting value and normalizing the value to one, which 
allows us to relate the ROIs to each other with a common starting value.
1.6 Research Goal
We seek to statistically represent the number of oscillations and the area under 
the oscillatory calcium fluorescence intensity Curve to predict cell network behavior to 
glutamate response, with the anticipation of gaining a better understanding of brain cell 
networking and communication This could lead to the establishment of "rules" by which 
healthy brain cells operate, which would, in turn, aid in the identification and 
understanding of brain cancer and neurodegenerative diseases. With this research, we 
seek to mathematically and statistically analyze experimental data involving the two 
types of brain cells described earlier namely neurons and astrocytes, to determine if 
combinations of multiple stimuli with glutamate will result in testable and predictable 
outcomes in cellular brain networks.
1.7 Outline
As observed in Figure 1.5, three sets of submaximal glutamate stimuli are 
successively added to primary rat cortical neurons as described in methods (Section 2.4). 
Once glutamate is added to the neurons, the glutamate remains in the cells, each 
stimulation is submaximal, in the sense that cells recover completely or to a large extent 
to baseline levels before the next stimulus is added.
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Figure 1.5: Successive treatment of rat brain cortical neurons with 250, 500, and 750
nM glutamate.
Gluatmate as indicated by arrows in Figure 1.5, elicits transient increases in 
[C a2+]j as visualized by increases in fluorescence intensity (Y- axis). Each tracing 
represents an individual neuron tracked over time at a frame rate of four seconds/frame 
(X- axis). Six representative neurons from over 40 cells are shown.
In Chapter 2, we describe previous calcium modeling and analysis efforts to 
provide context for this body of research. We also discuss various experimental 
arrangements used in data collection and the theories and justification for our modeling 
efforts and data analysis. In Chapter 3, we present a least square model for each 
Treatment level, to determine an algebraic model that best describe the fluctuations in 
the calcium data with equal time steps. Treatment levels represent successive or 
randomized glutamate addition to the cell culture. We advance on the idea of 
confidence plots and interval size to describe the tightest or loosest bound for each 
Treatment level. We define two variables in Chapter 4 namely, “Number of Spikes” 
and “Area under the Curve” for the data depleted of glia. Based on this information, we
apply statistical analysis approaches to study the Treatment effect on the number of 
calcium spikes. We also consider the “Area under the Curve” for each cell for each 
Treatment, representing the calcium load. Similarly, we apply statistical analysis 
methods to study the Treatment effect on the “Area under the Curve.” We apply the 
same techniques described to the data where glutamate stimuli have been administered 
over unequal time intervals in Chapter 4, and also to the data set with equal time 
intervals in Chapter 5. We analyze two data sets in Chapters 5 and 6  namely: one 
depleted of glia and another not depleted of glia, for the purpose of studying how 
different densities of astrocytes affects calcium dynamics. In Chapter 6 , we randomize 
the order of applying glutamate stimulus to the cell culture and perform the same 
analysis on the data set.
CHAPTER 2
LITERATURE REVIEW, EXPERIMENTAL 
SET UP AND DATA COLLECTION
2.1 Literature Review
An array of significant conclusions about calcium dynamics and oscillations can 
be drawn from utilizing computational models of calcium ions. These models allow us 
to theorize and apply intuitive reasoning. While many models, both deterministic and 
non-determini stic, have been developed to describe the dynamics of [C a2+]j responses in 
living cells, no one is working on statistical models to predict cellular brain networks, 
validated with fluorescence data. Fluorescence microscopy is more accurate and 
efficient than wide field microscopy when cells and nano- films are placed in same focal 
plane. More importantly, the likelihood of measuring [C a2+]i concentrations with high 
spatial and temporal resolution has contributed extensively to our understanding about 
the mechanism of cellular signaling and the very central function of calcium as the 
ubiquitous second messenger in cells.
2.2 Calcium Dynamics Models -  Literature Review
A model for voltage signaling in brain cell was developed by Hodgkin and 
Huxley in 1952 via a resistor capacitor circuit model for the neuron [9], Gating 
variables were used to model the various channel states. It was assumed that the
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concentration of ions inside remained constant and diffusion of ions longitudinally 
within the neuron also remained constant. Following this period, many models have 
been developed to describe the dynamic activities of calcium.
2.2.1 Reaction Diffusion Model
Guisoni and De Oliveira used a stochastic reaction- diffusion lattice model to 
study the dynamics of calcium in the cell, specifically in the endoplasmic reticulum 
(ER) membrane [7]. They placed calcium channels and calcium ions in two 
interpenetrating sub lattices connected by calcium release and diffusion. Calcium ion 
release occurs from the endoplasmic reticulum through the channels, and both can 
remain or depart through the membrane into the cytosol spontaneously. Numerical 
simulations were used to demonstrate a phase transition from an active state to an 
absorbing state, the end result of the catalytic calcium release.
A similar study was conducted by Holcman and Schuss when they proposed a 
reaction diffusion model of calcium dynamics in dendritic spines [10]. Dendritic 
spines are neuronal extensions that receive signals, normally from a single excitatory 
synapse. Within this model, they linked the biochemical changes made by calcium to 
structural changes which occurred at the level of the spine. The contraction of 
proteins as chemical actions was modeled by the reaction diffusion equations in an 
effort to show how calcium signaling is affected by changes in spine structure. 
Calcium ions bring about contraction of actin- myosin- type proteins. By doing so, a 
flow of cytoplasmic fluid is produced towards the dendrite shaft. Hence, the time of 
calcium dynamics in the spine is increased, which is virtually pure diffusion. The 
results from experiment and stimulation exposed dualistic time, i.e. two likely periods
of calcium dynamics in the spine. Stimulations indicate that calcium motion is driven 
by hydrodynamics and diffusion in the first and second period, respectfully. The 
model also showed how the dualistic time constants rely on spine geometry. The 
model projected that there were no dualistic time periods in the dispersion of the non­
reactive molecules in the spine. Through the experiment, the model’s prediction was 
confirmed.
The diffusion model was advanced by Patterson, Sneyd and Friel who used it to 
develop stimulus- evoked [C a2+]j responses by concentrating on how responses
elicited in specific cell types are defined by the [C a2+]j transport and buffering system
2+
that operate in the same cells [19]. Depolarization- evoked [C a  ]j responses were 
studied in sympathetic neurons under clamped voltage. They analyzed five cases of 
increasing complexity, comparing observed and calculated responses deduced from 
measured [C a2+]j handling properties. They established that [C a2+]j responses elicited 
by weak stimuli can be quantitatively reconstructed by a spatially uniform model 
incorporating the measured properties of [C a2+]j entry, buffering and removal. The 
model could not describe responses to strong depolarization but were steady with a 
diffusion model that incorporates the same [C a2+]j transportation and buffering given 
that endogenous buffers have low mobility.
While these models require modeling down to the substructures of the cells, for 
example, the cytoplasm, endoplasmic reticulum and mitochondria, our work seeks to use 
actual fluorescence data, which is taken over the entire cell to determine realistic models 
and parameters for predicting the dynamics of intracellular calcium.
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2.2.2 Data Driven Model
In another study of calcium dynamics, a simple model was used to describe 
how the dynamics of intracellular calcium can be inferred directly from experimental 
data without prior information of unknown parameters [22]. A possible approach to 
the case of intracellular calcium signals was studied. The paper advanced on the idea 
of a data driven model, a model that relies heavily on large data sets to analyze and 
simplify the measurements. The model may have predictive power and the ability to 
provide quantitative information in the case of [C a2+]j signals. We did not advance 
with this model, because the authors’ approach involve approximation of the [C a2+]j 
source in space and time.
In a separate paper, the same authors developed a unique method to determine 
the calcium release fluxes that lie beneath a fluorescent image [19]. From, an 
experimental and a numerical viewpoint, their results proved to be relatively precise. 
They revealed that the time development of calcium concentration inside the cells, with 
a pump and one buffer can be defined by utilizing a single closed equation, regardless of 
the buffer’s speed. Although additional studies are required, their results showed that 
comprehensive knowledge pertaining to the cytosol is not required in order to obtain a 
trustworthy equation for the intracellular calcium concentration.
2.2.3 Calcium Oscillation Model
A calcium oscillation is usually defined as a sequence of regenerative releases 
of stored calcium. A mathematical model was introduced to examine qualitative 
properties of [C a2+]i dynamics under the control of various [C a2+]i handling systems 
whose properties are specified based on literature values from multiple cell types [13].
This model helped various researchers develop different research paths about calcium 
signal generation and clarified the condition required for generation of [C a2+]j 
oscillation and waves [13].
Higgins, Cannell, and Sneyd developed a model of a buffering Sarcoplasmic/ 
Endoplasmic Reticulum Calcium Atpase (SERCA) pump and studied to ascertain if its 
inclusion in the calcium oscillation model had significant effects [8 ]. They established 
that the oscillations produced when the SERCA pump was in use, and did not buffer 
calcium, have larger amplitude and a slightly smaller period than when using the 
SERCA pump that buffers calcium. Also by using a bidirectional SERCA pump, 
elimination of futile cycling of calcium between the cytosol and endoplasmic reticulum 
was achieved when the cell was at rest.
In another work, it was demonstrated that [Ca2+]j oscillations do not occur by 
simple synchronization [20]. Channel clusters open and close in oscillatory fashion, 
but calcium oscillation originates from microscopic variation caused by stochastic 
binding of the ligands [Ca2+]j and IP3 to the receptor’s binding sites. The authors 
analyzed the stochastic data and show that internal properties can be inferred from 
global observations. Further analysis was done on information content of spontaneous 
and stimulated oscillations.
Atri et al, developed a cytosolic free [Ca2+]j oscillations model based on [Ca2+]j 
release through the inositol 1,4,5- trisphosphate (IP3 ) receptor/ [Ca2+]j channel (IP3 R) of 
a single intracellular [Ca2+]j pool [2]. The model serves to capture the vital microscopic 
mechanisms necessary in the production of intracellular [Ca2+]j and travelling waves in 
the Xenopus laevis oocyte. Cytosolic free calcium concentration transforms the IP3 R in a
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two phase manner, with Ca2+ release subdued by low and high cytosolic free calcium as 
evidenced by experimental results. The model studied that channel inactivation occurs at 
a slower time scale when compared to channel activation and produces cytosolic free 
calcium oscillations at constant IP3 Also, for calcium waves to propagate, channel 
inactivation must occur on a slower time scale. This modeling approach is not relevant to 
this work because the models are based on cellular substructure level.
2.2.4 Calcium Wave Model
Calcium oscillations vary over time and are known to control a huge array of 
cellular processes while intercellular or intracellular calcium waves vary over time and 
space. A calcium wave is a chain reaction of [C a2+]j discharge and uptake as a result of 
cortical reaction. A two-dimensional stochastic model of [Ca2+]j wave (ICW) spread in 
glia cells was developed by Lacobas et al, [12]. The model includes the contribution of 
external stimuli, ionotropic and metabotropic P2 receptors, exo-and ecto- nucleotidases, 
second messengers and gap junctions. An initial stimulus evokes ATP and UTP release 
from a single cell. Glia cells can respond to a variety of neurotransmitters with increase 
in intracellular [Ca2+]i levels that can be transmitted to nearby cells as intercellular 
[Ca2+]j waves, thereby providing long range glia [Ca2+]j signaling. While many calcium 
wave models were developed in [4], [11], [15], [24], none of this work models the whole 
cell employing fluorescence data.
2.3 Calcium Imaging Experiments -  Overview
For the experiments considered in this work, brain cells in culture are grown for 
eight to nine days in vitro (DIV). Some of these cultures are treated with Cytosine 
Arabinoside (Ara-C). Ara-C controls the amount of glial cells in the culture. Ara-C
(+Ara-C) treated cultures have fewer glia and more neurons. If the culture does not have 
Ara-C (-Ara-C), it will have more glia, but still have neurons that respond to stimulus 
(glutamate). As described in Chapter 1, glutamate is an excitatory neurotransmitter. 
Neurons respond to glutamate stimulus because when glutamate is added to the culture, 
it is expected that calcium enters the neurons. Calcium influx into the cell is represented 
by an increase in fluorescence because of the florescent probe for calcium being used 
(fluo- 3) in the experiments. Thus, glutamate stimulus results in an increased 
fluorescence intensity, which leads to an increase in calcium in the cells (usually the 
neuron). Because binding to the fluorescent probe by calcium is not covalent, i.e. it can 
come off and on, we are able to see the dynamics of calcium changes in the neurons. 
Therefore, we see peaks, oscillations, and multiple responses to multiple stimuli. 
Glutamate is added to the brain cells in three orderly, successive stages. First, before any 
addition, we record a short period of baseline (spontaneous) activity. In this period, 
neurons may spike indicating they are active. We hypothesize that spontaneously 
spiking neurons will be more responsive to subsequent glutamate stimuli. For example, 
stimuli (1- 3) are defined as: 250- 500- 750nM with respect to the order of application 
to the brain cell, where the values represent glutamate concentration at 250, 500, and 750 
nM, respectively. However, the order of applying the Treatments can be randomized for 
example, 750- 250- 500 nM. In the recording period, every four seconds images are 
repeatedly gathered. When the recording is done the polygons of regions of interest are 
identified as (ROIs). The ROIs separate one cell body where the motions of calcium 
changes while being measured.
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2.3.1 Primary Cortical Culture Preparation
By executing cervical disarticulation of Outbred Sprague-Dawley neonatal rats 
(age < 48 hrs) utilizing methods described in Section 2.3, cortical cells were obtained 
[16]. Following three days in vitro, the cell culture plates were divided in half; one 
portion of the culture was treated with a lOOx dilution of Cytosine Arabinoside ([Ara-C] 
ImM, Sigma- Aldrich) to exhaust glial cells from cultures. There were a total of three 
culture sets produced (n=21 rats and approximately 48 wells per culture type, co— culture 
and neurons.)
2.3.2 Calcium Fluorescence Imaging
Eight to nine days in vitro, cortical cultures were imaged by incubating cells 
in a loading solution, Pluronic acid (20% wt in Dimethylsiloxane, Sigma- Aldrich) at 
a lOOOx dilution and Fluo 3/Am (Invitrogen) at 500x dilution in Locke’s solution 
[17], for 45 minutes. Following, the cells were washed and recuperated in Locke’s 
solution and re-incubated for 30 minutes. While the cells were recuperating, fresh 
Glutamic acid ((GLU) 250, 500, and 750nM, Sigma Aldrich) concentrations were 
prepared in Locke’s solution. A recording of cells lacking treatment (baseline) was 
obtained over a defined time and GLU concentrations were added to the experiment 
at predetermined intervals without washing out the media between additions.
2.4 Mathematical/Statistical Modeling (Algebraic (Polynomial) Model)
In this work, we seek to perform a polynomial fit to the fluorescent data. Given 
an nth degree polynomial of the form,
y  = anTn + an~1Tn_1 + ......+ a 0  (2.1)
to derive an approximation to a given set of data,
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(Ti, y i), (.T2,y 2) , ..........., ( rmym), where m  >  n  + 1,
f (T )  is the best fitting Curve with least square error given by
<p =  T ! L i \ y i - f i  m 2 =
£™i[yi “  & rJ ?  +  a n -iT l1 1 + an_2T{1 2 +  .... +a0)]2(2.2)
where (Ti,y{) are given and an, an_1; an_2, ......,a 0  are unknown coefficients. To
determine the least square error, we take the first derivative of equation (2 .2 ) with 
respect to the unknown coefficients an and set the corresponding equations equal to zero 
to obtain
= 2 ^ ^  -  (anTn +  a ^ T ? - 1 +  an- 2T?~2 + ....+<■„)] = 0,
5^  = 21™, 77''’[y, -  (a„Tn +  an^ J ^ '  + a „ .2TI'~2 +  .... +a0)] = 0, 
~  = 2 £ S 1r r 2[y, -  (a„r" + a ^ j r 1 + a„-27T 2 +  ...+a„)] = 0,oa n —2
^ = 2 Z S » b i -  (a,r> + + an- 2TP~2 + .... +a0)] = 0.
Expanding the above equations, we obtain
J Z i  T?yt -  JZLi T?anTn -  Z™, T{lan- 1Tn'~1 -  T?an_2T* ~ 2  -
- - ^ 1 T > o  = 0 ,
e m "-1*  - i Z i T r - ' a n T *  - m i T r ^ n - i T 11- 1 -
 ZI^i7)n_1 a 0  = 0 ,
zzu 7T 2*  - e m ""2^ " - z ^ r V i r * - 1 - T i L xT r 2an- 2Tn- 2 -  
• • • - E r = i r 2 « 0  = o,
Z ”  1  Ti -  lEU  OnTf -  Z S i an-i7 ’/ l _ 1  -  Z S i  an-zT / 1 - 2  a 0  = o, 
and
v™ ^ Vm T2n n v m rr2n—l n v m rp2n—2 „ v™ thZ.i-11 i yi ~ anZui=i1 i an - lL i= \l i an-2 Zii=i 1 i ~  a 0  Zij=i1 i >
rra  7 ’TZ-l,, _  v m T 2 n _ 1  _  n v m T 2 n ~ 2  Vm T2 n _ 3Zii=i1 i y i  — u n Z i i = i  1 i a n - l  Z.i=i 1 i u n - 2  Z , i = i 1 i ~
o o Z ^ r r 1.
2 0
E m  f t i - 2 . ,  _  _ v m rp 2 n —2 _ v m T,2n—3 _ T '2 n -4i=l'i  y i — a n L i = i l i ~  a n - l  L i = x  1 i ~  a n - 2  2u i= i  1 i ~
o o Z S i r r 2,
Z E i *  =  a n Z £ i  7? -  a n_x J Z i  T r 1 -  a n - 2  J Z i T r 2 --------- a o ZEx 1.
The unknown coefficients an, an_x, an_2, ......., anda0 can be derived by solving the
above system of linear equations, which is precisely a least squares fit.
2.5 Statistical Variables 
2.5.1 “Number of Spikes”
We define a spike of calcium represented by fluorescence intensity xM as
xi < xM > xi+2 where i = 1, ,n  and n is the dimension of the data. If this inequality
is satisfied we check that x,+I> 1 .2 , i.e. 2 0  % above the baseline (where baseline = 1 ). 
We repeat the same routine for all fluorescence intensities in each neuron at each time 
stept, = 4 sec. Subsequently, we create a continuous dependent variable “Number of
Spikes” by counting all the spikes, jc;+1 , in each neuron by Treatment groups.
2.5.2 “Area under the Curve”
We define also a second variable: “Area under the Curve” by directly applying 
the trapezoidal rule, to determine the area under the oscillatory calcium fluorescence 
intensity Curve, f,
J* f { x ) d x  ~ ( b - a )  - - - - - -  , (2.3)
where a and b are time (seconds), f(a) and f(b) are the corresponding fluorescence 
intensities at the endpoints of the time interval. We sum all the evaluated area together 
to determine the “Area under the Curve” for each region of interest (cells).
2.6 Statistical Test/Analysis
2.6.1 Analysis Of Variance
Since our experiment involves application of glutamate (Treatment) stimulus to 
the brain cell, we seek to establish if different “Treatments” yield outcomes in our 
experiment involving k treatments, where k= 0, 1, 2, 3, corresponds to Pre-Treatment, 
Treatment 1, Treatment 2 and Treatment 3, respectively. We employ the statistic that 
evaluates the within and between group variations in one way analysis of variance often 
referred to as the sum of squares. Thus, to test whether or not the Treatments differ in the 
effects on the response variable (Neurons), we may test the null hypothesis 
= H2  = ••• = Pfc}
that all the treatments are equal in their effect against the alternative hypothesis 
Ha\ {at least two o f  the p^s d iffe rs} .
The fundamental design that unravels the analysis of variance test is the measure 
for the sum of square error that shows how well the model fits the data.
The ANOVA theory is based on the following model
Yij = ft; + e y , (2.3)
where ft; is the mean effect of treatment j and Gy are independent normal variables
e u~ n  (o, of~)
or
Yij~N(ft;, of  ) with variance o f .
The model does not take into account the possibility of different Oj.  In practice, 
when the mean and variance are different, the mean and variance are described by
2.6.2 Repeated ANOVA
To improve model coefficients, most importantly the sum of square error for 
Treatment for the one way ANOVA, repeated measures ANOVA is explored. A 
repeated measure is also referred to as within- subjects ANOVA, which is an extension 
of Paired T-Tests. Like T-Tests, a repeated measure ANOVA offers us the statistical 
tools to decide if changes have occurred over time. T-Tests compare mean scores at two 
different time periods for a single group of subjects. Repeated measures ANOVA 
compare the mean score at multiple time periods for a single group of subjects.
2.6.3 Tukey HSD Test
After performing the one way ANOVA, if the test leads to rejecting the null 
hypothesis (i.e. Treatment is different), it is imperative to determine which pairs of 
Treatment levels actually differ from the others. Best for all Pair-wise comparisons, the 
Tukey Honestly Significant Difference Test examines the difference between each pair 
of Treatment means.
2.6.4 Pair-wise T-Test
The Tukey HSD Test will not run on the repeated measure object, so we propose 
a Pair-wise T-Test with adjusted p-values to see which glutamate concentrations are 
significantly different. We adjust the p-values for: None, Holm, and Bonferroni to be 
certain if similarities occur.
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2.6.5 Friedman Rank Sum Test
To assess the similarities for the parametric tests described earlier, we consider 
also the non-parametric versions of these statistics tests. The Friedman test is analogous 
to the parametric repeated measure ANOVA. It is an extension of the sign test when we 
have two or more Treatments, and it is used to identify differences in Treatments across 
multiple tests.
2.6.6 Kruskall-Wallis Test
The Kruskall-Wallis Test is the non-parametric version for one way ANOVA for 
testing whether samples originate from the same distribution. The null hypothesis is that 
the population from which the samples originate have equal medians against the 
alternative that at least one of them is different. When we have a significant treatment 
effect, the Mann-Whitney U-Test will identify where the differences occur.
CHAPTER 3
MATHEMATICAL MODEL FOR 
CULTURE DEPLETED 
OF GLIA
3.1 Methodology
In this chapter, we present our modeling efforts for the one compartment 
modeling of the calcium data depleted of glia, and glutamate administered over equal 
time steps. Prior to fitting a function to model the relationship between two measured 
quantities, it is important to determine if a relationship exists between these quantities. In 
this work, the measurement of time against fluorescence intensity in each region of 
interest is observed. First, we categorize the data into four parts, namely Pre-Treatment, 
Treatments 1, 2 and 3, where Pre-Treatment is the period before the first 250nM 
glutamate addition to the neurons, and Treatments 1, 2, and 3 denote glutamate addition 
to the cell at 250nM, 500nM and 750nM concentrations, respectively.
Correlation measure is explored to measure the relationship between the two 
variables (“time” and “fluorescence intensity”). Correlation coefficients are the main 
result of correlation analysis, and the most common correlation coefficient is Pearson’s r 
[29]. It ranges from -  1.00 to +1.00. A correlation coefficient of -  1.00 represents a 
perfect negative correlation while + 1 . 0 0  represents a perfect positive correlation, and the
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close r is to one, the more closely the two variables are related. There is no correlation 
for a correlation coefficient of 0.00. We develop an algebraic (polynomial regression) 
model that describes the various activities of the intra- cellular calcium dynamics 
directly from fluorescence data. We plot the residuals of the fit and compute the model 
coefficients and also the norm of the residual as a measure of the goodness of fit. Also, 
we advance on the idea of plots and confidence bounds to unravel the uncertainty arising 
from the mean and standard deviation as an estimate of population parameters. The 
confidence bounds present a lower limit and upper limit that represent a range of values 
that will represent the true population parameter with a precise level of confidence, i.e. 
precision of estimation. Lastly, to determine how each Treatment group is tightly or 
loosely bounded when compared to the other Treatment groups, for individual 
Treatment, at each time step, we compute the difference between the upper bound and 
the lower bound and then compute the Euclidean norm of the vector for each of the four 
Treatment groups.
3.2 Algebraic Polynomial Model
To determine if a relationship exists between time and fluorescence intensity, a 
scatter plot is explored. The plot in Figure 3.1 is a scatter plot of averaged fluorescence 
intensity versus time (seconds) for Treatment 3, for example, used to analyze the 
relationship between the two variables “Fluorescence Intensity” and “Time.” The scatter 
plot shows a strong non-linear (Curve) relationship, which indicates a high correlation 
between the variables. There is a possibility that the time at which the intensity is 
measured is directly related to the fluorescence intensity; hence any change in the time 
variable will result in a reasonable predictable change in fluorescence intensity.
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Figure 3.1: Scatter plot for Treatment 3
Next, we try modeling the calcium data using various degree polynomial 
functions of the form
y  = anTn + a n~1Tn_1 + .....+ a0. (3.1)
MATLAB uses the prompt, P = poly f  it (t, y, n) to find the polynomial 
coefficients of the polynomial functions in descending powers, where n is the degree of 
the polynomial we want to fit.
3.3 Calculating Correlation Coefficient
The MATLAB prompt R = c o rrc o e ff(x ,y ) returns a 2 x 2 matrix R of 
correlation coefficients where the elements in the diagonal correspond to the perfect 
correlation of each variable with itself and are equal to one. The off diagonal elements 
represent the correlation coefficients for the variables observed. In Table 3.1, we observe 
that the correlation coefficient increases as the order of the polynomial model increases,
and the highest correlation values were observed in the eighth degree polynomial for 
each Treatment. Because there is little difference in the correlation coefficients between 
the seventh and eighth degree polynomials, we will explore the seventh degree fit. 
Furthermore, it is common practice in numerical analysis to avoid too high of a degree 
polynomial approximations due to increased oscillations that arise with higher degree 
polynomials.
Table 3.1 -  Correlation coefficient
Degree
Polynomial
Pre-Treatment Treatment 1 Treatment 2 Treatment 3
1 0.4395 0.6342 0.2551 0.8101
2 0.4638 0.9545 0.5868 0.8241
3 0.6352 0.9545 0.8190 0.8834
4 0.7351 0.9652 0.9182 0.9669
5 0.7478 0.9707 0.9383 0.9959
6 0.7488 0.9749 0.9383 0.9990
7 0.7521 0.9774 0.9468 0.9990
8 0.7711 0.9803 0.9612 0.9990
We observe that when we try to increase the order of our polynomial model i.e. 
for n= 4, 5, 6 ... MATLAB display the following warning:
Polynomial is badly conditioned. Removing repeated data points or centering and 
scaling may improve results.
This warning shows that the computed coefficients for the model will be highly 
sensitive to random errors in the response (the measured fluorescence intensity). To 
improve the accuracy of the model, we transform the predictors (the time) by 
normalizing their center and scale. This can be shown by computing the z -  scores:
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where x  is the predictor data, p is the mean of x, and cris the standard deviation of x. This 
centers the data at 0 with a standard deviation of 1. Once the data has been centered and 
scaled, model coefficients are computed for the data as a function of Z. These 
coefficients are different and more robust than the coefficient computed for Fluorescence 
as a function of Time, i.e. before scaling. The norm of residual and the form of model 
remain unchanged after scaling.
3.4 Best Fit for the Average Data Set
3.4.1 Averaged Pre-Treatment Fluorescence Data
This portion of the result applies the polyfit and polyval MATLAB functions to 
model the data. This yields a polynomial equation:
y = —0.0347z7 -  0.013z6 + O.llz5  -  0.03z4 + 0.015z3 + 0.16z2 -  0.19z + 0.94, (3.3) 
where z is centered and scaled from (3.2) with p = 26.513 and c = 16.764. The norm of 
residuals is found to be 0.28453.
Figure 3.2 illustrates the seventh degree polynomial fit and the residual plot for 
the averaged Pre-Treatment data. We observe that the seventh- degree fit does follow 
the basic shape of the data and slightly capture the smooth Curve on which the data 
seems to lie. The plot of the residuals illustrates the differences in the values of time 
predicted by the correlation and the experimental values of time. We do not observe a 
pattern in the residual plot, which shows that a different model might not be necessary. 
Also, the norm of the residual as measure of the deviation between the correlation and 
check for goodness of fit is found to be 0.28453, which is low and suggests a good fit.
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Figure 3.2: Pre-Treatment polynomial fit
3.4.2 Averaged Treatment 1 Fluorescence Data
Applying the polyfit and polyval MATLAB functions to model the data yields a 
polynomial equation
y = 0 . 4 4 z 7 -  0 . 4 9 z 6  -  2 . 6 z 5 -I- 1 . 4 z 4  +  4 . 3 z 3 -  2 . 6 z 2 -  0 . 2 3 z  + 1 1 ,  (3.4)
where z is centered and scaled from (3.2) with p = 184.8 and a = 75.769. The norm of 
residuals is found to be 4.4879.
In Figure 3.3, we observe that the model is more consistent than the model for 
the Pre-Treatment data in following the fluctuation in the data. Also the residual plot 
shows no pattern, an indication of a good fit.
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Figure 3.3: Treatment l polynomial fit
3.4.3 Averaged Treatment 2 Fluorescence Data
To model this data, polyfit and polyval MATLAB functions yield the polynomial 
equation
y = —2.2 z 7  — 0.049z6 + 13z5 — 4.3z4  — 16z3 + 6.9z2 — 1.8z + 24, (3.5)
where z is centered and scaled from (3.2) with p = 445.28 and a = 75.769. The norm of 
residuals is found to be 18.655.
The polynomial model in Figure 3.4 follows the fluctuation in the data and the 
residual plot is randomly distributed without a pattern.
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Figure 3.4: Treatment 2 polynomial fit
3.4o4 Averaged Treatment 3 Fluorescence Data
Applying the polyfit and polyval MATLAB functions to model the data yields a 
polynomial equation
y = 1.7z 7  -  12z 6  + 23z5 + 3.5z4  -  60z3 + 78z2 -  54z + 39, (3.6)
where z is centered and scaled from (3.2) with p. = 705.74 and o = 75.765. From Figure
3.5 the norm of residuals is found to be 26.30, and the residual plot exhibits no pattern 
thus suggesting a good fit.
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Figure 3.5: Treatment 3 polynomial fit
3.5 Confidence Bound for the Averaged Fluorescence Data
Confidence bounds are confidence intervals for predicted response. The width of 
the bound indicates the degree of certainty of our fit. We apply polyfit and polyval to 
each Treatment group to produce confidence bounds for a seventh degree polynomial 
model, and we define interval ±2 standard deviation which corresponds to 95% 
confidence intervals for large observations.
From the plot in Figure 3.6, we observe a small variation in the confidence plot 
before the application of the glutamate stimulus. Application of Treatments 1, 2 and 3 
increases the variations in Figures 3.7, 3.8 and 3.9.
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Figure 3.7: Confidence plot for Treatment 1
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Figure 3.9: Confidence plot for Treatment 3
3.6 Measure for the Confidence Interval Size
We compute the difference between the upper bound and the lower bound for 
each Treatment group and evaluate the Euclidean norm of the vector for each of the four
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treatments to determine how tight or loose the confidence bounds are by treatment 
groups, and the results are shown in Table 3.2.
Table 3.2 -  Size of Confidence Bound
Confidence Bound Size
Pre-Treatment 2.1793
Treatment 1 26.5212
Treatment 2 84.4442
Treatment 3 119.0599
We observe that the confidence interval size shows an increasing trend as 
Treatments 1, 2 and 3 are applied, and we can infer from the above result that Pre- 
Treatment which corresponds to baseline activity without addition of glutamate is the 
tightest bound (2.1793) while Treatment 3 which correspond to the 750nM addition of 
glutamate to the neurons is the loosest bound (119.0599), The tightest bound means that 
the cells are less active and behaving in a similar fashion, while the loosest bound 
suggests that the cells are more active and behaving with greater variability. It is not 
surprising that the greatest level of predictability is achieved for baseline cellular 
activity, prior to any glutamate stimulation.
CHAPTER 4
STATISTICAL EVALUATION OF 
DYNAMIC BRAIN CELL 
CALCIUM ACTIVITY
4.1 Overview
We seek to establish if combinations of multiple glutamate stimuli will result in 
testable and predictable outcomes in brain cells, such as neurons. In the physical 
experiment, baseline activities of the neurons were measured and recorded as Pre- 
Treatment, and glutamate addition to the neurons was described by three categories: 
Treatments 1, 2 and 3, each representing stimulation with different concentrations of 
glutamate at 15, 60 and 125 second, respectively. After defining what is meant by a 
“calcium spike,” we count the “Number of Spikes” in each cell for each treatment 
directly from the fluorescence intensity.
The “Number of Spikes” and the “Area under Curve” are both very important. 
We expect spikes with large “Areas under the Curve” to be followed by recovery 
periods, in which the cell must reset, and the second response after a big response may 
be less. Some cells that are not completely recovered to the baseline may not respond to 
the second stimulus and naive cells may respond more than cells already treated with 
stimulus. Thus we can make some rule for predicting cellular network for both cultures, 
with or depleted of glia.
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4.2 Statistical Design
4.2.1 Variables
Three Variables are defined in this part of the work, namely: “Number of 
Spikes,” “Area under the Curve,” and “Neurons.”
4.2.2 Methodology
Prior to fitting a model to describe the fluorescence data, it is imperative that we 
analyze the relationship between the variables: “Neurons” vs “Number of Spikes” and 
“Neurons” vs “Area under the Curve.” Scatter diagrams are used to determine if the 
variables are correlated. Histogram plots are used to visualize where the majority of the 
spikes and “Area under the Curve” fall by Treatment groups, how the data is distributed 
and their variations. As a good alternative to the histogram, we explore box plots of 
“Number of Spikes” and “Area under the Curve” by Treatment groups to see several 
simultaneous comparisons, e.g the data lowest value, highest value, median value, and 
sizes of the first and third quartile. We also use this measure to assess the degree to 
which the data cluster around the means or medians. We present tables of the indices and 
five number summary for the “Number of Spikes” and “Area under the Curve” to 
summarize the afforementioned. In the first instance, we analyze the variables by a one­
way ANOVA and advance with the repeated measure design to improve the model 
coefficients. T - Tests compare mean scores at two different time periods for a single 
group of subjects. The Tukey Honestly Significant Difference Test (HSD) is used to 
determine which pairs of Treatments are different in case of a significant treatment 
effect. Finally, we consider a non-parametric analysis (Friedman Rank Sum Test) to 
assess the similarities in the models and make constructive conclusions. We present the
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analysis in two parts, one for the “Number of Spikes” and the other for “Area under the 
Curve.”
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4.3 Results -  Cultures Treated With Ara-C
4.3.1 Descriptive Analysis -  “Number of Spikes”
Figure 4.1 shows the histogram plots for the variable “Number of Spikes” by 
Pre-Treatment and Treatments 1, 2, and 3. We can infer from Figure 4.1 that the 
“Number of Spikes” for Pre-Treatment and Treatments 1, 2 and 3 all have slightly 
skewed distributions, and the majority of the “Neurons” spike between zero and two 
times. However, the Treatment 2 group is distinctly different in showing a good 
population of cells spiking with four or more events.
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Figure 4.1: Histograms for “Number of Spikes” by Treatment, Pre-Treatment (upper 
left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
4.3.2 Scatter plots for “Number of Spikes” by Treatments
To determine if a relationship exists between the “Neurons” and “Number of 
Spikes,” a scatter diagram is explored to observe if the data is scattered with a pattern.
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Figure 4.2 shows no correlation between the two variables observed, i.e the “effect 
(Treatment)” is not related to the “cause (Neurons)” in any way. The “Number of 
Spikes” is randomly scattered with respect to the neurons, but we see some outliers in 
Pre-Treatment and Treatment 1, due to the extreme data points in both plots.
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Figure 4.2: Scatter Plots for “Number of Spikes” by Treatment, Pre-Treatment (upper 
left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
The scatter plots above show no direct relationship between the variables: 
“Number of Spikes” and “Neurons.” Most of the spikes in Pre-Treatment are zeros, and 
we observe fewer zero spikes in Treatment groups 1, 2, and 3.This suggests that cells are 
not spiking and staying close to baseline.
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4.3.3 Spike Indices- “Number of Spikes”
Table 4.1 shows a summary of the spike indices. Pre-Treatment has the lowest 
“Number of Spikes” (33) and the lowest mean Spike (0.578947). Treatment 2 has the 
highest “Number of Spikes” (269) and the highest mean (4.719298). The standard 
deviation and standard errors are listed. Based on the standard errors, 95% confidence 
intervals (Cl) also are listed. For the Pre-Treatment, the 95% Cl is 0.127506 to
0.3235224. This implies that if 100 similar samples were drawn, in 95 out of 100 tests, 
the mean “Number of Spikes” would fall between 0.13 and 0.32.
Table 4.1 -  Spike Indices -  “Number of Spikes”
95% 
Confidence 
interval for 
Mean
“Number
o f
Spikes”
Mean 
“Number 
o f  Spikes”
Standard
deviation
Standard
error
Lower
bound
Upper
bound
Pre-
T reatment
33 0.578947 0.962648 0.127506 0.323522 0.834372
Treatment
1
93 1.631579 2.192777 0.290440 1.049757 2.213401
Treatment
2
269 4.719298 4.530667 0.600102 3.517151 5.921446
Treatment
3
109 1.912281 2.055313 0.272233 1.366933 2.457629
The box plots in Figure 4.3 show the “Number of Spikes” by Treatment groups. 
Pre-Treatment is from a population centered on zero with standard deviation one from a 
distribution skewed to the right. Treatment 1 is from a population centered on one with 
standard deviation two and from a symmetric distribution. Treatment 2 is from a 
population centered on six with standard deviation five from a population skewed to the
42
left. Treatment 3 is from a population centered on one with standard deviation two from 
a distribution skewed to the right.
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Figure 4.3: Box plots for “Number of Spikes” by Treatments
Assessing the spread of the data, Pre-Treatment, Treatments 1 and 2 exhibit 
nonlinear increasing trends, but the trend drops sharply when the Treatment 3 is applied. 
Outliers can be seen in Pre-Treatment and Treatments 1.
4.3.4 Five Number Summaries (“Number of Spikes”)
The five number summaries from Table 4.2 display the dispersion of the data, 
highlighting the minimum and maximum “Number of Spikes.” The lower (Ql) and 
upper (Q3) quartile of the data show the middle 50% for the “Number of Spikes.” We
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observe that Treatment 2 has the highest “Number of Spikes” (12), the highest median 
“Number of Spikes” (6.00), the highest mean “Number of Spikes” (4.719), and highest 
upper quartile “Number of Spikes” (9.00). All four Treatment groups have the lowest 
“Number of Spikes” being zero. Also, we see an increasing trend (0.5789 -  4.719) in the 
mean “Number of Spikes” for Pre-Treatment and Treatments 1 and 2, but the trend drops 
(1.912) when Treatment 3 is applied. We can attribute this to the glutamate effect on 
“Number of Spikes.”
Table 4.2 -  Summary (“Number of Spikes”)
Min. 1st Qu. Median Mean 3rd Qu. Max.
0 . 0 0 0 0 . 0 0 0 1 . 0 0 0 2 . 2 1 1 3.000 1 2 . 0 0 0
Summary (“Number of Spikes,” Treatment!
• Pre-Treatment
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0 0 0 . 0 0 0 0 0 . 0 0 0 0 0.5789 1 . 0 0 0 0 3.0000
• Treatment: 1
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0 0 . 0 0 0 1 . 0 0 0 0 1.632 2 . 0 0 0 8 . 0 0 0
• Treatment: 2
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0 0 . 0 0 0 6 . 0 0 0 4.719 9.000 1 2 . 0 0 0
• Treatment: 3
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0 0 . 0 0 0 1 . 0 0 0 1.912 3.000 6 . 0 0 0
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4.3.5 Model Assumptions
Next, we check the normality assumption using the Kolmogorov-Smimov test 
and the homogeneity of variance assumption using the Bartlett Test. Kolmogorov tests 
the null hypothesis that the data comes from a normal distribution against the alternative 
that the data is not normal, while Bartlett tests the null hypothesis that the data has 
constant variance against the alternative the data does not have constant variance. 
Decision: Reject the null hypothesis if p-value is less than 0.05 in both tests.
Test for normality
Two-sample Kolmogorov-Smimov test 
Data: No spikes and Neurons 
D = 0.8026, p-value < 2.2e-16 
Alternative hypothesis: two-sided
Since the p-value (< 2.2e-16) is less than 0.05, we reject the null hypothesis and 
conclude that the data comes from a non-normal distribution.
Test for homogeneity of variance
Bartlett test of homogeneity of variances 
Data: “Areas,” by Treatment
Bartlett's K-squared = 120.4626, df = 3, p-value < 2.2e-16
Since the p-value (< 2.2e-16) is less than 0.05, we conclude that the assumption 
of constant variance is not satisfied.
Moreover, because we have a very large biological data set, the chance of 
normalty and homogenity of variance assumption being satisfied is low. Similarly, to 
account for this, we consider the non-parametric version of each test explored, i.e.
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Kruskal-Wallis test for the one way ANOVA and Friedman rank sum test for the 
repeated measure design to compare the similarities in both models. Parametric tests are 
more robust in the sense that you get slightly more statistical power to detect differences 
while non-parametric procedures are often criticized because:
1. Non-parametric tests do not make strong assumptions about the population. We 
cannot infer that the sample statistic is an estimate of the population parameter.
2. The non-parametric tests are ranked tests, transforming the measurements into ranked 
data. Thus, precision is degraded.
3. Statistical power of non-parametric tests is lower than that of their parametric 
counterparts.
To further investigate our findings from the descriptive analysis performed 
earlier, we explore the one way ANOVA to test the null hypothesis that all the mean 
“Number of Spikes” by treatment are equal and drawn from the same population against 
the alternative hypothesis that not all the mean “Number of Spikes” are equal and drawn 
from a non-identical population.
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
The result from Table 4.3 indicates that there i s . a statistically significant 
difference in the three degrees freedom test among the three groups of Treatments, our 
degree of freedom, DF = 3 (p-value 3.32e—13), i.e. they all come from non-identical 
populations.
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Table 4.3 -  ANOVA
Df Sum Sq Mean Sq F value Pr(>F)
| Treatment 3 534.7 178.22 23.38 3.32e-13
***
Residuals 224 1707.2 7.62
Signif. codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 V 0.1 ‘ 5 1
To determine which pairs of treatment levels are significantly different from each 
other, we look at a Tukey HSD Pair-wise comparison test of all the treatment levels (TO 
-  Tl, TO -  T2, TO -  T3, T1 -  T2, Tl -  T3, T2 -  T3), where TO, T l, T2, T3 represents 
Pre-Treatment, Treatment 1, Treatment 2, and Treatment 3, respectively.
4.3.6 Test for Difference in Means 
Hypothesis Test
H o : M^spikes(trt0)=M^spikes(trt1)=  H sp ik es(trt2)=  ^ sp ik es(tr t3)
Against the alternative hypothesis that
fI sp ik es(tr ti)^ ^ sp ik e s (tr tj) ,
where i = 0 (Pre-Treatment), 1, 2 and j = 1, 2, 3.
4.3.7 Tukey Multiple Comparisons of Means
Table 4.4 shows the 95% Pair-wise comparison between the Treatment means. 
Differences between Treatments means are significant at five percent level if the 
confidence interval around the estimation of the difference does not contain zero. From 
Table 4.4, we see T2 -  TO, T2 -  T l, and T3 -  T2 Treatment means are significantly 
different because the interval around them does not contain zero. Tl -  TO, T3 -  TO, and 
T3 -  Tl Treatment means are not statistically significant because the intervals around 
the means contain zero. This can also be visualized by the plot in Figure 4.4.
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Table 4.4 -  Treatment -  Tukey HSD Test
Diff Lwr upr padj
1 -0 1.0526316 -0.285916922 2.391180 0.1781146
2 -0 4.1403509 2.801802376 5.478899 0 . 0 0 0 0 0 0 0o1<<> 1.3333333 -0.005215167 2.671882 0.0513216
2 -1 3.0877193 1.749170797 4.426268 0 . 0 0 0 0 0 0 1
3 -1 0.2807018 -  1.057846746 1.619250 0.9483967
3 -2 -2.8070175 -4.145566045 -  1.468469 0.0000009
95% family-wise confidence level
2
5
-2 O 2 4-4
Differences in m ean  levels of Treatment
Figure 4.4: Intervals that contain zero indicates that the Treatments are not significant
and significant for those without zero.
Based on the ANOVA test in Table 4.3, and to improve model coefficient, a 
repeated measure design is considered.
4.3.8 Repeated Measure Analysis of Variance for “Number of Spikes”
The source of variability in this repeated measure analysis is “Treatments” and 
“Neurons.” We are interested in the effect of Treatment and this treatment effect is 
nested within each of the Neurons. The error term is “Neurons/Treatment,” read as 
“Treatment within Neurons.”
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4.3.9 Repeated Analysis of Variance -  Hypothesis Test
H0: we want to test the null hypothesis that the means of all “Number of Spikes” 
by treatment are equal (Identical population)
Against the alternative hypothesis that
Hj: Not all “Number of Spikes” means are equal (non-identical population)
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
From Table 4.5, we observe once “Neurons” variability is parceled out, we do 
have a significant “Treatment” main effect, (p-value -  0.000101) in the three degree 
freedom test.
Table 4.5- Repeated ANOVA
Error: Neurons
Df Sum Sq Mean Sq F value Pr(>F)
Residuals 1 0.000794 0.000794
Error: Subject: Treatment
Df Sum Sq Mean Sq
Treatment 3 372.5 124.2
Error: Within
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 170.6 56.85 7.362 0 . 0 0 0 1 0 1
***
Residuals 2 2 0 1698.8 7.72
Signif. codes: 0 ‘***’ 0.001 ‘**’ 0.01 **’ o © ©
But we cannot ascertain which pairs of the treatment levels are significant from 
others. To account for this multiplicity of tests, we consider first the unadjusted p-values
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using the Pair-wise T-Test. We then adjust the p-values for the Bonferroni and Holm 
methods.
4.3.10 Pair-wise Comparisons Using Paired T-Tests 
Hypothesis Test
^ sp ik e s(tr t0)= ^ 'sp ik es(tr t1)= ^ 'sp ik es(tr t2)= ^ 'sp ik es(tr t3)
Against the alternative hypothesis that
^ sp ik e s (tr ti)* ^ sp ik es (tr tj ) ,
Where i -  0 (Pre-Treatment), 1, 2 and j = 1, 2, 3.
Tables 4.6, 4.7, and 4.8 contain the p-values from the Pair-wise T-Test, and we 
see significant differences in all comparisons in our post-hoc tests, except in Treatment 3 
when compared to Treatment 1, and the adjustments all result in an increased p-value for 
all the methods. Consistently, T l- TO, T2 -  TO, T2 -  T l, T3 -  TO, and T3 -  T2 pairs are
significantly different at a = 0.05.
Table 4.6 -  P-value adjustment method: none 
Data: No spikes and Treatment
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 0 . 0 0 0 2 2 - -
Treatment 2 8 .6 e- 1 0 1.5e-07
Treatment 3 2.3e-06 0.38746 2.4c 07
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Table 4.7 -  P-value adjustment method: bonferroni
Data: No spikes and Treatment
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 0.0013 - -
Treatment 2 5.2e-09 8.8e-07 -
Treatment 3 1.4e-05 1 . 0 0 0 0 1.5e-06
Table 4.8 -  P-value adjustment method: holm
Data: No spikes and Treatment
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 0.00044 - -
Treatment 2 5.2e-09 7.3e-07 -
Treatment 3 6.9e-06 0.38746 9.7e-07
Next, we considered a non-parametric version (Kruskal-Wallis and Friedman 
Test) of the one way ANOVA and repeated measures for comparison to previous 
analysis. It is known that the nonparametric tests are less powerful than the parametric 
tests, the reason why we explored the parametric tests earlier. The non-parametric tests 
are rank tests. In these types of tests, we rank (or place in order) each observation from 
our data set. Clearly, the biological data usually do not meet the conditions for applying 
parametric tests or the normality assumptions. However, in this area, researchers are 
cautious when using non-parametric tests, and it is a good idea to consider both analyses 
for consistency.
4.3.11 Kruskal-Wallis Rank Sum Test
Data: No spikes by Treatment
Kruskal-Wallis chi-squared = 179.2180, df = 3, p-value < 2.2e-16
Since p-value < 2.2e-16 is less than 0.05, we observe a significant treatment 
effect, i.e. the mean “Number of Spikes” by Treatment differs. This result is consistent 
with the parametric test shown in Table 4.3.
4.3.12 Friedman Rank Sum Test
Data: “Number of Spikes,” Treatment and Neurons
Friedman chi-squared = 43.7868, df = 3, p-value = 3.247e—12
The formula reads “Number of Spikes” as a function of Treatment given 
“Neurons” and in this analysis “Neurons” was treated as a blocking variable. Since p- 
value = 3.247e-12 is less than 0.05, the result indicates that the mean “Number of 
Spikes” differs significantly for Pre-Treatment and Treatments 1-3. This result is 
consistent with the parametric test performed in Table 4.5.
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4.3.13 Descriptive Analysis -  “Area under the Curve”
Figure 4.5 shows the histogram plots for the variable “Area under the Curve” by 
Pre-Treatment and Treatments 1, 2, and 3. We can infer from Figure 4.5 that the “Area 
under the Curve” for Pre-Treatment and Treatments 1, 2 and 3 each have a slightly 
skewed distribution, and the “Area under the Curve” gets wider as the Treatments are 
being applied.
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Figure 4.5: Histograms for “Area under the Curve” by Treatment, Pre-Treatment (upper 
left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
4.3.14 Scatter plots for “Area under the Curve” by Treatments
To see if a relationship exists between the “Neurons” and “Area under the 
Curve,” a scatter diagram is explored to observe whether the data is scattered with a
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pattern. Figure 4.6 shows no correlation between the two variables observed, i.e the 
“effect (Treatment)” is not related to the “cause (Neurons)” in any way.
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Figure 4.6: Scatter plots for “Area under Curve” by Treatment, Pre-Treatment (upper 
left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
The scatter plots above show no direct relationship between the variables: “Area 
under the Curve” and “Neurons.” We observe that most of the Neurons are clustered 
around the mean in the Pre-Treatment diagram.
4.3.15 Area Indices -  “Area under the Curve”
Table 4.9 shows a summary of the spike indices. Pre-Treatment has the lowest 
total “Area under the Curve” (3414.16596) and lowest mean (59.89765). Treatment 3
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has the highest total “Area under the Curve” (28067.65972) and highest mean 
(492.4151). The standard deviation and standard errors are listed. Based on the standard 
errors, 95% confidence intervals (Cl) also are listed. For the Pre-Treatment, the 95% Cl 
is 57.05824 to 62.73706. This implies that if 100 similar samples were drawn, in 95 out 
of 100 tests, the mean “Area under the Curve” would fall between 57.06 and 63.74.
Table 4.9 -  Area Indices -  “Area under the Curve”
95%
confidence 
interval 
for mean
Total Area 
under the 
Curve
Mean 
Area 
under the 
Curve
Standard
deviation
Standard
error
Lower
bound
Upper
bound
Pre-
Treatment
3414.16596 59.89765 10.70120 1.41741 57.05824 62.73706
Treatment
1
20161.43645 353.7094 225.26330 29.83685 293.9390 413.4798
Treatment
2
26303.27374 461.4609 284.23651 37.64805 386.0428 536.8790
Treatment
3
28067.65972 492.4151 375.35302 49.71672 392.8205 592.0096
The box plots in Figure 4.7 show the “Area under the Curve” by Treatment 
groups. Pre-Treatment is from a population centered on 60 with standard deviation 10 
from a distribution with extremely short tails. Treatment 1 is from a population centered 
on 300 with standard deviation 220 and from a distribution skewed to the right, as the 
top whisker is much longer than the bottom whisker and the line is gravitating towards 
the bottom of the box. Treatment 2 is from a population centered on 400 with standard 
deviation 280 from a slightly symmetric distribution. Treatment 3 is from a population 
centered on 550 with standard deviation 380 from a distribution skewed to the left, as the
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top whisker is much longer than the bottom whisker and the line is ascending towards 
the top of the box.
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Figure 4.7: Box plots for "Area under the Curve" by Treatments
The box plots in Figure 4.7 demonstrate a non-linearly increasing trend. This 
implies that as the treatments are applied the “Area under the Curve” gets wider, and 
also we see that the median 50% of the data is increasing and we note a possible outlier 
in Treatment 2.
4.3.16 Five Number Summaries (“Area under the Curve”)
The five number summaries from Table 4.10 display the dispersion of the data, 
highlighting the minimum and maximum “Area under the Curve.” The lower (Ql) and 
upper (Q3) quartiles of the data show the middle 50% for the “Area under the Curve.” 
We observe that Treatment 3 has the highest “Area under the Curve” (1397), the highest
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median “Area under the Curve” (515), the highest mean “Area under the Curve” (492.4), 
and highest upper quartile “Area under the Curve” (738.5).While Pre-Treatment has the 
lowest mean, lowest median, lowest lower and lowest upper inter quartile range, as well 
at the lowest minimum “Area under the Curve.” Also, we see an increasing trend (59.90 
-  492.4) in the mean “Area under the Curve” for Pre-Treatment, Treatments 1, 2 and 3, 
as well as for the other measures in Table 4.10. We can attribute this to the glutamate 
effect on “Area under the Curve.”
Table 4.10 -  Summary (“Area under the Curve”)
Min. 1st Qu. Median Mean 3rd Qu. Max.
0.6971 86.3200 199.1000 341.9000 561.9000 1397.0000
Summary (“Area under the Curve,” Treatment!
• Pre-Treatment
Min 1st Q. Median Mean 3rd Q. Max.
42.52 55.06 57.60 59.90 63.72 112.40
• Treatment: 1
Min 1st Q. Median Mean 3rd Q. Max.
88.55 162.80 298.70 353.70 510.50 958.00
• Treatment: 2
Min 1st Q. Median Mean 3rd Q. Max.
79.63 2 2 1 . 1 0 395.40 461.50 637.70 1273.00
• Treatment: 3
Min 1st Q. Median Mean 3rd Q. Max.
0.6971 124.8000 515.0000 492.4000 738.5000 1397.0000
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4.3.17 Model Assumptions 
Test for normality
Two-sample Kolmogorov-Smimov test 
Data: “Areas,” and Neurons 
D = 0.8991, p-value < 2.2e-16 
Alternative hypothesis: two-sided
Since the p-value (< 2.2e-16) is less than 0.05, we reject the null hypothesis and 
conclude that the data comes from a non-normal distribution.
Test for homogeneity of variance
Bartlett test of homogeneity of variances 
Data: “Areas,” by Treatment
Bartlett's K-squared = 321.6431, df = 3, p-value < 2.2e-16
Also, since the p-value (< 2.2e-16) is less than 0.05, we conclude that the 
assumption of constant variance is not satisfied.
We would expect these assumptions not to be satisfied since we are dealing with 
a large biological data set, but to account for these variations, we consider both the 
parametric and non-parametric versions of all tests employed in this analysis for 
comparison, and rely also on analysis of outliers in making constructive conclusions.
To further investigate our findings from the descriptive analysis performed 
earlier, we seek to test the null hypothesis that all the mean “Area under the Curve” by 
treatment are equal and drawn from the same population, against the alternative 
hypothesis that not all the mean “Area under the Curve” are equal and drawn from a 
non-identical population, and we reject the null hypothesis if P-value < a where a=0.05.
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The result from Table 4.11 indicates that there is a statistically significant 
difference in the three degrees freedom test among the three group of treatment, our 
degree of freedom, DF = 3 (p-value <2e-16 ), i.e. they all come from non-identical 
populations.
Table 4.11 -ANOVA
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 6647020 2215673 32.52 <2e-16 ***
Residuals 224 15262148 68135
Signif. codes: 0 ‘***’ 0.001 0.01 0.05 V 0.1 ‘ ’ 1
To determine which pairs of treatment levels are significantly different from each 
other, we look at a Tukey HSD Pair-wise comparison test of all the treatment levels (TO 
-  Tl, TO -  T2, TO -  T3„ T1 -  T2, T1 -  T3, T2 -  T3).
4.3.18 Test for Difference in Means 
Hypothesis Test
H o: M^Area(trt0)=M^Area(trti )=M^Area(trt2)=M^Area(trt3)
Against the alternative hypothesis that
H l : MArea(trti)*^Area(trtj)
where i = 0 (Pre-Treatment), 1, 2 and j = 1, 2, 3.
4.3.19 Tukey Multiple Comparisons of Means
95% family-wise confidence level 
Fit: aov(formula = Areas ~ Treatment)
Table 4.12 shows the 95% Pair-wise comparison between the Treatment means. 
Differences between Treatment means are significant at the five percent level if the
confidence interval around the estimation of the difference does not contain zero and 
from Table 4.12 T1 -  TO, T2 -  TO, T3 -  TO and T3 -  T1 Treatment means are 
significantly different, because the intervals around the means do not contain zero. 
While T2 -  T1 and T3 -  T2 Treatment means are not statistically significant, because the 
intervals around the means contain zero. This can also be visualized by the plot in Figure
4.8.
Table 4.12 -  Treatment -  Tukey HSD Test
Diff lwr upr padj
1 -0 293.81176 167.25185 420.3717 0 . 0 0 0 0 0 0 0
2 -0 401.56329 275.00338 528.1232 0 . 0 0 0 0 0 0 0
3 -0 432.51743 305.95752 559.0773 0 . 0 0 0 0 0 0 0
2 -1 107.75153 -  18.80838 234.3114 0.1253453
3 -1 138.70567 12.14576 265.2656 0.0254490
3 -2 30.95414 -95.60577 157.5141 0.9212748
9 _
8  - 
8 -
C<l “
r t  “
Differences in mean levels of Treatment
95% family-wise confidence level
-100 100
Figure 4.8: Intervals that contain zero indicates that the Treatments are not significant
and significant for those without zero.
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Based on the ANOVA result from Table 4.11, to improve model coefficients, a 
repeated measure design is considered.
4.3.20 Repeated Measure Analysis of Variance for “Area under the Curve”
The source of variability in this repeated measure analysis is “Treatments” and 
“Neurons.” We are interested in the effect of Treatment and this treatment effect is 
nested within each of the Neurons. The Error term is “Neurons/Treatment,” read as 
“Treatment within Neurons.”
4.3.21 Repeated Analysis of Variance -  Hypothesis Test
Ho.- we want to test the null hypothesis that the mean “Area under the Curve” by 
treatment are equal (Identical population)
Against the alternative hypothesis that
Hi: Not all the mean “Area under the Curve” are equal (non-identical population) 
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
We observed in Table 4.13, once “Neurons” variability is parceled out, we do 
have a significant “Treatment” main effect, (p-value -1.12e-06) in the three degree 
freedom test.
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Table 4.13 -  Repeated ANOVA
Error: Neurons
Df Sum Sq Mean Sq F value Pr(>F)
Residuals 1 150472 150472
Error: Neurons:Treatment
Df Sum Sq Mean Sq
Treatment 3 4579648 1526549
Error: Within
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 2214933 738311 1 0 . 8 6 1.12e-06
***
Residuals 2 2 0 14964115 68019
Signif. codes: Q <•***’ 0  0 0 1  ‘ * * ’ 0 0 1 0.05 V 0.1 ‘ ’ 1
But we cannot ascertain which pairs of the treatment levels are significant from 
others. To account for this multiplicity of tests, we consider first the unadjusted p-values 
using the Pair-wise T-Test. We then adjust the p-values for Bonferroni and Holm 
methods.
In Tables 4.14, 4.15 and 4.16, we see significant differences in all comparisons in 
our post-hoc tests, except in Treatment 3 when compared to Treatment 2 and the 
adjustments all result in an increased p-value for all the methods. Also, consistently TI­
TO, T2 -  TO, T2 -  Tl, T3 -  TO, T3 -  T1 pairs are significantly different at a = 0.05.
Table 4.14 -  P-value Adjustment Method: None
• Data: Areas and Treatment
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 5.4e-14 — —
Treatment 2 2.5e-15 1.7e-07
Treatment 3 4.5e-12 1.5e-06 0 . 2 2
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Table 4.15 -  P-value Adjustment Method: Bonferroni
• Data: Areas and Treatment
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 3.3e-13 —
Treatment 2 1.5e-14 1.0e-06
Treatment 3 2.7e-l 1 8.9e-06 1
Table 4.16 -  P-value Adjustment Method: Holm
• Data: No spi ces and Treatment
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 2.7e-13 —
Treatment 2 1.5e-14 5.1c 07 —
Treatment 3 1 .8 e - l 1 3.0e-06 0 . 2 2
Next, we considered a non-parametric version (Kruskal-Wallis and Friedman 
Test) of the one way ANOVA and repeated measures for comparison to previous 
analysis.
4.3.22 Kruskal-Wallis Rank Sum Test
Data: “Areas,” by Treatment
Kruskal-Wallis chi-squared = 256.4087, df = 3, p-value < 2.2e-16
Since p-value < 2.2e-16 is less than 0.05, we observe a significant treatment 
effect, i.e. the mean “Area under the Curve” by Treatment differs. This result is 
consistent with the parametric test displayed in Table 4.11.
4.3.23 Friedman Rank Sum Test
Data: “Area under the Curve,” Treatment and Neurons 
Friedman chi-squared = 119.1684, df = 3, p-value < 2.2e-16
The formula reads “Area under the Curve” as a function of Treatment given 
“Neurons” and in this analysis “Neurons” was treated as a blocking variable. Because p-
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value < 2.2e-16 is less than 0.05, the result indicates that the mean “Area under the 
Curve” differs significantly for Pre-Treatment and Treatments 1-3. This result is 
consistent with the parametric test shown in Table 4.13.
4.4 Results and Discussion
Descriptive analysis on the variable “Number of Spikes” and “Area under the 
Curve” shows that the Treatment groups appear to be different or unequal when neurons 
are treated with glutamate of increasing concentrations. While each of the three 
successive stimuli continued to increase in glutamate concentration, unexpectedly, the 
most spiking activity is observed in Treatment 2, which is an intermediate concentration, 
i.e. T1<T2<T3. We hypothesize that the highest concentration Treatment 3 leads to 
fewer spikes due to synchrony of neuronal activity. This is supported by the “Area under 
the Curve” result, where indeed the highest glutamate concentration results in the largest 
calcium load. This result is consistent with the highest glutamate stimulation resulting in 
the strongest calcium load (Figures 4.3 and 4.7).
To further investigate the descriptive measure performed earlier, a one-way 
ANOVA is considered to examine the effect of the independent variable Treatment with 
four levels, on the dependent variable “Number of Spikes” and “Area under the Curve.” 
In Table 4.3, the amount of variability in the response variable (Sum of square error- 
treatment) is reported (534.7), which is high compared to a smaller sum of square which 
indicates a better model. Our preliminary analysis in Table 4.3 shows a significant 
treatment effect with p-value (3.32e-13). To determine which pairs of the Treatment 
groups differ, a Tukey HSD test is explored. The result reveals Treatment 3 as compared 
to Treatments 0 and 1 as equal. We cannot expect Treatment 3 and 1 to be different due
to the closeness of their mean “Number of Spikes” from Table 4.1. Also Treatment 1 as 
compared to 0 is equal, but the difference is significant when Treatment 2, (with the 
highest “Number of Spikes’Vmean spike) is compared to Treatments 0, 1 and 3. To 
improve our model coefficient, a repeated ANOVA is considered. Our analysis shows a 
greatly reduced sum of square error (170.6) for Treatment when compared to the one­
way ANOVA where the sum of square error for Treatment is 534.7, an indication that 
the repeated measure model is a better model. Also our post-hoc test for the one way 
ANOVA shows only half of the Pair-wise comparison to be significant, that is, three 
pairs out of six comparisons. However, the post-hoc test in the repeated design model 
showed five pairs as significant. Only Treatment 3 compared to Treatment 1 is equal, i.e. 
not different or significant, which corresponds with our result from the descriptive 
analysis performed earlier because of the closeness of the mean “Number of Spikes” 
from both groups.
Lastly, to further analyze if combinations of multiple stimuli with glutamate will 
result in the same testable and predictable outcome in brain cells for the analysis in this 
work, our next direction will be same glutamate concentrations as this experiment but 
with equal time intervals for Treatments 1, 2, and 3, and analyzing this results with 
variables: “Number of Spikes” and “Area under the Curve,” in Chapter 5.
CHAPTER 5
STATISTICAL EVALUATION OF DYNAMIC 
BRAIN CELL CALCIUM ACTIVITY 
DATA WITH EQUAL TIME 
STEPS.
5.1 Overview
Two types of culture are analyzed in this chapter namely: 1) a culture treated 
with Ara-C (+Ara-C), that possesses fewer glia, and more neurons, the main response 
cells we will examine and 2) a culture without Ara-C (-Ara-C), that has more astrocytes, 
but still also has neurons that respond to stimulus (glutamate).
We seek to establish if combinations of multiple glutamate stimuli will result in 
similar testable and predictable outcomes in brain cells, such as neurons as in Chapter 
4. The data set analyzed in this chapter includes cultures treated with Ara-C and 
cultures not treated with Ara-C. In the physical experiment, the methods employed 
were previously discussed in Section 2.4. Baseline activities of the neurons are 
measured and recorded as Pre-Treatment, and glutamate addition to the neurons is 
described by three categories: Treatments 1, 2 and 3, each representing stimulation 
with different concentrations of glutamate at 250, 500 and 750 nM, administered at 
pre-determined equal time steps. As described in Chapter 4, after defining what is
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meant by a “calcium spike,” we count the “Number of Spikes” in each cell for each 
treatment directly from the fluorescence intensity.
5.2 Methodology
Prior to fitting a model to describe the fluorescence data, we analyze the 
relationship between the variables: “Neurons” vs “Number of Spikes” and “Neurons” vs 
“Area under the Curve.” Scatter diagrams are used to determine if the variables are 
correlated. Histogram plots are used to visualize where the majority of the spikes and 
areas fall by Treatment groups, how the data is distributed and its variations. As a good 
alternative to the histogram, we explore box plots of “Number of Spikes” and “Area 
under the Curve” by Treatment groups to see several simultaneous comparisons, e.g the 
data lowest value, highest value, median value, and sizes of the first and third quartiles. 
We also use this measure to assess how the data cluster (or do not cluster) around the 
means or medians. We present tables of the indices and five number summary for the 
“Number of Spikes” and “Area under the Curve” to summarize the afforementioned. In 
the first instance, we analyze the variables by a one-way ANOVA and advance with the 
repeated measure design to improve the model coefficients. But before this, it is 
imperative we check the model assumptions underlying the aforementioned analysis. We 
check the normality assumption using the Kolmogorov-Smimov test and the 
homogeneity of variance assumption by the Bartlett test.
We present the analysis in two parts, one for the “Number of Spikes” and the 
other for “Area under the Curve,” each for cultures treated with Ara-C and not treated 
with Ara-C.
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5.3 Results -  Cultures Treated with Ara-C 
5.3.1 Descriptive Analysis -  “Number of Spikes”
Figure 5.1 illustrates the histogram plots for the variable “Number of Spikes” by 
Pre-Treatment and Treatments 1, 2, and 3. We can deduce from Figure 5.1 that the 
“Number of Spikes” for Pre-Treatment and Treatments 1, 2 and 3 all have slightly 
skewed distributions, although the Treatment groups 1, 2 and 3 are distinctly different 
than Pre-Treatment in showing a good population of cells spiking with five or more 
events.
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Figure 5.1: Histograms for “Number of Spikes” by Treatment, Pre-Treatment (upper 
left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
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5.3.2 Scatter Plots for “Number of Spikes” by Treatments
To establish if a relationship exists between the “Neurons” and “Number of 
Spikes,” a scatter diagram is explored to observe if the data is scattered with a pattern. 
Figure 5.2 shows no correlation between the two variables observed, i.e the “effect 
(Treatment)” is not related to the “cause (Neurons)” in any way. The “Number of 
Spikes” is randomly scattered with respect to the neurons. We observe fewer spikes in 
Pre-Treatment and majority of the neurons resting at zero.
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Figure 5.2: Scatter Plots for “Number of Spikes” by Treatment, Pre-Treatment (upper 
left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
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The scatter plots above show no direct relationship between the variables: 
“Number of Spikes” and “Neurons.” In Pre-Treatment, most of the cells do not spike, 
and we observe fewer instances of zero spikes in Treatment groups 1, 2, and 3.
5.3.3 Spike Indices -  “Number of Spikes”
Table 5.1 shows a summary of the spike indices. Pre-Treatment has the lowest 
“Number of Spikes” (45) and the lowest mean “Number of Spikes” (0.35340). 
Treatment 2 has the highest “Number of Spikes” (767) and the highest mean “Number of 
Spikes” (6.0390). The standard deviation and standard errors are listed. Based on the 
standard errors, 95% confidence intervals (Cl) are also listed. For Treatment 1, the 95% 
Cl is 4.576558 to 5.927379. This implies that if 100 similar samples were drawn, in 95 
out of 100 tests, the mean “Number of Spikes” would fall between 4.6 and 5.9.
Table 5 .1 -  Spike indices -  “Number of Spikes”
95% 
Confidence 
interval for 
Mean
“Number
of
Spikes”
Mean
“Number
of
Spikes”
Standard
deviation
Standard
error
Lower
Bound
Upper
bound
Pre-
Treatment
45 0.35430 0.782016 0.069393 0.217005 0.491657
Treatment
1
667 5.2520 3.846187 0.341294 4.576558 5.927379
Treatment
2
767 6.0390 4.183113 0.371191 5.304793 6.773947
Treatment
3
684 5.3860 3.809027 0.337997 4.716942 6.054712
The box plots in Figure 5.3 show the “Number of Spikes” by Treatment groups. 
Pre-Treatment is from a population centered on zero with standard deviation one, from a 
distribution skewed to the right. Treatment 1 is from a population centered on five with 
standard deviation of eight and from a symmetric distribution. Treatment 2 is from a 
population centered on six with a standard deviation of nine from a symmetric 
distribution. Treatment 3 is from a population centered on six with standard deviation of 
nine from a distribution skewed to the left.
N u m b er  o f  S p ik e s  b y  T r e a tm e n t
Treatments (P re ,1 ,2,3)
Figure 5.3: Box plots for “Number of Spikes” by Treatments
Assessing the spread of the data, Pre-Treatment, Treatments 1 and 2 exhibit 
nonlinear increasing trends, but the trends remain constant when the Treatment 3 is 
applied, considering the 50% median for the data. Outliers can be seen in Pre-Treatment.
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It is hypothesized that the Treatment 3 median remains the same because the Neurons 
have been stimulated twice already with glutamate.
5.3.4 Five Number Summaries (“Number of Spikes”)
The five number summaries from Table 5.2 display the dispersion of the data, 
highlighting the minimum and maximum “Number of Spikes.” The lower (Ql) and 
upper (Q3) quartiles of the data show the middle 50% for the “Number of Spikes.” We 
observe that Treatments 1 and 2 have the highest “Number of Spikes” (16), Treatments 2 
and 3 have the highest median “Number of Spikes” (6.00), while Treatment 3 has the 
highest mean “Number of Spikes” (6.039), and highest upper quartile “Number of 
Spikes” (9.00). All four Treatment groups have the lowest “Number of Spikes” being 
zero. Also, we see an increasing trend (0.3543 -  6.039) in the mean “Number of Spikes” 
for Pre-Treatment and Treatments 1 and 2, but the trend drops slightly (5.386) when 
Treatment 3 is applied.
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Table 5.2 -  Summary (“Number of Spikes”)
Min. 1st Qu. Median Mean 3rd Qu. Max.
0.000 0.000 3.000 4.258 8 . 0 0 0 16.000
Summary (“Number of Spikes.” Treatment)
• Pre-Treatment
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0 0  0 . 0 0 0 0  0 . 0 0 0 0 0.3543 0 . 0 0 0 0 4.0000
• Treatment: 1
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0 2 . 0 0 0 5.000 5.252 8 . 0 0 0 16.000
• Treatment: 2
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0 3.000 6 . 0 0 0 6.039 9.000 16.000
• Treatment: 3
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0 2 . 0 0 0 6 . 0 0 0 5.386 9.000 14.000
5.3.5 Model Assumptions
Next, we check the normality assumption using the Kolmogorov-Smimov test 
and homogeneity of variance assumption using the Bartlett Test. Kolmogorov tests the 
null hypothesis that the data comes from a normal distribution against the alternative that 
the data is not normal, while Bartlett tests the null hypothesis that the data has constant 
variance against the alternative the data does not have constant variance.
Decision: Reject the null hypothesis if p-value is less than 0.05 in both tests.
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Test for normality
Two-sample Kolmogorov-Smimov test 
Data: No spikes and Neurons 
D = 0.8819, p-value < 2.2e-16 
Alternative hypothesis: two-sided
Since the p-value (< 2.2e-16) is less than 0.05, we reject the null hypothesis and 
conclude that the data comes from a non-normal distribution.
Test for homogeneity of variance 
Bartlett test of homogeneity of variances 
Data: No spikes by Treatment
Bartlett's K-squared = 270.1386, df = 3, p-value < 2.2e-16
Since the p-value (< 2.2e-16) is less than 0.05, we conclude that the assumption 
of constant variance is not satisfied.
To further investigate our findings from the descriptive analysis performed 
earlier, we explore the one way ANOVA to test the null hypothesis that all the mean 
“Number of Spikes” by treatment are equal and drawn from the same population against 
the alternative hypothesis that not all the mean “Number of Spikes” are equal and drawn 
from a non-identical population.
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
The result from Table 5.3 indicates that there is a statistically significant 
difference in the three degrees freedom test among the three groups of Treatments, our 
degree of freedom, DF = 3 (p-value <2e-16), i.e. they all come from non-identical 
populations, with a 95% confidence bound.
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Table 5.3 -  ANOVA
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 2625 875.1 73.83 <2e-16 ***
Residuals 504 5974 11.9
Signif. codes: 0 ‘***’ 0.001 0.01 **’ 0.05 0.1 ‘ ’ 1
We also test the analysis with 90% and 99% confidence bounds to assess if 
differences occur in the analysis, and the results are consistent with the result in Table 
5.3. To determine which pairs of treatment levels are significantly different from each 
other, we look at a Tukey HSD Pair-wise comparison test of all the treatment levels (TO 
-  T l, TO -  T2, TO -  T3, Tl -  T2, Tl -  T3, and T2 -  T3).
5.3.6 Test for Difference in Means 
Hypothesis Test
H o ■ M^spikes(trt0)=  M^spikes(trt1)=  H sp ik es(trt2)=  f^spikes(trt3)
Against the alternative hypothesis that
l-fspikes(trti)*: H spikes(trtj),
where i = 0 (Pre-Treatment), 1, 2 and j = 1, 2, 3.
5.3.7 Tukey Multiple Comparisons of Means
Table 5.4 shows the 95% Pair-wise comparison between the Treatment means. 
Differences between Treatment means are significant at the five percent level if the 
confidence interval around the estimation of the difference does not contain zero. From 
Table 4-4, we see that Tl -  TO, T2 -  TO, and T3 -  TO Treatment means are significantly 
different because the intervals around the means do not contain zero. While T2 -  T l, T3
75
-  T l, and T3 -  T2 Treatment means are not statistically significant because the intervals 
around their means contain zero. This can also be visualized by the plot in Figure 5.4.
Table 5.4 -  Treatment -  Tukey HSD Test
Diff lwr «pr padjo1 4.8976378 3.7839954 6.0112802 0 . 0 0 0 0 0 0 0
2 -0 5.6850394 4.5713969 6.7986818 0 . 0 0 0 0 0 0 0
3 -0 5.0314961 3.9178536 6.1451385 0 . 0 0 0 0 0 0 0
2 -1 0.7874016 -  0.3262409 1.9010440 0.2638898
3 -1 0.1338583 -  0.9797842 1.2475007 0.9896809
3 -2 -0.6535433 -  1.7671858 0.4600991 0.4306008
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Figure 5.4: Intervals that contain zero indicates that the Treatments are not significant
and significant for those without zero.
Based on the ANOVA test in Table 5.3, and to improve model coefficient, a 
repeated measure design is considered.
5.3.8 Repeated Measure Analysis of Variance for “Number of Spikes”
The source of variability in this repeated measure analysis is “Treatments” and 
“Neurons.” We are interested in the effect of Treatment and this treatment effect is
95% family-wise confidence level
-i- —r~ 
4O 2
Differences in mean levels of Treatment
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nested within each of the Neurons. The error term is “Neurons/Treatment,” read as 
“Treatment within Neurons.”
5.3.9 Repeated Analysis of Variance -  Hypothesis Test
H0: we want to test the null hypothesis that the means of all “Number of Spikes” 
by treatment are equal (Identical population)
Against the alternative hypothesis that
Hi: Not all “Number of Spikes” means are equal (non-identical population)
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
We observe in Table 5.5, once “Neurons” variability is parceled out, we do have 
a significant “Treatment” main effect, (p-value -  2.4e-08) in the three degree freedom 
test.
Table 5.5 -  Repeated ANOVA
Error: Neurons
Df Sum Sq Mean Sq F value Pr(>F)
Residuals 1 134 134
• Error: Neurons:Treatment
Df Sum Sq Mean Sq
Treatment 3 2230 743.3
• Error: Within
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 460 153.25 13.27 2.4e-08 ***
Residuals 500 5776 11.55
Signif. codes: Q i***? Q QQ| Q Q2 4*5 0.05 V 0.1 ‘ ’ 1
But we cannot ascertain which pairs of the treatment levels are significant from 
others. To account for this multiplicity of tests, we consider first the unadjusted p-values
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using the Pair-wise T-Test. We then adjust the p-values for Bonferroni and Holm 
methods.
5.3.10 Pair-wise Comparisons Using Paired T-Tests 
Hypothesis Test
Ho • Hspikes(trt0)= M^spikes(trt1)=  M-spikes(trt2)= M^spikes(trt3)
Against the alternative hypothesis that
Hspikes(trtj)* ^spikes(trtj),
Where i = 0 (Pre-Treatment), 1, 2 andj = 1, 2, 3.
Tables 5.6, 5.7, and 5.8 contain the p-values from the Pair-wise T-Test, and we 
see significant differences in all comparisons in our post-hoc tests for Pre-Treatment. 
Other adjustments all result in increased p-values for each of the methods. Consistently, 
T2 -  Tl, T3 -  Tl, and T3 -  T2 pairs are not significantly different at a = 0.05 for all the 
methods explored, except for Treatments 3 and 1 which is significant for the adjustment 
“none” (0.037).
Table 5.6 -  P-value Adjustment Method: None
Data: No spikes anc Treatment
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 <2e-16 — —
Treatment 2 <2e-16 0.037 —
Treatment 3 <2e-16 0.722 0.096
Table 5.7 -  P-value adjustment method: Bonferroni 
Data: No spikes and Treatment______________________________
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 <2e-16 —
Treatment 2 <2e-16 0 . 2 2 —
Treatment 3 <2e-16 1 . 0 0 0 0 0.58
Table 5.8 -  P-value adjustment method: Holm
Data: No spikes and Treatment
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 <2e-16 — —
Treatment 2 <2 e -l 6 0 . 1 1
Treatment 3 <2e-16 0.72 0.19
Next, we consider a non-parametric version (Kruskal-Wallis and Friedman Test) 
of the one way ANOVA and repeated measures for comparison to previous analysis.
5.3.11 Kruskal-Wallis Rank Sum Test 
Data: No spikes by Treatment
Kruskal-Wallis chi-squared = 182 4418, df = 3, p-value < 2.2e-16
Since p-value < 2.2e-16 is less than 0.05, we observe a significant treatment 
effect, i.e. the mean “Number of Spikes” by Treatment differs. This result is consistent 
with the parametric test shown in Table 5.3.
5.3.12 Friedman Rank Sum Test
Data: “Number of Spikes,” Treatment and Neurons 
Friedman chi-squared = 46.5877, df = 3, p-value = 4.253e-10
The formula reads “Number of Spikes” as a function of Treatment given 
“Neurons” and in this analysis “Neurons” is treated as a blocking variable. Since the P- 
value (4.253e-10) is less than 0.05; the result indicates that the mean “Number of
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Spikes” differs significantly for Pre-Treatment and Treatments 1-3. This result is 
consistent with the parametric test performed in Table 5.5.
5.3.13 Descriptive Analysis -  “Area under the Curve”
Figure 5.5 shows the histogram plots for the variable “Area under the Curve” by 
Pre-Treatment and Treatments 1, 2, and 3. We can infer from Figure 5.5 that the “Area 
under the Curve” for Pre-Treatment and Treatments 1, 2 and 3 each have a slightly 
skewed distribution, and the “Area under the Curve” gets wider as the Treatments are 
being applied.
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Figure 5.5: Histograms for “Area under the Curve” by Treatment, Pre-Treatment (upper 
left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
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We note that using equal scale in Figure 5.5 for both axes hide some behaviours 
due to outliers.
5.3.14 Scatter Plots for “Area under the Curve” by Treatments
To see if a relationship exists between the “Neurons” and “Area under the 
Curve,” a scatter diagram is explored to observe whether the data is scattered with a 
pattern. Figure 5.6 shows no correlation between the two variables observed, i.e the 
“effect (Treatment)” is not related to the “cause (Neurons)” in any way, but we see some 
outliers in Treatment 3.
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Figure 5.6: Scatter plots for “Area under Curve” by Treatment, Pre-Treatment (upper 
left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
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The scatter plots above show no direct relationship between the variables: “Area 
under the Curve” and “Neurons.”
5.3.15 Area Indices -  “Area under the Curve”
Table 5.9 shows a summary of the Area indices. Pre-Treatment has the lowest 
total “Area under the Curve” (6627.62528) and lowest mean (52.18603). Treatment 3 
has the highest total “Area under the Curve” (2562110.909) and highest mean (20174.1). 
The standard deviation and standard errors are listed. Based on the standard errors, 95% 
confidence intervals (Cl) also are listed. For the Pre-Treatment, the 95% Cl is 46.30363 
to 58.06842. This implies that if 100 similar samples were drawn, in 95 out of 100 tests, 
the mean “Area under the Curve” would fall between 46.30 and 58.07.
Table 5.9 -  Area indices
95%
confidence 
interval 
for mean
Total Area 
under the 
Curve
Mean 
Area 
under the 
Curve
Standard
deviation
Standard
error
Lower
bound
Upper
bound
Pre-
Treatment
6627.62528 52.18603 33.49784 2.972453 46.30363 58.06842
Treatment
1
302638.3405 2382.979 5955.276 528.4453 1337.201 3428.757
Treatment
2
760708.6544 5989.832 16159.38 1433.914 3152.159 8827.505
Treatment
3
2562110.909 20174.1 69992.19 6210.803 7883.105 32465.098
The box plots in Figure 5.7 show the “Area under the Curve” by Treatment 
groups. Pre-Treatment is from a population centered on 52 with standard deviation 34 
from a distribution with extremely short tails. Treatment 1 is from a population centered
on 483 with standard deviation 5955 and from a distribution skewed to the right. 
Treatment 2 is from a population centered on 602 with standard deviation 16159 from a 
distribution with short tails. Treatment 3 is from a population centered on 582 with 
standard deviation 69992 from a distribution skewed to the right. We observe that the 
“Area under the Curve” gets wider as the order of adding the glutamate stimulus 
increases.
Area un d er the cu rv e  by T reatm ent
i$
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Figure 5.7: Box plots for "Area under the Curve" by Treatments
The box plots in Figure 5.7 demonstrate a non-linearly increasing trend. This 
implies that as the treatments are applied the “Area under the Curve” gets wider and we 
note possible outliers in Treatment groups 1, 2 and 3.
5.3.16 Five Number Summaries (“Area under the Curve”)
The five number summaries from Table 5.10 display the dispersion of the data, 
highlighting the minimum and maximum “Area under the Curve.” The lower (Ql) and
upper (Q3) quartiles of the data show the middle 50% for the “Area under the Curve.” 
We observe that Treatment 3 has the highest first quartile (Ql) “Area under the Curve” 
(325.4), the highest median “Area under the Curve” (581.8), the highest mean “Area 
under the Curve” (20170.0), and highest upper quartile “Area under the Curve” (5053.0). 
Pre-Treatment has the lowest mean, lowest median, lowest lower and upper inter quartile 
range, as well at the lowest minimum “Area under the Curve.” Also, we see an 
increasing trend (52.19 -  20170.0) in the mean “Area under the Curve” for Pre- 
Treatment and Treatments 1, 2 and 3, as well as for the other measures in Table 5.10. 
We can attribute this to the glutamate effect on “Area under the Curve.”
Table 5.10 -  Summary (“Area under the Curve”)
Min. 1st Qu. Median Mean 3rd Qu. Max.
0 . 0 0 0
Summary (Area, Treatment)
• Pre-Treatment
Min 1st Q. Median Mean 3rd Q. Max.
0.0000 40.99 51.61 52.19 54.84 279.50
• Treatment: 1
Min 1st Q. Median Mean 3rd Q. Max.
1.53 323.00 483.00 2383.00 1033.00 35150.00
• Treatment: 2
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0 322.9 602.1 5990.0 3014.0 102700.0
• Treatment: 3
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0 325.4 581.8 20170.0 5053.0 626000.0
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5.3.17 Model Assumptions 
Test for normality
Two-sample Kolmogorov-Smimov test 
Data: “Areas,” and Neurons 
D = 0.7264, p-value < 2.2e-16 
Alternative hypothesis: two-sided
Since the p-value (< 2.2e-16) is less than 0.05, we reject the null hypothesis and 
conclude that the data comes from a non-normal distribution.
Test for homogeneity of variance 
Bartlett test of homogeneity of variances 
Data: “Areas,” by Treatment
Bartlett's K-squared = 2240.336, df = 3, p-value < 2.2e-16
Also, since the p-value (< 2.2e-16) is less than 0.05, we conclude that the 
assumption of constant variance is not satisfied.
We would expect that these assumptions will not to be satisfied since we are 
dealing with a large biological data, but to account for this we will consider both the 
parametric and non-parametric analysis for comparison and also an outlier analysis in 
making constructive conclusions. To further investigate our findings from the descriptive 
analysis performed earlier, we seek to test the null hypothesis that all the mean “Area 
under the Curve” by treatment are equal and drawn from the same population, against 
the alternative hypothesis that not all the mean “Area under the Curve” are equal and 
drawn from a non-identical population and we reject the null hypothesis if p-value < a 
where a=0.05.
85
The result from Table 5.11 indicates that there is a statistically significant 
difference in the three degrees freedom test among the three groups of Treatments, our 
degree of freedom, DF = 3 (p-value 3.32e-05), i.e. they all come from non-identical 
populations.
Table 5.11— ANOVA
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 3.100e+10 1.033e+10 7.955 3.43e-05
***
Residuals 504 6.546e+ll 1.299e+09
Signif. codes: 0 ‘***’ 0.001 '**’ 0.01 0.05 V 0.1 ‘ ’ 1
To determine which pairs of treatment levels are significantly different from each 
other, we look at a Tukey HSD Pair-wise comparison test of all the treatment levels (TO 
-  Tl, TO -  T2, TO -  T3, Tl -  T2, Tl -  T3, and T2 -  T3).
5.3.18 Test for Difference in Means 
Hypothesis Test
H q: MArea(trt0)= MArea(trtx)=MArea(trt2)= MArea(trt3)
Against the alternative hypothesis that
(^Area(trti)^ MArea(trtj),
where i = 0 (Pre-Treatment), 1, 2 and j = 1, 2, 3.
5.3.19 Tukey Multiple Comparisons of Means
Table 5.12 shows the 95% Pair-wise comparison between the Treatment means. 
Differences between Treatment means are significant at the five percent level if the 
confidence interval around the estimation of the difference does not contain zero. From
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Table 5.12, we see T3 -  TO, T3 -  T l, and T3 -  T2 Treatment means are significantly 
different, because the interval around the means do not contain zero. Tl -  TO, T2 -  TO, 
and T2 -  Tl Treatment means are not statistically significant, because the interval 
around the mean contain zero. This can also be visualized by the plot in Figure 5.8.
Table 5 .12- Treatment -  Tukey HSD Test
Diff lwr upr padj
1 -0 2330.793 -  9326.993 13988.58 0.9554099
2 -0 5937.646 -5720.141 17595.43 0.5551303
3 -0 20121.916 8464.129 31779.70 0.0000626
2 -1 3606.853 -  8050.934 15264.64 0.8555597
3 -1 17791.123 6133.336 29448.91 0.0005511
3 -2 14184.270 2526.483 25842.06 0.0097675
9 _T“
-1
Figure 5.8: Intervals that contain zero indicates that the Treatments are not significant
and significant for those without zero.
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Based on the ANOVA result from Table 5.11, to improve model coefficients, a 
repeated measure design was considered.
87
5.3.20 Repeated Measure Analysis of Variance for “Area under the Curve”
The source of variability in this repeated measure analysis is “Treatments” and 
“Neurons.” We are interested in the effect of Treatment and this treatment effect is 
nested within each of the Neurons. The error term is “Neurons/Treatment,” read as 
“Treatment within Neurons.”
5.3.21 Repeated Analysis Of Variance -  Hypothesis Test
H0: we want to test the null hypothesis that the mean “Area under the Curve” by 
treatment are equal (Identical population)
Against the alternative hypothesis that
Hi: Not all the mean “Area under the Curve” are equal (non-identical population) 
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
From Table 5.13, we observe once “Neurons” variability is parceled out, we do 
not have a significant “Treatment” main effect, (p-value -  0.973) in the three degree 
freedom test, i.e. the glutamate effect is not significant.
Table 5.13— Repeated ANOVA
Error: Neurons
Df Sum Sq Mean Sq F value Pr(>F)
Residuals 1 5.644e+09 5.644e+09
Error: Subject: Treatment
Df Sum Sq Mean Sq
Treatment 3 3.729e+10 1.243e+10
Error: Within
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 2.936e+08 9.786e+07 0.076 0.973
Residuals 500 6.424e+ll 1.285e+09
8 8
Next, we consider a non-parametric version (Kruskal-Wallis and Friedman Test) 
of the one way ANOVA and repeated measures for comparison to previous analysis.
5.3.22 Kruskal-Wallis Rank Sum Test 
Data: “Areas,” by Treatment
Kruskal-Wallis chi-squared = 258.8095, df = 3, p-value < 2.2e-16
Since p-value (< 2.2e-16) is less than 0.05, we observe a significant treatment 
effect, i.e. the mean “Area under the Curve” by Treatment differs. This result is 
consistent with the parametric test displayed in Table 5.11.
5.3.23 Friedman Rank Sum Test
Data: “Area under the Curve,” Treatment and Neurons 
Friedman chi-squared = 220.8109, df = 3, p-value < 2.2e-16
The formula reads “Area under the Curve” as a function of Treatment given 
“Neurons” and in this analysis “Neurons” is treated as a blocking variable. Because, the 
p-value (4.253e-10) is less than 0.05, the result indicates that the mean “Area under the 
Curve” differs significantly for Pre-Treatment and Treatments 1-3. This result is not 
consistent with the parametric test shown in Table 5.13.
5.3.24 Outliers Analysis
Because outliers can affect normality and homogeneity of variance assumptions 
severely, we rely heavily on residual plots to check for outliers because this approach is 
more subjective than the normality and constant variance assumptions given a large data 
set. As noted in Figures 5.6 and 5.7, we explore the plots of Cook distance and standard 
residuals versus the fitted in Figures 5.9 and 5.10 to check for outliers. From the plots 
we observe that data points 460, 472, and 479 are outliers, and they are deleted. After
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performing the same outliers analysis on the new data set, we observe that data points 
461, 463 are outliers, and they are deleted also. An observation with a standard residual 
that exceeds three in absolute value is conventionally considered as an outlier. The 
outliers are deleted from our data set, and we repeat the process to check for the points 
closest to that point. We repeat the same outliers check analysis, and the conditions are 
satisfied in Figures 5.11 and 5.12. Thus, we delete five data points from a total of 508 
observations in the original variable (“Area under the Curve”). We use the remaining 
503 observations for the rest of the analyses in this section.
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Figure 5.9: Cook’s distance plot
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Figure 5.10: Standard residuals versus fitted
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Figure 5.11: Cook’s distance plot
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Figure 5.12: Standard residuals versus fitted
From Table 5.145 we observe a huge decrease in the Mean “Area under the 
Curve” in Treatment 3 when compared to Table 5.9 with outliers.
Table 5.14 -  Area indices without outliers
95%
confidence 
interval 
for mean
Total Area 
under the 
Curve
Mean 
Area 
under the 
Curve
Standard
deviation
Standard
error
Lower
bound
Upper
bound
Pre-
Treatment
6627.62528 52.18603 33.49784 2.972453 46.30363 58.06842
Treatment
1
302638.3405 2382.979 5955.276 528.4453 1337.201 3428.757
Treatment
2
760708.6544 5989.832 16159.38 1433.914 3152.159 8827.505
Treatment
3
1024887.729 8400.719 20481.32 1854.292 4729.659 12071.779
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The plot in Figure 5.13 reveals the width of Treatment 3 box plot as smaller 
when compared to the plot in Figure 5.7.
Area und er th e  cu r v e  by T reatm ent
o
Treatments (Pre, 1, 2, 3)
Figure 5.13: Box plots for "Area under the Curve" without outliers by Treatments
The result from Table 5.15 indicates that there is a statistically significant 
difference in the three degrees freedom test among the three groups of treatments, our 
degree of freedom, DF = 3 (p-value 2.94e-06), i.e. they all come from won-identical 
populations.
Table 5.15 -  ANOVA without Outliers
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 5.163e+09 1.721e+09 9.745 2.94e-06
***
Residuals 499 8.813e+10 1.766e+08
Signif. codes: 0 ‘***’ 0.001 0.01 0.05 V 0.1 ‘ ’ 1
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To determine which pairs of treatment levels are significantly different from each 
other, we look at a Tukey HSD Pair-wise comparison test of all the treatment levels (TO 
-  Tl, TO -  T2, TO -  T3, Tl -  T2, Tl -  T3, T2 -  T3).
5.3.25 Test for Difference in Means 
Hypothesis Test
H 0  ■ MArea(trt0)=  M^Area(trt1)=  MArea(trt2)= MArea(trt3)
Against the alternative hypothesis that
H i :  ^Area(trtj)*MArea(trtj),
where i — 0 (Pre-Treatment), 1, 2 and j = 1, 2, 3.
5.3.26 Tukey Multiple Comparisons of Means
95% family-wise confidence level 
Fit: aov (formula = Areas ~ Treatment)
Table 5.16 shows the 95% Pair-wise comparison between the Treatment means. 
Differences between Treatment means are significant at five percent level if the 
confidence interval around the estimation of the difference does not contain zero. From 
Table 5.15 T2 -  TO, T3 -  TO and T3 -  Tl Treatment means are significantly different 
because the intervals around the means do not contain zero. While Tl -  TO, T2 -  T l , and 
T3 -  T2 Treatment means are not statistically significant because the intervals around 
the means contain zero. This can also be visualized by the plot in Figure 5.14.
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Table 5.16 -  Treatment -  Tukey HSD Test
Diff lwr Upr padj
1 -0 2330.793 -  1954.7747 6616.361 0.4987177
2 -0 5937.646 1652.0781 10223.214 0.0021969
3 -0 8017.796 3732.2283 12303.364 0 . 0 0 0 0 1 1 2
2 -1 3606.853 -678.7149 7892.421 0.1332374
3 -1 5687.003 1401.4353 9972.571 0.0037628
3 -2 2080.150 -2205.4176 6365.718 0.5945516
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Figure 5.14: Intervals that contain zero indicates that the Treatments are not significant
and significant for those without zero.
Based on the result in Table 5.14, and to improve the model coefficients, a 
repeated measure design is considered for the data without outliers for comparison to the 
previous analysis.
5.3.27 Repeated Analysis of Variance -  Hypothesis Test
The source of variability in this repeated measure analysis is “Treatments” and 
“Neurons.” We are interested in the effect of Treatment and this treatment effect is
95% family-wise confidence level
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nested within each of the Neurons. The error term is “Neurons/Treatment,” read as 
“Treatment within Neurons.”
H0: we want to test the null hypothesis that the means of all “Area under the 
Curve” by treatment are equal (Identical population)
Against the alternative hypothesis that
Hi: Not all “Area under the Curve” means are equal (non-identical population)
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
We observed in Table 5.17, once “Neurons” variability is parceled out, we do not 
have a significant “Treatment” main effect, (p-value -  0.812) in the three degree 
freedom test.
Table 5.17- Repeated ANOVA without Outliers
Error: Neurons
Df Sum Sq Mean Sq F value Pr(>F)
Residuals 1 1.412e+09 1.412e+09
Error: Neurons:Treatment
Df Sum Sq Mean Sq
Treatment 3 5.927e+09 1.976e+09
Error: Within
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 1.659e+08 55300640 0.319 0.812
Residuals 495 8.579e+10 173307894
Signif. codes: 0 ‘***’ 0.001 ***’ 0.01 0.05 V 0.1 ‘ ’ 1
Next, we consider a non-parametric version (Kruskal-Wallis and Friedman Test) 
of the one way ANOVA and repeated measures for comparison to previous analysis.
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5.3.28 Kruskal-Wallis Rank Sum Test -  without Outliers
Data: “Areas,” by Treatment
Kruskal-Wallis chi-squared = 256.8695, df = 3, p-value < 2.2e-16
Since p-value (< 2.2e-16) is less than 0.05, we observe a significant treatment 
effect, i.e. the mean “Area under the Curve” by Treatment differs. This result 
corresponds with the analysis in Table 5.15.
5.3.29 Friedman Rank Sum Test
Data: “Area under the Curve,” Treatment and Neurons 
Friedman chi-squared = 206.0134, df = 3, p-value < 2.2e-16
The formula reads “Area under the Curve” as a function of Treatment given 
“Neurons” and in this analysis “Neurons” is treated as a blocking variable. Because, the 
p-value (< 2.2e-l 6 ) is less than 0.05, the result indicates that the mean “Area under the 
Curve” differs significantly for Pre-Treatment and Treatments 1-3. This result does not 
agree with the parametric test shown in Table 5.17.
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5.4 Results -  Cultures Not Treated With Ara-C
The results presented in this section involve cultures not treated with Ara-C. 
Recall that this culture has more glia but still have neurons responding to glutamate 
stimulus.
5.4.1 Descriptive Analysis -  “Number of Spikes”
Figure 5.15 depicts the histogram plots for the variable “Number of Spikes” by 
Pre-Treatment and Treatments 1, 2, and 3. We can infer from Figure 5.15 that the 
“Number of Spikes” for Pre-Treatment and Treatments 1, 2 and 3 all have slightly 
skewed distributions. Also, we observe an increasing trend in the maximum “Number of 
Spikes” for each Treatment and the majority of the “Neurons” spike between zero and 
two times.
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Figure 5.15: Histograms for “Number of Spikes” by Treatment, Pre-Treatment (upper 
left), Treatment l (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
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5.4.2 Scatter Plots for “Number of Spikes” by Treatments
To determine if a relationship exists between the cells and “Number of Spikes,” a 
scatter diagram is explored to observe if the data is scattered with a pattern. Figure 5.16 
shows no correlation between the two variables observed, i.e the “effect (Treatment)” is 
not related to the “cause (Neurons)” in any way. We observe more cells resting at zero 
with respect to “Number of Spikes,” and we see some outliers in Pre-Treatment due to 
the extreme data points in the plot.
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Figure 5.16: Scatter Plots for “Number of Spikes” by Treatment, Pre-Treatment (upper 
left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
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5.4.3 Spike Indices for Culture without Ara-C
Table 5.18 shows a summary of the Spike indices. Pre-Treatment has the lowest 
“Number of Spikes” (21) and the lowest mean Spike (0.18104). Treatment 1 has the 
highest “Number of Spikes” (123) and the highest mean (1.06035). The standard 
deviation and standard errors are listed. Based on the standard errors, 95% confidence 
intervals (Cl) also are listed. For the Pre-Treatment, the 95% Cl is 0.070956 to 
0.291113. This implies that if 100 similar samples were drawn, in 95 out of 100 tests, the 
mean “Number of Spikes” would fall between 0.07 and 0.29.
Table 5.18 -  Spike Indices for Culture without Ara-C
95% 
Confidence 
interval 
for Mean
“Number
of
Spikes”
Mean
“Number
of
Spikes”
Standard
deviation
Standard
error
Lower
bound
Upper
bound
Pre-
Treatment
2 1 0.18104 0.598536 0.055572 0.070956 0.291113
Treatment
1
123 1.06035 2.21571 0.2057235 0.652846 1.467844
Treatment
2
1 0 0 0.86207 2.29895 0.213452 0.439262 1.284876
Treatment
3
90 0.7759 2.18726 0.203082 0.373596 1.178129
The box plots in Figure 5.17 show the “Number of Spikes” by Treatment Groups. 
Pre-Treatment and Treatments 2 and 3 are from a population centered on zero from 
distributions skewed to the right. Treatment 1 is from a population centered on one with 
standard deviation two and from a distribution skewed to the right. We observe fewer 
Spikes due to the ratio of glia to neurons in this culture.
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Figure 5.17: Box plots for “Number of Spikes” by Treatments
Assessing the spread of the data, we observe a slightly nonlinear increasing trend 
in Treatments 1, but the trend drops as Treatment 2 and 3 are applied. Outliers can be 
seen in ali the treatment groups.
5.4.4 Five Number Summaries (“Number of Spikes”)
The five number summaries from Table 5.19 display the dispersion of the data, 
highlighting the minimum and maximum “Number of Spikes.” The lower (Ql) and 
upper (Q3) quartiles of the data show the middle 50% for the “Number of Spikes.” We 
observe that Treatment groups 2 and 3 have the highest “Number of Spikes” (12). 
Treatment 1 has the highest mean “Number of Spikes” (1.0604) and highest upper 
quartile “Number of Spikes” (1.00). All four Treatment groups have the minimum
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“Number of Spikes,” first quartile, median and third quartile equal zero, except 
Treatment 1 whose third quartile range is 1.000. Also, we see an increase in the mean 
“Number of Spikes” once Treatment 1 is applied, but the increase drops as Treatments 2 
and 3 are applied. We can attribute this to the effect of two stimuli added to the culture 
resulting to the Neurons reacting less to the third stimulus.
Table 5 .19- Summary (“Number of Spikes”)
Min. 1st Qu. Median Mean 3rd Qu. Max.
0 . 0 0 0 0 . 0 0 0 0 . 0 0 0 0.7198 0 . 0 0 0 1 2 . 0 0 0  |
Summary (“Number of Spikes,” Treatment)
• Pre-Treatment
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0 0  0 . 0 0 0 0 0 . 0 0 0 0 0.18104 0 . 0 0 0 0 4.0000
• Treatment: 1
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0 0 . 0 0 0 0 . 0 0 0 0 1.0604 1 . 0 0 0 1 0 . 0 0 0
• Treatment: 2
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0 0 . 0 0 0 0 . 0 0 0 0.8621 0 . 0 0 0 1 2 . 0 0 0
• Treatment: 3
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0 0 . 0 0 0 0 . 0 0 0 0.7759 0 . 0 0 0 1 2 . 0 0 0
5.4.5 Model Assumptions 
Test for normality
Two-sample Kolmogorov-Smimov test 
Data: No spikes and Neurons 
D = 0.9138, p-value < 2.2e-16
102
Alternative hypothesis: two-sided
Since the p-value (< 2,2e-16) is less than 0.05, we reject the null hypothesis and 
conclude that the data comes from a non-normal distribution.
Test for homogeneity of variance 
Bartlett test of homogeneity of variances 
Data: No spikes by Treatment
Bartlett's K-squared = 181.1646, df = 3, p-value < 2.2e-16
Since the p-value (< 2.2e-16) is less than 0.05, we conclude that the assumption 
of constant variance is not satisfied.
Because we are dealing with a large biological data set, we cannot expect these 
assumptions to be satisfied, but to account for this we consider both the parametric and 
non-parametric versions of all tests employed in this analysis for comparison. We also 
rely also on outlier analysis in making constructive conclusions.
To further investigate our findings from the descriptive analysis performed 
earlier, we seek to test the null hypothesis that all the mean “Number of Spikes” by 
treatment are equal and drawn from the same population, against the alternative 
hypothesis that not all the mean “Number of Spikes” are equal and drawn from a non­
identical population.
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
The result from Table 5.20 indicates that there is a statistically significant 
difference in the three degrees freedom test among the three groups of Treatments, our 
degree of freedom, DF = 3 (p-value 0.00502), i.e. they all come from non-identical 
populations.
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Table 5.20 -  ANOVA
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 49.8 16.612 4.333 0.00502** |
Residuals 460 1763.7 3.834
Signif. codes: 0 ‘***’ 0.001 ***’ 0.01 ‘*’ 0.05 V 0.1 ‘ ’ 1
To determine which pairs of treatment levels are significantly different from each 
other, we look at a Tukey HSD Pair-wise comparison test of all the Treatment levels (TO 
-  Tl, TO -  T2, TO -  T3, T1 -  T2, T1 -  T3, T2 -  T3).
5.4.6 Test for Difference in Means 
Hypothesis Test
H o : ^ sp ik es(tr t0)=  M^spikes(trt1)=  M-spikes(trt2)=  H sp ik es(trt3)
Against the alternative hypothesis that
H i:  Hspikes(trt{)=£M^pikes(trtj),
where i = 0 (Pre-Treatment), 1, 2 and j = 1, 2, 3.
5.4.7 Tukey Multiple Comparisons of Means
Table 5.21 shows the 95% Pair-wise comparison between the Treatment means. 
Differences between Treatment means are significant at five percent level if the 
confidence interval around the estimation of the difference does not contain zero. From 
Table 5.21, we see Tl -  TO and T2 -  TO Treatment means are significantly different 
because the intervals around the means do not contain zero. T3 -  TO, T2 -  T l, T3 -  Tl, 
and T3 -  T2 Treatment means are not statistically significant because the intervals 
around the means contain zero. This can also be visualized by the plot in Figure 5.18.
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Table 5.21 -  Treatment -  Tukey HSD Test
Diff lwr upr padj
1 -0 0.8793103 0.21635750 1.5422632 0.0037968
2 -0 0.6810345 0.01808163 1.3439873 0.0414637
3 -0 0 0.5948276 -0.06812526 1.2577804 0.0964318
2 -1 -0.1982759 -0.86122871 0.4646770 0.8674535
3 -1 -  0.2844828 -0.94743561 0.3784701 0.6857453
3 -2 -  0.0862069 -0.74915974 0.5767460 0.9870006
95% family-wise confidence level
s
8
5
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Differences in mean levels of Treatment
Figure 5.18: Intervals that contain zero indicates that the Treatments are not significant
and significant for those without zero.
Based on the result from Table 5.20, and to improve the model coefficients, a 
repeated measure design is considered.
5.4.8 Repeated Measure Analysis of Variance for “Number of Spikes”
The source of variability in this repeated measure analysis is “Treatments” and 
“Neurons.” We are interested in the effect of Treatment and this treatment effect is 
nested within each of the Neurons. The error term is “Neurons/Treatment,” read as 
“Treatment within Neurons.”
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5.4.9 Repeated Analysis Of Variance -  Hypothesis Test
H0: we want to test the null hypothesis that the mean “Number of Spikes” by 
treatment are equal (Identical population)
Against the alternative hypothesis that
Hi: Not all the mean “Number of Spikes” are equal (non-identical population)
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
From Table 5.22, we observe once “Neurons” variability is parceled out, we do 
have a significant “Treatment” main effect, (p-value -  0.00731) in the three degree 
freedom test.
Table 5 .22 - Repeated ANOVA
Error: Neurons
Df Sum Sq Mean Sq F value Pr(>F)
B1M SSIM B ' XIl”*'1) , N()-W_ ■ ’
Error: Subject: Treatment
Df Sum Sq Mean Sq
m m m m m
Error: Within
Df Sum Sq Mean Sq F value Pr(>F)
Residuals
w s s s m
456 1668.5
—
3.659
Signif. codes: 0 ‘***’ 0.001 ***’ 0.01 ‘*’ 0.05 V 0.1 ‘ ’ 1
But we cannot ascertain which pairs of the Treatment levels are significant from 
others. To account for this multiplicity of tests, we consider first the unadjusted p-values 
using the Pair-wise T-Test. We then adjust the p-values for the Bonferroni and Holm 
methods.
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5.4.10 Pair-wise Comparisons using Paired T-Tests 
Hypothesis Test
H o : H spikes(trt0)=  M^spikes(trtx)=  ^ sp ik es(tr t2)=  ^ sp ik es(tr t3)
Against the alternative hypothesis that
M-spikes(trti)=£ M-spikes(trtj)
Where i -  0 (Pre-Treatment), 1, 2 and j = 1, 2, 3.
Tables 5.23, 5.24, and 5.25 contain the p-values from the Pair-wise T-Test, and 
we see significant differences in all comparisons in our post-hoc tests when compared to 
Pre-Treatment, except in T3 -  TO (p-value 0.0125). Consistently, T2 -  T l, T3 -  T l, and 
T3 -  T2 pairs are not significantly different at a  = 0.05 for all adjustments.
Table 5.23 -  P-value adjustment method: None
Data: No spikes ant Treatment
Pre-Treatment Treatment 1 Treatment 2
I Treatment 1 6.1e-06 — -
Treatment 2 0.00091 0.23276
| Treatment 3 0.00209 0.07895 0.46819
Table 5.24 -  P-value adjustment method: Bonferroni
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 3.6e-05
Treatment 2 0.0054 1 . 0 0 0 0 —
Treatment 3 0.0125 0.4737 1 . 0 0 0 0
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Table 5.25 -  P-value adjustment method: Holm
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 3.6e-05 — —
Treatment 2 0.0045 0.4655
Treatment 3 0.0083 0.2369 0.4682
Next, we considered a non-parametric version of ANOVA (Kruskal- Wallis Test) 
and repeated measures (Friedman Test) for comparison to previous analysis.
5.4.11 Kruskal-Wallis Rank Sum Test 
Data: No spikes by Treatment
Kruskal-Wallis chi-squared = 18.7012, df = 3, p-value = 0.0003152
Since p-value = 0.0003152 is less than 0.05, we observe a significant treatment 
effect, i.e. the mean “Number of Spikes” by Treatment differs. This result is in 
agreement with the parametric test displayed in Table 5.20.
5.4.12 Friedman Rank Sum Test
Data: “Number of Spikes,” Treatment and Neurons 
Friedman chi-squared = 38.1114, df = 3, p-value = 2.677e-08
The formula reads “Number of Spikes” as a function of Treatment given 
“Neurons” and in this analysis “Neurons” is treated as a blocking variable. Since p-value 
= 2.677e-08 is less than 0.05, the result indicates that the mean “Number of Spikes” 
differs significantly for Pre-Treatment and Treatments 1 - 3 .  This result is in agreement 
with the parametric test shown in Table 5.22.
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5.4.13 Descriptive Analysis -  “Area under the Curve”
Figure 5.19 shows the histogram plots for the variable “Area under the Curve” by 
Pre-Treatment and Treatments 1, 2, and 3. We can infer from Figure 5.19 that the 
“Area under the Curve” for Pre-Treatment and Treatments 1, 2 and 3 each have a 
slightly skewed distribution.
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Figure 5.19: Histograms for “Area under the Curve” by Treatment, Pre-Treatment (upper 
left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
We note that using equal scale in Figure 5.19 for both axis hides some 
behaviours due to outliers.
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5.4.14 Scatter “Area under the Curve” by Treatments
To see if a relationship exist between the “Neurons” and “Area under the Curve,” 
a scatter diagram is explored to observe whether the data is scattered with a pattern. 
Figure 5.20 shows no correlation between the two variables observed, i.e the “effect 
(Treatment)” is not related to the “cause (Neurons)” in any way, but we see some 
outliers in Treatment groups 1, 2, and 3.
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Figure 5.20: Scatter Plots for “Area under the Curve” by Treatment, Pre-Treatment 
(upper left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower
right)
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5.4.15 Area indices for culture without Ara-C
Table 5.26 shows a summary of the Area indices. Pre-Treatment has the lowest 
total “Area under the Curve” (6262.9994) and lowest mean (53.99137). Treatment 1 has 
the highest total “Area under the Curve” (1309264.336) and highest mean (11286.76). 
The standard deviation and standard errors are listed. Based on the standard errors, 95% 
confidence intervals (Cl) also are listed. For the Pre-Treatment, the 95% Cl is 48.86802 
to 59.11473. This implies that if 100 similar samples were drawn, in 95 out of 100 tests, 
the mean “Area under the Curve” would fall between 48.87 and 59.12.
Table 5.26 -  Area indices for culture without Ara-C
95%
confidence 
interval 
for mean
Total Area 
under the 
Curve
Mean 
Area 
under the 
Curve
Standard
deviation
Standard
error
Lower
bound
Upper
bound
Pre-
Treatment
6262.9994 53.99137 27.85744 2.586498 48.86802 59.11473
Treatment
1
1309264.336 11286.76 119010.1 11049.81 -10600.78 33174.30
Treatment
2
1246499.944 10745.68 113531 10541.09 -  10134.18 31625.54
Treatment
3
1102686.185 9505.915 100345 9316.799 -  8948.87 27960.70
The box plots in Figure 5.21 shows the “Area under the Curve” by Treatment 
groups. Pre-Treatment is from a population centered on 53 with standard deviation 28 
from a distribution with extremely short tails. Treatment 1 is from a population centered 
on 11287 with standard deviation 119010 and from a distribution skewed to the right. 
Treatment 2 is from a population centered on 10746 with standard deviation 113531
from a distribution skewed to the right. Treatment 3 is from a population centered on 
9506 with standard deviation 100345 from a distribution skewed to the right.
Area under the curve by Treatm ent
I
Treatments (Pre, 1 , 2 , 3 )
Figure 5.21: Box plots for "Area under the Curve" by Treatments
From the box plots in Figure 5.21 the median 50% of the data cannot be 
interpreted due to the outliers in Treatment groups 1, 2 and 3. We will redo the plot later 
on after excluding the outliers for better interpretation of the box plot.
5.4.16 Five Number Summaries (“Area under the Curve”)
The five number summaries from Table 5.27 display the dispersion of the data, 
highlighting the minimum and maximum “Area under the Curve.” The lower (Ql) and 
upper (Q3) quartile of the data shows the middle 50% for the “Area under the Curve.” 
We observe that Treatment 1 has the highest “Area under the Curve” (1282000.0), the 
highest median “Area under the Curve” (173.4), the highest mean “Area under the
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Curve” (11290.0), and highest upper quartile “Area under the Curve” (216.3). Pre- 
Treatment has the lowest mean, lowest median, lowest lower and upper inter quartile 
range, as well at the lowest minimum “Area under the Curve.”
Table 5.27 -  Summary (“Area under the Curve”)
Min. 1st Qu. Median Mean 3rd Qu. Max.
5.1 49.9 94.7 7898.0 180.1 1282000.0
Summary t“Area under the Curve,” Treatment)
Pre-Treatment
Min 1st Q. Median Mean 3rd Q. Max.
27.77 48.21 50.60 53.99 53.09 329.90
Treatment: 1
Min 1st Q. Median Mean 3rd Q. Max.
58.9 121.4 173.4 11290.0 216.3 1282000.0
Treatment: 2
Min Is* Q. Median Mean 3rd Q. Max.
17.5 65.8 131.3 10750.0 206.1 1223000.0
Min Is* Q. Median Mean 3rd Q. Max.
5.1 28.0 86.4 9506.0 143.4 1081000.0
5.4.17 Model Assumptions 
Test for normality
Two-sample Kolmogorov-Smirnov test 
Data: “Areas,” and Neurons 
D = 0.4246, p-value < 2.2e-16 
Alternative hypothesis: two-sided
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Since the p-value (< 2.2e-16) is less than 0.05, we reject the null hypothesis and 
conclude that the data comes from a non-normal distribution.
Test for homogeneity of variance 
Bartlett test of homogeneity of variances 
Data: “Areas,” by Treatment
Bartlett's K-squared = 1771.96, df = 3, p-value < 2.2e-16
Also, since the p-value (< 2.2e-16) is less than 0.05, we conclude that the 
assumption of constant variance is not satisfied.
We do not expect these assumptions to be satisfied since we are dealing with a 
large biological data set, but to account for this, we consider both the parametric and 
non-parametric versions of all tests employed in this analysis for comparison. We also 
conduct analysis for potential outliers.
To further investigate our findings from the descriptive analysis performed 
earlier, we seek to test the null hypothesis that all the mean “Area under the Curve” by 
treatment are equal and drawn from the same population, against the alternative 
hypothesis that not all the mean “Area under the Curve” are equal and drawn from a 
non-identical population.
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
The result from Table 5.28 indicates that the Treatment effect is not statistically 
significant in the three degrees freedom test among the three group of treatment, our 
degree of freedom, DF = 3 (p-value 0.79), i.e. the glutamate effect is not significant on 
the culture not depleted of glia.
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Table 5.28 -  ANOVA
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 9.710e+09 3.237e+09 0.349 0.79
Residuals 460 4.269e+12 9.280e+09
Signif. codes: 0  ‘***’ 0 . 0 0 1 '**> o.oi 0.05 V 0.1 ‘ ’ 1
5.4.18 Repeated Analysis of Variance -  Hypothesis Test
The source of variability in this repeated measure analysis is “Treatments” and 
“Neurons.” We are interested in the effect of Treatment and this treatment effect is 
nested within each of the Neurons. The error term is “Neurons/Treatment,” read as 
“Treatment within Neurons.”
H0: we want to test the null hypothesis that the means of all “Area under the 
Curve” by treatment are equal (Identical population)
Against the alternative hypothesis that
Hi: Not all “Area under the Curve” means are equal (non-identical population)
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
We observed in Table 5.29, once “Neurons” variability is parceled out, we do not 
have a significant “Treatment” main effect, (p-value -  0.722) in the 3 degree freedom 
test. This implies that the glutamate effect is not significant on the culture.
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Table 5.29 -  Repeated ANOVA
Error: Neurons
Df Sum Sq Mean Sq F value Pr(>F)
Residuals 1 1.529e+10 1.529e+10
Error: Neurons:Treatment
Df Sum Sq Mean Sq
Treatment 3 2.477e+09 825829533
Error: Within
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 1.241e+10 4.137e+09 0.444 0.722
Residuals 456 4.249e+12 9.317e+09
Signif. codes; 0 '***’ 0.001 '**’ 0.01 0.05 V 0.1 ‘ ’ 1
Next, we consider a non-parametric version (Kruskal-Wallis and Friedman Test) 
of the one way ANOVA and repeated measures for comparison to previous analysis.
5.4.19 Kruskal-Wallis Rank Sum Test 
Data: “Areas,” by Treatment
Kruskal-Wallis chi-squared = 157.5803, df = 3, p-value < 2.2e-16
Since p-value < 2.2e-16 is less than 0.05, we observe a significant treatment 
effect, i.e. the mean “Number of Spikes” by Treatment differs. This result is not 
consistent with the parametric test displayed in Table 5.28.
5.4.20 Friedman Rank Sum Test 
Data: “Areas,” Treatment and Neurons
Friedman chi-squared = 204.9, df = 3, p-value < 2.2e-16
The formula reads “Areas” as a function of Treatment given “Neurons” and in 
this analysis “Neurons” is treated as a blocking variable. Also, Since the p-value (< 
2.2e-16) is less than 0.05, the result indicates that the mean “Area under the Curve”
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differs significantly for Pre-Treatment and Treatments 1-3. This result is not consistent 
with the parametric test performed in Table 5.29.
5.4.21 Outliers Analysis
As noted in Figures 5.19 and 5.20 with respect to the outliers in the plots, we 
explore the plots of Cook distance and standard residuals versus the fitted in Figures
5.22 and 5.23 to check for outliers. From the plots we observe that data points 
corresponding to 150, 266, and 382 in Figure 5.22 are outliers, and they are deleted. 
Therefore, we delete three data points from a total of 464 observations in the original 
variable (“Area under the Curve”). We use the remaining 461 observations for the rest of 
the analyses in this section.
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Figure 5.22: Cook’s distance plot
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Figure 5.23: Standard residuals versus fitted
From Table 5.30, we observe a huge decrease in the mean “Area under the 
Curve” in Treatments 1, 2 and 3 when compared to Table 5.26 with outliers.
Table 5.30 -  Area indices without outliers
95%
confidence 
interval for 
mean
Total Area 
under the 
Curve
Mean 
Area 
under the 
Curve
Standard
deviation
Standard
error
Lower
bound
Upper
bound
Pre-
Treatment
6117.858287 53.19877 26.63327 2.483565 48.27884 58.11869
Treatment
1
27252.85775 236.9814 259.5079 24.19923 189.0429 284.9199
Treatment
2
23532.68714 204.6321 305.2687 28.46645 148.2402 261.0239
Treatment
3
21757.02236 189.1915 404.7344 37.74168 114.4255 263.9575
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The plot in Figure 5.24 shows a decreasing trend after Treatment 1 was applied 
as compared to the plot in Figure 5.21 that exhibits an increasing trend. We observe how 
a single cell can skew the width of the boxplot.
Area under the curve by Treatment
o
Treatments (Pre, 1,2,3)
Figure 5.24: Box plots for "Area under the Curve" without outliers by Treatments
Next, we re-analyze the data without the outliers using one way ANOVA and the 
repeated measure design to see if Treatment effect is significant and to observe if model 
coefficients canbe improved. The result is presented in Tables 5.31 and 5.33.
The result from Table 5.31 indicates that there is a statistically significant 
difference in the three degrees freedom test among the three groups of Treatments, our 
degree of freedom, DF = 3 (p-value 5,77e-06 ***), i.e. they all come from non-identical 
populations. This significant effect is not valid in the analysis shown in Table 5.28 with 
the outliers.
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Table 5.31 -  ANOVA without outliers
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 2256949 752316 0.349 5.77e-06
***
Residuals 457 37064376 81104
Signif. codes: 0 ‘***’ 0.001 0.01 0.05 V 0.1 ‘ ’ 1
To determine which pairs of treatment levels are significantly different from each 
other, we look at a Tukey HSD Pair-wise comparison test of all the treatment levels (TO 
-  T l, TO -  T2, TO -  T3, Tl -  T2, Tl -  T3, and T2 -  T3).Table 5.30 shows the 95% Pair­
wise comparison between the Treatment means. Differences between Treatment means 
are significant at the fi ve percent level if the confidence interval around the estimation of 
the difference does not contain zero and from the Table 5.32 Tl -  TO, T2 -  TO and T3 -  
TO Treatment means are significantly different, because the intervals around the means 
do not contain zero. While T2 - Tl and T3 -  Tl and T3 -  T2 Treatment means are not 
statistically significant, because the intervals around the means contain zero. This can 
also be visualized by the plot in Figure 5.25.
Table 5.32 -  Treatment
Diff lwr upr padjo1fH 183.78260 86.84664 280.71857 0.0000084
2 -0 151.43329 54.49733 248.36926 0.0003822Oi 135.99273 39.05676 232.92870 0.0018726
2 -1 -32.34931 -  129.28528 64.58666 0.8251708
3 -1 -47.78987 -  144.72584 49.14609 0.5817613
3 -2 -  15.44056 -  112.37653 81.49540 0.9766004
1 2 0
95% family-wise confidence level
9r*
8
ck
5 
3
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Differences in mean levels of Treatment
Figure 5.25: Intervals that contain zero indicates that the Treatments are not significant
and significant for those without zero.
Based on the ANOVA analysis in Table 5.31, and to improve model coefficient, 
a repeated measure design is considered.
5.4.22 Repeated Measure ANOVA for “Area under the Curve”
The source of variability in this repeated measure analysis is “Treatments” and 
“Neurons.” We are interested in the effect of Treatment and this treatment effect is 
nested within each of the Neurons. The error term is “Neurons/Treatment,” read as 
“Treatment within Neurons.”
From Table 5.33, we observe once outliers are deleted and “Neurons” variability 
is parceled out, we do have a significant “Treatment” main effect, (p-value -  I.14e-07) 
in the three degree freedom test. This result is not consistent with the analysis in Table 
5.29, where the Treatment effect is not significant because of the outliers in the data set.
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Table 5.33 -  Repeated ANOVA without Outliers
Error: Neurons
Df Sum Sq Mean Sq F value Pr(>F)
Residuals 1 3547865 3547865
Error: Subject: Treatment
Df Sum Sq Mean Sq
Treatment 3 825840 275280
Error: Within
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 2610639 870213 12.16 1.14e-07
***
Residuals 452 . 32336315 71541
Signif. codes: 0 ‘***’ 0.001 ‘**’ 0.01 **’ 0.05 V 0.1 ‘ ’ 1
To determine which pairs of the Treatment levels are significant from others, we 
consider first the unadjusted p-values using the Pair-wise T-Test. We then adjust the p- 
values for the Bonferroni and Holm methods.
Table 5.34 -  P-value Adjustment Method: None
Data: Areas and Treatment
Pre-Treatment Treatment 1 Treatment 2
I Treatment 1 5.2e-13 —
Treatment 2 1.7e-07 0.02441
Treatment3 0.00025 0.00738 0.32704
Table 5.35 -  P-value adjustment method: Bonferroni
Data: Areas and Treatment
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 3.1e-12 _ —
Treatment 2 9.9e-07 0.1464 —
Treatment 3 0.0015 0.0443 1
1 2 2
Table 5.36 -  P-value adjustment method: Holm
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 3.1e-12 —
Treatment 2 8.3e-07 0.049 —
Treatment 3 0 . 0 0 1 0 . 0 2 2 0.327
In Tables 5.34, 5.35 and 5.36, we see significant differences in all comparison in 
our post-hoc tests, except in Treatment 3 when compared to Treatment 2 and Treatment 
2 to Treatment 1 for the Bonferroni and Holm methods. The adjustments all result in an 
increased p-value for all the methods. Also, consistently T l-  TO, T2- TO, T3- TO, and 
T3- Tl pairs are significantly different at a = 0.05.
Next, we consider a non-parametric version of ANOVA (Kruskal- Wallis Test) 
and repeated measures (Friedman Test) for comparison to previous analysis.
5.4.23 Kruskal-Wallis Rank Sum Test 
Data: “Areas,” by Treatment
Kruskal-Wallis chi-squared = 158.8132, df = 3, p-value < 2.2e-16
Since p-value < 2.2e-16 is less than 0.05, we observe a significant treatment 
effect, i.e. the mean “Area under the Curve” by Treatment differs. This result is 
consistent with the parametric test shown in Table 5.31.
5.4.24 Friedman Rank Sum Test 
Data: “Areas,” Treatment and Neurons
Friedman chi-squared = 202.1478, df = 3, p-value < 2.2e-16
The formula reads “Areas” as a function of Treatment given “Neurons” and in 
this analysis “Neurons” is treated as a blocking variable. Since the p-value (< 2.2e-16) is
less than 0.05, the result indicates that the mean “Area under the Curve” differs 
significantly for Pre-Treatment and Treatments 1-3. This result is consistent with the 
parametric test performed in Table 5.33.
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5.5 Conclusions and Summaries/Comparison
Table 5.37 -  Variable: “Number of Spikes”
STATISTICAL
TESTS
SIMILARITIES(+Ara-
C/-Ara-C)
DIFFERENCES 
+ Ara-C -Ara-C
Histogram Plots Both come from 
skewed distributions 
(Figures, 5.1 and 5.34)
Culture with Ara- 
C shows activities 
with 4 + Spikes. 
(Figure 5.1)
Majority of the 
spikes between 
0 and 2 (Figure 
5.34)
Scatter Plots Neurons resting at zero 
in Pre-Treatment for 
both plots (Figures 5.2 
and 5.15)
Neurons randomly 
scattered with 
respect to 
“Number of 
Spikes” except in 
Pre-Treatment 
(Figure 5.2)
Fewer spikes 
and majority of 
the Neurons 
resting at zero. 
We can 
attribute this 
response to the 
presence of glia 
cells which 
impacts the 
activities of the 
Neurons.(Figure 
5.15)
Spike Indices N/A More activity, T2 
has maximum 
“Number of 
Spikes” and 
highest mean 
“Number of 
Spikes” (Table 
5.1)
Less activity, 
Tl has 
maximum 
“Number of 
Spikes” and 
highest mean 
“Number of 
Spikes” (Table 
5.18).
Box Plots Minimum “Number of 
Spikes” for all the 
Treatment groups 0. 
Outliers in Pre- 
Treatment, T2 and T3 
have equal Q3 (Figures 
5.3 and 5.17).
Tl from 
population with 
long tail. 
Nonlinear 
increasing trend in 
Pre-Treatment,
T l, and T2. Trend 
remained constant 
in T3 (Figure 5.3)
Tlfrom a 
population with 
short tail. Non­
linear
increasing trend 
in Pre-
Treatment and 
T l . Trend drops 
sharply and 
remains 
constant in T2 
and T3 (Figure 
5.17)
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Table 5.37 continued
ANOVA Both analyses show 
significant treatment 
effects (Tables 5.3 and 
5.20)
Sum of square 
error for
Treatment is 2625 
(Table 5.3)
Sum of square 
error for 
Treatment is 
49.8 (Table 5.20)
Tukey HSD T2-T1, T3-T1, T3-T2 
pairs not significant 
(Figures 5.4 and 5.17)
Test reveals three 
pairs as
significant T1-T0, 
T2-T0 and T3-T0 
(Figure 5.4)
Test reveals two 
pairs as 
significant T I­
TO, T2-T0 
(Figure 5.18)
Repeated
ANOVA
Both analyses reveal 
significant treatment 
effect (Table 5.5)
Sum of square 
error Treatment is 
460 (Table 5.5)
Sum of square 
error Treatment 
is 44.5 (Table 
5.22)
Pair-wise T Consistently T2-T1, T3- 
Tl, and T3-T2 pairs are 
not significantly different 
(Table 5.6 and 5.23)
T2-T1 is 
significant
T2-T1 is not 
significant
Kruskal-
Wallis
Test reveals significant 
treatment effect
Kruskal-wallis 
chi-squared is 
182.4418
Kruskal-wallis 
chi-squared is 
18.7012
Friedman
Rank
Test reveals significant 
treatment effect
Friedman chi- 
squared is 
46.5877
Friedman chi- 
squared is 
38.1114
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Table 5.38 -  Variable: “Area under the Curve”
STATISTICAL
TESTS
SIMILARITIES 
(+Ara-C /-Ara-C)
DIFFERENCES 
+Ara-C -Ara-C
Histogram Plots Both plots slightly 
skewed to the right 
(Figures 5.5 and 
5.20)
Smaller Area under 
the Curve observed 
(Figure 5.1)
Wider area under 
the Curve 
observed (Figure 
5.20)
Scatter Plots Both have neurons 
resting at zero in TO 
and we observe 
outliers in both 
plots (Figures 5.6 
and 5.20)
Some activity in 
Treatments 1, 2 and 3 
(Figure 5.6)
Less activity in all 
the Treatment 
levels (Figure 
5.20)
Area Indices Pre-Treatment has 
the lowest mean, 
lowest total Area 
under the Curve for 
both cultures 
(Tables 5.9 and 
5.26)
T3 has the maximum 
total Area under the 
Curve, and highest 
mean Area under the 
Curve (Table 5.9)
Tl has the 
maximum total 
Area under the 
Curve, and highest 
mean Area under 
the Curve (Table 
5.26)
Box Plots Both plots have 
outliers in T3 
(Figures 5.7 and 
5.21)
We observe a 
nonlinear increasing 
trend in Pre- 
Treatment, T l, T2 and 
T3. (Figure 5.7)
Non-increasing 
trend (Figure 5.21)
ANOVA N/A Significant treatment 
effect, p-value (3.43e- 
05) (Table 5.11)
Treatment effect 
not significant 
(Table 5.28)
Tukey HSD N/A Test reveals three 
pairs as significant T3 
-TO, T 3-T 1 and T3 
-T 2  (Figure 5.8)
N/A
Repeated
ANOVA
Treatment effect 
not significant 
(Tables 5.13 and 
5.29)
Sum of square error 
Treatment is 
2.936e+08 (Table 
5.13)
Sum of square 
error Treatment is 
1.24let-10 (Table 
5.229)
Pair-wise T N/A N/A N/A
Kruskal-Wallis Test reveals 
significant 
treatment effect
Kruskal-Wallis chi- 
squared is 258.8095
Kruskal-Wallis 
chi-squared is 
157.5803
Friedman Rank Test reveals 
significant 
treatment effect
Friedman chi-squared 
is 220.8109
Friedman chi- 
squared is 204.9
127
5.6 Conclusion on Outliers
One way ANOVA shows a significant treatment effect for both cultures treated 
or not treated with Ara-C, (Tables 5.15 and 5.31).Recall that we do not have a significant 
treatment effect for cultures not treated with Ara-C in our ANOVA with outliers (Table 
5.28). The corresponding Tukey HSD test reveals three pairs as significant for both 
cultures (Figures 5.14 and 5.24). However the repeated ANOVA shows cultures not 
depleted of glia as significantly different with respect to Treatment effects, (Table 5.33) 
when compared to the analysis in Table 5.28 where Treatment effect is not significant. 
The culture depleted of glia (Table 5.17) is consistent with the analysis in Table 5.13 as 
not significant to Treatment effects. The corresponding T-Test for the significant 
treatment effect for culture not depleted of glia reveals five pairs as significantly 
different for the Holm and None adjustment methods while T3 -  T2 is not significant. 
Finally both non-parametric tests under this analysis are significant.
CHAPTER 6
RANDOMIZED CULTURE TREATED 
WITH/WITHOUT ARA-C.
6.1 Overview
Thus far, we have administered the scheme of stimulation as follows: 250-500- 
750nM, for data with equal or unequal time steps. Our work in this chapter randomizes 
the order as follows: 500-250-750nM with equal time steps and these results are 
compared with more typical stimuli where we keep increasing glutamate concentration 
from 250-750nM, These values are chosen because they represent sub threshold stimuli, 
in that the cells or some cells have the ability to recover (the stimuli are not toxic).This is 
the best model for a functional, brain cell network as opposed to a model where cells are 
sacrificed (used for example in models for stroke and ischemia). First, we test 
experiments where stimuli are defined as: 500-250-750nM, where the values represent 
glutamate concentration. After addition of each glutamate stimulus, the glutamate 
remains in the well containing cells, so any return to baseline fluorescence indicates 
recovery of the cell. The glutamate is added to the cells in the form of 25ul in a pre­
existing volume of 475ul already on the cells, so the change in volume upon addition to 
the cells is only five percent
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Two types of culture are analyzed in this chapter namely: 1) a culture treated 
with Ara-C (+Ara-C), that possesses fewer glia, and more neurons, the main response 
cells we will examine and 2) a culture without Ara-C (-Ara-C), that has more astrocytes, 
but still also has neurons that respond to stimulus (glutamate).
6.2 Statistical Design 
6.2.1 Variables
Three Variables are defined in this part of the work, namely: “Number of 
Spikes,” “Area under the Curve,” and “Neurons.”
6.2.2 Methodology
Prior to fitting a model to describe the fluorescence data, it is appropriate to 
analyze the relationship between the variables: “Neurons” vs “Number of Spikes” and 
“Neurons” vs “Area under the Curve.” Scatter diagrams are used to determine if there 
exists a relationship between the variables. Histogram plots are used to visualize where 
the majority of the spikes and “Area under the Curve” fall by Treatment groups and to 
visualize how the data is distributed and its variations. As a good alternative to the 
histogram, we explore box plots of “Number of Spikes” and “Area under the Curve” by 
Treatment groups to see several simultaneous comparisons, e.g the data lowest value, 
highest value, median value, and sizes of the first and third quartiles. We also use this 
measure to assess the degree to which the data clusters around the means or medians.
We present tables of the indices and five number summary for the “Number of 
Spikes” and “Area under the Curve” to summarize the afforementioned. In the first 
instance, we check model assumptions, and we analyze the variables by a one-way 
ANOVA. We advance with the repeated measure design to improve the model
coefficients. The Tukey HSD test and Pair-wise T-Test are used to determine which 
pairs of Treatments are different in case of a significant treatment effect. Finally, we 
consider a non-parametric analysis (Friedman Rank Sum Test and Kruskal-Wallis Test) 
to assess the similarities in the models and make constructive conclusions. We present 
the analysis in two parts, one for the “Number of Spikes” and the other for “Area under 
the Curve” for each culture depleted and not depleted of glia.
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6.3. Results -  Cultures Treated With Ara-C
6.3.1 Descriptive Analysis -  “Number of Spikes”
Figure 6.1 depicts the histogram plots for the variable “Number of Spikes” by 
Pre-Treatment and Treatments 1, 2, and 3. We can deduce from Figure 6.1 that the 
“Number of Spikes” for all the Treatment groups have slightly skewed distributions, 
although the Treatment groups 1, 2 and 3 are distinctly different than Pre-Treatment in 
showing a good population of cells spiking with four or more events.
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Figure 6.1: Histograms for “Number of Spikes” by Treatment, Pre-Treatment (upper 
left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
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6.3.2 Scatter Plots for “Number of Spikes” by Treatments
To establish if a relationship exists between the “Neurons” and “Number of 
Spikes,” a scatter diagram is explored to observe if the data is scattered with a pattern. 
Figure 6.2 shows no correlation between the two variables observed, i.e the “effect 
(Treatment)” is not related to the “cause (Neurons)” in any way. The “Number of 
Spikes” is randomly scattered with respect to the neurons in Treatment groups 1, 2 and 
3. We observe fewer spikes in Pre-Treatment, with the majority of the neurons resting at 
zero.
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Figure 6.2: Scatter Plots for “Number of Spikes” by Treatment, Pre-Treatment (upper 
left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
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The scatter plots above show no direct relationship between the variables: 
“Number of Spikes” and “Neurons.” In Pre-Treatment, most of the cells do not spike, 
but we observe fewer instances of zero spikes in Treatment groups 1, 2, and 3.
6.3.3 Spike Indices -  “Number of Spikes”
Table 6.1 shows a summary of the spike indices. Pre-Treatment has the lowest 
“Number of Spikes” (18) and the lowest mean “Number of Spikes” (0.2195). Treatment 
3 has the highest “Number of Spikes” (319) and the highest Mean “Number of Spikes” 
(3.89024). The standard deviation and standard errors are listed. Based on the standard 
errors, 95% confidence intervals (Cl) are also listed. For Treatment 3, the 95% Cl is 
2.945960 to 4.834528. This implies that if 100 similar samples were drawn, in 95 out of 
100 tests, the mean “Number of Spikes” would fall between 2.95 and 4.84.
Table 6.1 -  Spike Indices -- “Number of Spikes”
95% 
Confidence 
interval 
for Mean
“Number
of
Spikes”
Mean
“Number
of
Spikes”
Standard
deviation
Standard
error
Lower
bound
Upper
bound
Pre-
T reatment
18 0.2195 0.544884 0.060173 0.099788 0.339236
Treatment
I
290 3.53659 3.15522 0.348436 2.843307 4.229864
Treatment
2
285 3.47561 3.625103 0.400326 2.679087 4.272132
Treatment
3
319 3.89024 4.297591 0.474590 2.945960 4.834528
The box plots in Figure 6.3 show the “Number of Spikes” by Treatment groups. 
Pre-Treatment is from a population centered on zero with standard deviation one from a 
distribution skewed to the right, the neurons have not been hit with the stimulus, and 
thus we observe fewer activities with respect to the “Number of Spikes.”Treatment 1 is 
from a population centered on three with standard deviation five from a symmetric 
distribution, the neurons are hit with an intermediate stimulus (500nM), and we observe 
a rapid response to the glutamate effect. Treatment 2 is from a population centered on 
two with standard deviation three from a distribution skewed to the right. Here the 
neurons are hit with the lowest stimulus (250nM), and thus the response to the glutamate 
effect is less. Treatment 3 is from a population centered on four with standard deviation 
seven from a distribution skewed to the right. We observe that the cells have been 
stimulated twice and the cells are probably responding slowly before the highest 
stimulus (750nM) is applied, and we see another jump in the cell reaction to the 
glutamate effect.
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N u m b e r  o f  S p ik e s  by T r e a tm e n t
Treatments (Pre,1,2,3)
Figure 6.3: Box plots for “Number of Spikes” by Treatments
Assessing the spread of the data, Pre-Treatment and Treatments 1 exhibit 
nonlinear increasing trends, but the trend drops once Treatment 2 is applied. We observe 
an increase in the middle 50% of the data when the third stimulus is applied.
6.3.4 Five Number Summaries (“Number of Spikes”)
The five number summaries from Table 6.2 display the dispersion of the data, 
highlighting the minimum and maximum “Number of Spikes.” The lower (Ql) and 
upper (Q3) quartiles of the data show the middle 50% for the “Number of Spikes.” We 
observe that Treatments 1 and 3 have the highest “Number of Spikes” (14) and the 
highest median “Number of Spikes” (3.00), while Treatment 3 has the highest mean 
“Number of Spikes” (3.890), and highest upper quartile “Number of Spikes” (7.00). All 
four Treatment groups have the lowest “Number of Spikes” being zero. Also, we see an 
increasing trend (0.2195 -  3.537) in the mean “Number of Spikes” for Pre-Treatment
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and Treatments 1, but the trend drops slightly (3.476) when Treatment 2 is applied. 
Subsequently, we observe an increase in mean “Number of Spikes” when Treatment 3 is 
applied (3.890).
Table 6.2 -  Summary (“Number of Spikes”)
Min. 1st Qu. Median Mean 3rd Qu. Max.
0.000 0.000 1.000 2.780 5.000 14.000
Summary (“Number of Spikes,” Treatment)
Pre-Treatment
Min 1st Q. Median Mean 3rd Q. Max.
0.0000 0.0000 0.0000 0.2195 0 . 0 0 0 0 3.0000
Treatment: 1
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0 1 . 0 0 0 3.000 3.537 5.000 14.000
Treatment: 2
Min I s* Q. Median Mean a <9 Max.
0 . 0 0 0 0 . 0 0 0 2 . 0 0 0 3.476 6 . 0 0 0 13.000
Treatment: 3
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0 0 . 0 0 0 3.000 3.890 7.000 14.000
6.3.5 Model Assumptions 
Test for normality
Two-sample Kolmogorov-Smimov test 
Data: No spikes and Neurons 
D = 0.8384, p-value < 2.2e-16 
Alternative hypothesis: two-sided
Since the p-value (< 2.2e-16) is less than 0.05, we reject the null hypothesis and 
conclude that the data comes from a non-normal distribution.
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Test for homogeneity of variance
Bartlett test of homogeneity of variances 
Data: No spikes by Treatment
Bartlett's K-squared = 226.9934, df = 3, p-value < 2.2e-16
Since the p-value (< 2.2e—16) is less than 0.05, we conclude that the assumption 
of constant variance is not satisfied.
To further investigate our findings from the descriptive analysis performed 
earlier, we seek to test the null hypothesis that all the mean “Number of Spikes” by 
treatment are equal and drawn from the same population, against the alternative 
hypothesis that not all the mean “Number of Spikes” are equal and drawn from a non­
identical population.
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
From Table 6.3 above we observe a statistically significant difference in the three 
degrees freedom test among the three groups of Treatments, our degree of freedom, DF 
= 3 (p-value 1.41e-13), i.e. they ail come from non-identical populations.
Table 6.3 -  ANOV A
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 725 241.76 23.1 1.41 e—13 
***
Residuals 324 3391 10.47
To determine which pairs of treatment levels are significantly different from each 
other, we look at a Tukey HSD Pair-wise comparison test of all the treatment levels (TO 
-  T l, TO -  T2, TO -  T3, T l-  T2, T l-  T3, T2 -  T3).
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6.3.6 Test for Difference in Means 
Hypothesis Test
H o : M^spikes(trt0)=  M^spikes(trt!)= H sp ik es(trt2)=  f^spikes(trt3)
Against the alternative hypothesis that
H i '■ M^spikes(trtj)^ M-spikes(trtj),
where i = 0 (Pre-Treatment), 1, 2 and j = 1, 2, 3.
6.3.7 Tukey Multiple Comparisons of Means
Table 6.4 shows the 95% Pair-wise comparison between the Treatment means. 
Differences between Treatment means are significant at the five percent level if the 
confidence interval around the estimation of the difference does not contain zero. From 
Table 6.4, we see Tl -  TO and T2 -  TO and T3 -  TO Treatment means are significantly 
different because the intervals around the means do not contain zero. T2 -  T l, T3 -  Tl, 
and T3 — T2 Treatment means are not statistically significant because the intervals 
around the means contain zero. This can also be visualized by the plot in Figure 6.4.
Table 6.4 -  Treatment -  Tukey HSD Test
Diff lwr Upr padj
1 -0 3.31707317 2.0123483 4.621798 0 . 0 0 0 0 0 0 0
2 -0 3.25609756 1.9513726 4.560822 0 . 0 0 0 0 0 0 0
3 -0 3.67073171 2.3660068 4.975457 0 . 0 0 0 0 0 0 0
2 -  1 -  0.06097561 -  1.3657005 1.243749 0.9993706
3 -1 0.35365854 -0.9510664 1.658383 0.8970326
3 -2 0.41463415 -  0.8900908 1.719359 0.8446731
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Figure 6.4: Intervals that contain zero indicates that the Treatments are not significant
and significant for those without zero.
Based on the result in Table 6.3, to improve the model coefficients, a repeated 
measure design is considered.
6.3.8 Repeated Measure Analysis of Variance for “Number of Spikes”
The source of variability in this repeated measure analysis is “Treatments” and 
“Neurons.” We are interested in the effect of Treatment and this treatment effect is 
nested within each of the Neurons. The error term is “Neurons/Treatment,” read as 
“Treatment within Neurons.”
6.3.9 Repeated Analysis of Variance -  Hypothesis Test
H0: we want to test the null hypothesis that the mean “Number of Spikes” by 
treatment are equal (Identical population)
Against the alternative hypothesis that
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Hi: Not all the mean “Number of Spikes” are equal (non-identical population)
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
From Table 6.5, we observe once “Neurons” variability is parceled out, we do 
have a significant “Treatment” main effect, (p-value -  4.28e-10) in the three degree 
freedom test.
Table 6.5 -  Repeated ANOVA
Error: Neurons
Df Sum Sq Mean Sq F value Pr(>F)
Residuals 1 204.7 204.7
Error: Subject: Treatment
Df Sum Sq Mean Sq
Treatment 3 376.2 125.4
Error: Within
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 478.1 159.38 16.68 4.28e-10
***
Residuals 320 3057.1 9.55
Signif. codes: 0 ‘***’ 0.001 ‘ * * 5 0  0 1 0.05 V 0.1 ‘ ’ 1
But we cannot ascertain which pairs of the treatment levels are significant from 
others. To account for this multiplicity of tests, we consider first the unadjusted p-values 
using the Pair-wise T-Test. We then adjust the p-values for the Bonferroni and Holm 
methods.
6.3.10 Pair-wise Comparisons using Paired T-Tests 
Hypothesis Test
^ 0  • M^spikes(trt0)=  ^ sp ik es(tr t1)=  f*spikes(trt2)=  M-spikes(trt3)
Against the alternative hypothesis that
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H i - M^pikes(trtj)=£M^pikes(trtj),
where i = 0 (Pre-Treatment), 1, 2 and j = 1, 2, 3.
Tables 6 .6 , 6.7, and 6 . 8  contain the p-values from the Pair-wise T-Test, and we 
see significant differences in all comparisons in our post-hoc tests when compared to 
Pre-Treatment. Consistently, T2- T l, T3- T l, and T3- T2 pairs are not significantly 
different at a = 0.05 for all adjustments.
Table 6 . 6  -  P-value adjustment method: None
Data: No spikes and Treatment
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 4.3e-15 —
Treatment 2 3.3e-12 0.87 —
Treatment 3 3.2e-ll 0.37 0.24
Table 6.7 -  P-value adjustment method: Bonferroni
Data: No spikes ant Treatment
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 2.6e-14 —
Treatment 2 2 .0 e-l 1 1 . 0 0 0 0 —
Treatment3 1.9e-10 1 1 . 0 0 0 0
Table 6 . 8  -  P-value adjustment method: Holm
Data: No spikes and Treatment
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 2.6e-14 — —
Treatment 2 1 .6 e - l l 0.87 -  ■
Treatment 3 1.3e-10 0.74 0.72
Next, we consider a non-parametric version of ANOVA (Kruskal-Wallis Test) 
and repeated measures (Friedman Test) for comparison to previous analysis.
6.3.11 Kruskal-Wallis Rank Sum Test
Data: No spikes by Treatment
Kruskal-Wallis chi-squared = 84.5982, df = 3, p-value < 2.2e—16
Since p-value < 2.2e-16 is less than 0.05, we observe a significant treatment 
effect, i.e. the mean “Number of Spikes” by Treatment differs. This result is in 
agreement with the parametric test displayed in Table 6.2.
6.3.12 Friedman Rank Sum Test
Data: “Number of Spikes,” Treatment and Neurons 
Friedman chi-squared = 79.035, df = 3, p-value < 2.2e-16
The formula reads “Number of Spikes” as a function of Treatment given 
“Neurons” and in this analysis “Neurons” is treated as a blocking variable. Since the p- 
value < 2.2e-16 is less than 0.05, the result indicates that the mean “Number of Spikes” 
differs significantly for Pre-Treatment and Treatments 1-3. This result is in agreement 
with the parametric test shown in Table 6.4.
142
6.3.13 Descriptive Analysis -  “Area under the Curve”
Figure 6.5 shows the histogram plots for the variable “Area under the Curve” by 
Pre-Treatment and Treatments 1, 2, and 3. We can infer from Figure 6.5 that the “Area 
under the Curve” for Pre-Treatment and Treatments 1, 2 and 3 each have a slightly 
skewed distribution.
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Figure 6.5: Histograms for “Area under the Curve” by Treatment, Pre-Treatment (upper 
left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
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6.3.14 Scatter Plots for “Area under the Curve” by Treatments
To determine if a relationship exists between the “Neurons” and “Area under the 
Curve,” a scatter diagram is explored to observe whether the data is scattered with a 
pattern. Figure 6 . 6  shows no correlation between the two variables observed, i.e the 
“effect (Treatment)” is not related to the “cause (Neurons)” in any way, but we see some 
outliers in Treatments 1, 2 and 3.
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Figure 6 .6 : Scatter Plots for “Area under the Curve” by Treatment, Pre-Treatment (upper 
left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
From the scatter plots above, we observe more activities in Treatment 1 with 
respect to the “Area under the Curve.”
144
6.3.15 Area Indices -  “Area under the Curve”
Table 6.9 is a representation for summarizing the Area indices. Pre-Treatment 
has the lowest total “Area under the Curve” (5634.174) and lowest mean (68.70944). 
Treatment 3 has the highest total “Area under the Curve” (212793.57) and highest mean 
(2595.043). The standard deviation and standard errors are listed. Based on the standard 
errors, 95% confidence intervals (Cl) also are listed. For the Treatment 1, the 95% Cl is 
187.5478to 2484.4609. This implies that if 100 similar samples were drawn, in 95 out of 
100 tests, the mean “Area under the Curve” would fall between 187.55 and 2484.46.
Table 6.9 -  Area indices
95%
confidence 
interval 
for mean
Total 
Area 
under the 
Curve
Mean 
Area 
under the 
Curve
Standard
deviation
Standard
error
Lower
bound
Upper
bound
Pre-
Treatment
5634.174 68.70944 146.8564 16.21757 36.44156 100.97732
Treatment
1
109552.36 1336.004 5226.812 577.2048 187.5478 2484.4609
Treatment
2
156141.98 1904.17 12566.56 1387.744 -  857.0053 4665.3462
Treatment
3
212793.57 2595.043 19944.65 2202.518 -  1787.276 6977.363
The box plots in Figure 6.7 show the “Area under the Curve” by Treatment 
groups. Pre-Treatment is from a population centered on 6 8  with standard deviation 147 
from a distribution with extremely short tails. Treatment 1 is from a population centered 
on 1336 with standard deviation 5227 and from a distribution with extremely short tails.
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Treatment 2 is from a population centered on 1904 with standard deviation 12567. 
Treatment 3 is from a population centered on 2595.04 with standard deviation 19944.65 
from a distribution skewed to the right with extremely short tails. We observe in Figure 
6.7, the “Area under the Curve” increases with glutamate stimulus of 250nM and 
750nM. We may hypothesize that the recovery time for the Neurons to baseline is slow, 
justifying why we observe less spiking activities in Treatment 2 in Figure 6.3.
Area under the curve by Treatment
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Treatments (Pre, 1,2,3)
Figure 6.7: Box plots for "Area under the Curve" by Treatments
The box plots in Figure 6.7 show an increase in the middle 50% of the data when 
Treatment 1, 2 and 3 are applied. Also we note possible outliers in Treatments 1, 2 and 
3. We will redo the plot later on after excluding the outliers for better interpretation of 
the box plot.
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6.3.16 Five Number Summaries (“Area under the Curve”)
The five number summaries from Table 6.10 display the dispersion of the data, 
highlighting the minimum and maximum “Area under the Curve.” The lower (Ql) and 
upper (Q3) quartiles of the data show the middle 50% for the “Area under the Curve.” 
We observe that Treatment 3 has the highest “Area under the Curve” (181000.00), the 
highest median “Area under the Curve” (280), the highest mean “Area under the Curve” 
(2595), and highest upper quartile “Area under the Curve” (393.60).While Pre- 
Treatment has the lowest mean, median, lower and upper inter quartile range. We 
expect the result from Pre-Treatment since the Neurons are resting at baseline with fewer 
activities. Also, we expect Treatment 3 with the 750nM stimulus to have the largest 
“Area under the Curve” because the cells have been stimulated twice with a high 
glutamate concentration from the baseline. Subsequent additions result in larger “Area 
under the Curve” because the cells are no longer na'ive to the glutamate stimulus.
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Table 6.10 -  Summary (“Area under the Curve”)
Min. 1st Qu. Median Mean 3rd Qu. Max.
11.92 63.78 292.00 1476.00 604.80 181000.00
Summarv (Area under the Curve, Treatment)
• Pre-Treatment
Min 1st Q. Median Mean 3rd Q. Max.
34.48 48.64 53.10 68.71 55.19 1381.00
• Treatment: 1
Min 1st Q. Median Mean 3rd Q. Max.
18.54 368.10 680.60 1336.00 927.40 47380.00
• Treatment: 2
Min 1st Q. Median Mean 3rd Q. Max.
11.92 283.80 411.30 1904.00 624.20 114200.00
• Treatment: 3
Min 1st Q. Median Mean 3rd Q. Max.
19.01 205.30 280.00 2595.00 393.60 181000.00
6.3.17 Model Assumptions 
Test for normality
Two-sample Kolmogorov-Smimov test 
Data: “Areas,” and Neurons 
D = 0.7378, p-value < 2.2e-16 
Alternative hypothesis: two-sided
Since the p-value (< 2.2e-16) is less than 0.05, we reject the null hypothesis and 
conclude that the data comes from a non-normal distribution.
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Test for homogeneity of variance
Bartlett test of homogeneity of variances 
Data: “Areas,” by Treatment
Bartlett's K-squared = 758.2207, df = 3, p-value < 2.2e-16
Also, since the p-value (< 2.2e-16) is less than 0.05, we conclude that the 
assumption of constant variance is not satisfied. We expect these assumptions not to be 
satisfied because we are dealing with a large set of biological data, but to account for this 
we consider both the parametric and non-parametric analyses for comparison.
To further investigate our findings from the descriptive analysis performed 
earlier, we seek to test the null hypothesis that all the mean “Area under the Curve” by 
treatment are equal and drawn from the same population, against the alternative 
hypothesis that not all the mean “Area under the Curve” are equal and drawn from a 
non-identical population.
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
The result from Table 6 .11 indicates that the glutamate effect is not significant in 
the three degrees freedom test among the three groups of Treatments, our degree of 
freedom, DF = 3 (p-value =0.587), i.e. they all come from identical populations.
Table 6.11 -  ANOVA
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 2.817e+08 93907871 0.644 0.587
Residuals 324 4.723e+10 145762103
Signif. codes: 0 ‘***’ 0.001 0.01 0.05 V 0.1 ‘ ’ 1
Based on the ANOVA result from Table 6.11, to improve model coefficients, a 
repeated measure design is considered.
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6.3.18 Repeated Measure Analysis of Variance for “Area under the Curve”
The source of variability in this repeated measure analysis is “Treatments” and 
“Neurons.” We are interested in the effect of Treatment and this treatment effect is 
nested within each of the Neurons. The error term is “Neurons/Treatment,” read as 
“Treatment within Neurons.”
6.3.19 Repeated Analysis of Variance -  Hypothesis Test
H0: we want to test the null hypothesis that the mean “Area under the Curve” by 
treatment are equal (Identical population)
Against the alternative hypothesis that
Hi: Not all the mean “Area under the Curve” are equal (non-identical population) 
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
From Table 6.12, we observe once “Neurons” variability is parceled out, we do 
not have a significant “Treatment” main effect, (p-value -  0.0828) in the three degree 
freedom test, i.e. the glutamate effect is not significant.
Table 6.12- Repeated ANOVA
Error: Neurons
Df Sum Sq Mean Sq F value Pr(>F)
Residuals 1 1.026e+09 1.026e+09
Error: Subject: Treatment
Df Sum Sq Mean Sq
Treatment 3 20143479 6714493
Error: Within
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 9.583e+08 319448574 2.246 0.0828
Residuals 320 4.550e+10 142201573
Signif. codes: 0 ‘***’ 0.001 <**> o oi «*» o.05 V 0.1 ‘ ’ 1
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Next, we consider a non-parametric version (Kruskal-Wallis and Friedman Test) 
of the one way ANOVA and repeated measures for comparison to previous analysis.
6.3.20 Kruskal-Wallis Rank Sum Test 
Data: “Areas,” by Treatment
Kruskal-Wallis chi-squared = 180.313, df = 3, p-value < 2.2e-16
Since p-value (< 2.2e-16) is less than 0.05, we observe a significant treatment 
effect, i.e. the mean “Area under the Curve” by Treatment differs. This result is not 
consistent with the parametric test in Table 6.11.
6.3.21 Friedman Rank Sum Test
Data: “Area under the Curve,” Treatment and Neurons 
Friedman chi-squared = 185.9707, df = 3, p-value < 2.2e-16
The formula reads “Area under the Curve” as a function of Treatment given 
“Neurons” and in this analysis “Neurons” is treated as a blocking variable. Because, p- 
value < 2.2e-16is less than 0.05, the result indicates that the mean “Area under the 
Curve” differs significantly for Pre-Treatment and Treatments 1-3. This result is not 
consistent with the parametric test displayed in Table 6.13.
6.3.22 Outliers Analysis
As noted in Figures 6 . 6  and 6.7, we explore the plots of Cook distance and 
standard residuals versus the fitted values in Figures 6 . 8  and 6.9 to check for outliers. 
From the plots we observe that data points 83, 165, and 247 are outliers, and they are 
deleted. After performing the same outlier analysis on the new data set, we observe that 
data points 1, 149, 230, 272, 110, 97, 8 6 , 256 and 152 are outliers, and they are deleted 
also. The outliers check analysis condition is satisfied in Figures 6.11 and 6.12. In
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summary, we delete 12 data points from a total of 328 observations in the original 
variable (“Area under the Curve”). The remaining 316 observations are used for the rest 
of the analyses in this section.
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Next, we re-plot the box plot in Figure 6.7 without the outliers and we observe a 
decreasing trend in the plot after the application of Treatment 1 in Figure 6.12. We 
observe an increase in the middle 50% of the data once the cells are stimulated with 
500nM, but the increase drops in Treatments 2 and 3.
A rea u n d er the cu rve  by T re a tm e n t
oo
Treatm ents (Pre, 1 , 2 , 3 )
Figure 6.12: Box plots for "Area under the Curve" by Treatments
Also, we display the Area indices excluding the outliers in Table 6.13. We 
observe a decrease in the mean “Area under the Curve” when we compare these indices 
to Table 6.9.
154
Table 6.13 -  Area indices without Outliers
95%
confidence 
interval 
for mean
Total Area 
under the 
Curve
Mean 
Area 
under the 
Curve
Standard
deviation
Standard
error
Lower
Bound
Upper
bound
Pre-
Treatment
4253.528383 52.5127 7.487172 0.831908 50.85715 54.16825
Treatment
1
47341.43427 614.8238 325.8088 37.12936 540.8743 688.7734
Treatment
2
36950.94825 461.8869 262.8798 29.39086 403.3858 520.3879
Treatment
3
26866.70857 340.0849 223.2957 25.12273 290.0694 390.1004
Next, we will re-analyze the data set without outliers to determine consistency in 
the previous analysis with outliers.
Table 6.14 — ANOVA without Outliers
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 13514969 4504990 80.94 <2e-16 ***
Residuals 313 17420506 55657
Signif. codes: 0 c***’ 0.001 ***’ 0.01 0.05 V 0.1 ‘ ’ 1
The result from Table 6.14 indicates that there is a statistically significant 
difference in the three degrees freedom test among the three groups of treatments, our 
degree of freedom, DF = 3 (p-value 2.94e-06), i.e. they all come from non-identical 
populations. This result is not consistent with ANOVA test in Table 6.11. To determine 
which pairs of treatment levels are significantly different from each other, we look at a
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Tukey HSD Pair-wise comparison test of all the treatment levels (TO — T1, TO — T2, TO -  
T3, T1 -  T2, T1 -  T3, T2 -  T3).
6.3.23 Test for Difference in Means 
Hypothesis Test
Hq: HArea(trt0)=^Area(trt1)=fAArea(trt2)=^Area(trt3)
Against the alternative hypothesis that
MArea(trti)*MArea(trtj)
where i = 0 (Pre-Treatment), 1, 2 and j = 1, 2, 3.
6.3.24 Tukey Multiple Comparisons of Means
95% family-wise confidence level 
Fit: aov(formula = Areas ~ Treatment)
Table 6.15 shows the 95% Pair-wise comparison between the Treatment means. 
Differences between Treatment means are significant at five percent level if the 
confidence interval around the estimation of the difference does not contain zero. From 
Table 6.15, all pair wise comparisons of the Treatment means are significantly different 
because the interval around each mean does not contain zero. This can also be visualized 
by the plot in Figure 6.13.
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Table 6.15 -  Treatment -  Tukey HSD Test
Diff Iwr Upr P ad.j
1 -0 562.3111 465.3262 659.29600 0 . 0 0 0 0 0 0 0
2 -0 409.3742 313.3261 505.42226 0 . 0 0 0 0 0 0 0©Iro 287.5722 191.2188 383.92568 0 . 0 0 0 0 0 0 0
2 -1 -  152.9370 -250.2168 -55.65713 0.0003591
3 -1 -  274.7389 -  372.3202 -177.15757 0 . 0 0 0 0 0 0 0
3 -2 -  121.8019 -218.4523 -25.15160 0.0068622
9
8
csl
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Figure 6.13: Intervals that contain zero indicates that the Treatments are not significant
and significant for those without zero.
Based on the result in Table 6.14, and to improve the model coefficients, a 
repeated measure design is considered for the data without outliers for comparison to the 
previous analysis.
95%  fam ily-w ise confidence level
-400 -200 200 4 0 00 6 0 0
Differences in m ean levels of Treatment
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6.3.25 Repeated Analysis Of Variance -  Hypothesis Test
The source of variability in this repeated measure analysis is “Treatments” and 
“Neurons.” We are interested in the effect of Treatment and this treatment effect is 
nested within each of the Neurons. The error term is “Neurons/Treatment,” read as 
“Treatment within Neurons.”
H0: we want to test the null hypothesis that the means of all “Area under the 
Curve” by treatment are equal (Identical population)
Against the alternative hypothesis that
Hi: Not all “Area under the Curve” means are equal (non-identical population)
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
We observe in Table 6.16, once “Neurons” variability is parceled out, we do 
have a significant “Treatment” main effect, (p-value -  6.09e-12) in the 3 degree freedom 
test. This result is not consistent with the analysis in Table 6.12.
Table 6.16 -  Repeated ANOVA without Outliers
• Error; Neurons
Df Sum Sq Mean Sq F value Pr(>F)
Residuals 1 10471 10471
• Error: Neurons:Treatment
Df Sum Sq Mean Sq
| Treatment 3 11409309 3803103
• Error: Within
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 3190389 1063463 20.13 6.09e-12
***
Residuals 309 16325305 52833
Signif. codes: 0 1***’ 0.001 0.01 ‘ * 5 0.05 V 0.1 ‘ 5 1
Next, we consider a non-parametric version Kruskal-Wallis of the one way 
ANOVA and for comparison to previous analysis.
6.3.26 Kruskal-Wallis Rank Sum Test -  without Outliers
Data: “Areas,” by Treatment
Kruskal-Wallis chi-squared -  184.8564, df = 3, p-value < 2.2e-16
Since p-value (< 2.2e-16) is less than 0.05, we observe a significant treatment 
effect, i.e. the mean “Area under the Curve” by Treatment differs. This result 
corresponds with the analysis in Table 6.13.
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6.4 Results -  Cultures Not Treated With Ara-C 
6.4.1 Descriptive Analysis -  “Number of Spikes”
Figure 6.14 depicts the histogram plots for the variable “Number of Spikes” by 
Pre-Treatment and Treatments 1, 2, and 3. We can infer from the histogram plots that the 
“Number of Spikes” for Pre-Treatment and Treatments 1, 2 and 3 all have slightly 
skewed distributions. Also, we observe an increasing trend in the maximum “Number of 
Spikes” for each Treatment, and the majority of the “Neurons” spike between zero and 
two times.
H istogram  o f  Pre-treatm ent H istogram  o f  T reatm ent 1
8
8 -
_n D T~
4
I
10
Pre-treatment - Number of Spikes
2 6
n r
8
- 1 
10
Treatment 1 - Number of Spikes
H istogram  o f  T reatm ent 2 H istogram  o f  T reatm ent 3
8  -I 
§
8  H
~ r
4
I
10
T
2
n r
4
I
6
I
10
Treatment 2 - Number of Spikes Treatment 3 - Number of Spikes
Figure 6.14: Histograms for “Number of Spikes” by Treatment, Pre-Treatment (upper
left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
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6.4.2 Scatter Plots for “Number of Spikes” by Treatments
To establish if a relationship exists between the “Neurons” and “Number of 
Spikes,” a scatter diagram is explored to observe if the data is scattered with a pattern. 
Figure 6.15 shows no correlation between the two variables observed, i.e the “effect 
(Treatment)” is not related to the “cause (Neurons)” in any way. We observe more 
neurons resting at zero with respect to “Number of Spikes,” and we see some outliers in 
Treatment groups 1, 2 and 3 due to the extreme data points in the plot.
I
»
*5
S c a tte r  P lo t  for  P re- trea tm en t
O   r
S c a tte r  P lo t for  T r e a tm e n t 1
20 40 60
Neurons
1
■6
o
CO
CO
o  o
o o o  o  
<a> o  o z d  o
o
0 20 40 60 80
Neurons
S c a tte r  P lo t  for  T rea tm en t 2 S c a t te r  P lo t for  T r e a tm e n t 3
I
w
o
co
CO
CM C O C O  
OTO O O  O O  O  <Q>
O
o 20 40 60 80
$
a.w
t>
oT—
00
CO
CM > o  o  o  o  o  
o  o  <n> aoo o  o o
o
0 20 40 60 80
Neurons Neurons
Figure 6.15: Scatter Plots for “Number of Spikes” by Treatment, Pre-Treatment (upper
left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
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6.4.3 Spike Indices for culture without Ara-C
Table 6.17 shows a summary of the spike indices. Pre-Treatment has the lowest 
“Number of Spikes” (11) and the lowest mean spike (0.144737). Treatment 3 has the 
highest “Number of Spikes” (71) and the highest mean (0.934211). The standard 
deviation and standard errors are listed. Based on the standard errors, 95% confidence 
intervals (Cl) also are listed. For Treatment 3, the 95% Cl is 0.551230 to 1.317191. This 
implies that if 100 similar samples were drawn, in 95 out of 100 tests, the mean 
“Number of Spikes” would fall between 0.55 and 1.32.
Table 6.17 -  Spike indices for culture without Ara-C
95% 
Confidence 
interval 
for Mean
“Number
of
Spikes”
Mean
“Number
of
Spikes”
Standard
deviation
Standard
error
Lower
bound
Upper
bound
Pre
Treatment
1 1 0.144737 0.481773 0.0552632 0.034647 0.254827
Treatment
1
.59 0.776316 1.717352 0.196994 0.383884 1.168748
Treatment
2
35 0.460526 1.136554 0.130372 0.200813 0.720240
Treatment
3
71 0.934211 1.675991 0.192249 0.551230 1.317191
The box plots in Figure 6.16 show the “Number of Spikes” by Treatment groups. 
Treatments 1, 2 and 3 are each from a population centered on zero and a distribution 
skewed to the right. Pre-Treatment is from a population centered on zero with standard 
deviation 0.5 and from a distribution with an extremely short tail. We observe in the box
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plot, that we have less Neurons responding to the glutamate stimulus because of the 
changing ratio of glia to neurons, but we can see an increase with 500nM glutamate 
concentration in Treatment 1 and a decrease when 250nM is applied in Treatment 2 and 
another increase with the addition of 750nM.
Number of Spikes by Treatment
00
o
Treatments (Pre,1,2,3)
Figure 6.16: Box plots for “Number of Spikes” by Treatments
Assessing the spread of the data, we observe a slightly nonlinear increasing trend 
in Treatment 1, but the trend drops as Treatment 2 is applied. Outliers can be seen in all 
the treatment groups.
6.4.4 Five Number Summaries (“Number of Spikes”)
The five number summaries from Table 6.18 display the dispersion of the data, 
highlighting the minimum and maximum “Number of Spikes.” The lower (Ql) and 
upper (Q3) quartiles of the data show the middle 50% for the “Number of Spikes.” We
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observe that Treatment 1 has the highest “Number of Spikes” (10). Treatment 3 has the 
highest mean “Number of Spikes” (0.9342), and both Treatments 1 and 3 have the 
highest upper quartile “Number of Spikes” (1.00). All four Treatment groups have the 
minimum “Number of Spikes,” first quartile, median and third quartile equal zero. Also, 
we see an increase in the mean “Number of Spikes” once Treatment 1 is applied, but the 
increase drops as Treatment 2 is applied. We observe an increase again when Treatment 
3 is applied.
Table 6.18 — Summary (“Number of Spikes”)
Min. 1st Qu. Median Mean 3rd Qu. Max.
0 . 0 0 0 0 . 0 0 0 0 . 0 0 0 0.5789 1 . 0 0 0 1 0 . 0 0 0
Summary (“Number of Spikes,” Treatment)
• Pre-Treatment
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0 0 0 . 0 0 0 0 0 . 0 0 0 0 0.1447 0 . 0 0 0 0 2 . 0 0 0 0
• Treatment: 1
Min 1st Q. Median Mean 3rd Q. Max.
0.000 0 . 0 0 0 0 . 0 0 0 0 0.7763 1 . 0 0 0 1 0 . 0 0 0
• Treatment: 2
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0  0 . 0 0 0 0 . 0 0 0 0.4605 0.250 8 . 0 0 0 0
• Treatment: 3
Min 1st Q. Median Mean 3rd Q. Max.
0 . 0 0 0  0 . 0 0 0 0 . 0 0 0 0.9342 1 . 0 0 0 9.0000
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6.4.5 Model Assumptions 
Test for normality
Two-sample Kolmogorov-Smimov test 
Data: No spikes and Neuros 
D = 0.9243, p-value < 2.2e-16 
Alternative hypothesis: two-sided
Since the p-value (< 2.2e-16) is less than 0.05, we reject the null hypothesis and 
conclude that the data comes from a non-normal distribution.
Test for homogeneity of variance 
Bartlett test of homogeneity of variances 
Data: No spikes by Treatment
Bartlett's K-squared = 110.8856, df = 3, p-value < 2.2e-16
Since the p-value (< 2.2e-16) is less than 0.05, we conclude that the assumption 
of constant variance is not satisfied.
To further investigate our findings from the descriptive analysis performed 
earlier, we seek to test the null hypothesis that all the mean “Number of Spikes” by 
treatment is equal and drawn from the same population, against the alternative 
hypothesis that not all the mean “Number of Spikes” is equal and drawn from a non­
identical population.
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
The result from Table 6.19 indicates that there is a statistically significant 
difference in the three degrees freedom test among the three groups of Treatments, our
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degree of freedom, DF = 3 (p-value 0.00182), i.e. they all come from non-identical 
populations.
Table 6.19-ANOVA
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 27.9 9.316 5.117 0.00182 **
Residuals 300 546.2 1.821
Signif. codes: 0 ‘***’ 0.001 0.01 0.05 V 0.1 4 ’ 1
To determine which pairs of treatment levels are significantly different from each 
other, we look at a Tukey HSD Pair-wise comparison test of all the treatment levels (TO 
-  Tl, TO -  T2, TO -  T3, T1 -  T2, Tl -  T3, T2 -  T3).
6.4.6 Test for Difference in Means 
Hypothesis Test
H o : M-spikes(trt0)=  M^spikes(trt1)=  M^spikes(trt2)=  ^ sp ik es(tr t3)
Against the alternative hypothesis that
M ^pikes(trtj)*M ^pikes(trtj),
where i = 0 (Pre-Treatment), 1, 2 and j = 1, 2, 3.
6.4.7 Tukey Multiple Comparisons of Means
Table 6.20 shows the 95% Pair-wise comparison between the Treatment means. 
Differences between Treatment means are significant at five percent level if the 
confidence interval around the estimation of the difference does not contain zero. From 
Table 6.20, we see Tl -  TO and T3 -  TO Treatment means are significantly different 
because the intervals around the means do not contain zero. T2 -  TO, T2 -  T l, T3 -  Tl,
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and T3 -  T2 Treatment means are not statistically significant because the interval around 
each mean contains zero. This can also be visualized by the plot in Figure 6.18.
Table 6.20 -  Treatment -  Tukey HSD Test
Diff lwr d r® n padj
1 -0 0.6315789 0.06610427 1.1970536 0.0216916
2 -0 0.3157895 -0.24968521 0.8812642 0.4737118
3 -0 0.7894737 0.22399900 1.3549484 0.0020473
2 -1 -0.3157895 -0.88126416 0.2496852 0.4737118
3 -1 0.1578947 -  0.40757994 0.7233694 0.8885322
3 -2 0.4736842 -0.09179047 1.0391589 0.1357374
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Figure 6.17: Intervals that contain zero indicates that the Treatments are not significant
and significant for those without zero.
Based on the result from Table 6.19, and to improve the model coefficients, a 
repeated measure design is considered.
6.4.8 Repeated Measure Analysis of Variance for “Number of Spikes”
The source of variability in this repeated measure analysis is “Treatments” and 
“Neurons.” We are interested in the effect of Treatment and this treatment effect is
95% family-wise confidence level
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nested within each of the Neurons. The Error term is “Neurons/Treatment,” read as 
“Treatment within Neurons.”
6.4.9 Repeated Analysis of Variance -  Hypothesis Test
H0: we want to test the null hypothesis that the mean “Number of Spikes” by 
treatment are equal (Identical population)
Against the alternative hypothesis that
Hi: Not all the mean “Number of Spikes” are equal (non-identical population)
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
From Table 6.21, we observe once “Neurons” variability is parceled out, we do 
have a significant “Treatment” main effect, (p-value -  9.75e-05) in the three degree 
freedom test.
Table 6.21 -  Repeated ANOVA
Error: Neurons
Df Sum Sq Mean Sq F value Pr(>F)
Residuals 1 40.3 40.3
Error: Subject: Treatment
Df Sum Sq Mean Sq
Treatment 3 15.21 5.07
Error: Within
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 35.7 11.908 '"T  A A A/.zyy 9.75e-05
***
Residuals 296 482.9 1.631
Signif. codes: 0  ***♦’ 0 . 0 0 1 0  0 1 0.05 V 0.1 ‘ ’ 1
But we cannot ascertain which pairs of the treatment levels are significant from 
others. To account for this multiplicity of tests, we consider first the unadjusted p-values
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using the Pair-wise T-Test. We then adjust the p-values for the Bonferroni and Holm 
methods.
6.4.10 Pair-wise Comparisons using Paired T-Tests 
Hypothesis Test
H o • [4spikes(trt0)=  M^spikes(trt!)= M^spikes(trt2)=  H sp ik es(trt3)
Against the alternative hypothesis that
H i:  M^spikes(trtj)^M^spikes(trtj),
where i -  0 (Pre-Treatment), 1, 2 and j = 1, 2, 3.
Tables 6.22, 6.23, and 6.24 contain the p-values from the Pair-wise T-Test, and 
we see significant differences in all comparisons in our post-hoc tests, except in 
Treatment groups 2 and 3 when compared to Treatment 1. All adjustments result in 
increased p-values.
Table 6.22 -  P-value Adjustment Method: None
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 0.00057
Treatment 2 0.00455 0 . 1 0 1 2 1 —
Treatment 3 5.2e-05 0.48007 0 . 0 0 1 2 1
Table 6.23 -  P-value adjustment method: Bonferroni 
Data: No spikes and Treatment______________________
Pre-Treatment Treatment 1 Treatment 2
Treatment 1 0.00344 —
Treatment 2 0.02730 0.60724
Treatment 3 0.00031 1 . 0 0 0 0 0 0.00725
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Table 6.24 -  P-value adjustment method: Holm 
Data: No spikes and Treatment____________________
Pre-Treatment Treatment 1 Treatment 2
| Treatment 1 0.00287 —
Treatment 2 0.01365 0.20241
Treatment 3 0.00031 0.48007 0.00484
Next, we consider a non-parametric version of ANOVA (Kruskal-Wallis Test) 
and repeated measures (Friedman Test) for comparison to previous analysis.
6.4.11 Kruskal-Wallis Rank Sum Test 
Data: No spikes by Treatment
Kruskal-Wallis chi-squared = 20.7939, df = 3, p-value = 0.0001162
Since p-value (0.0001162) is less than 0.05, we observe a significant treatment 
effect, i.e. the mean “Number of Spikes” by Treatment differs. This result is in 
agreement with the parametric test performed in Table 6.19.
6.4.12 Friedman Rank Sum Test
Data: “Number of Spikes,” Treatment and Neurons 
Friedman chi-squared = 32.2355, df = 3, p-value = 4.668e-07
The formula reads “Number of Spikes” as a function of Treatment given 
“Neurons” and in this analysis “Neurons” is treated as a blocking variable. Since the p- 
value (4.668e-07) is less than 0.05, the result indicates that the mean “Number of 
Spikes” differs significantly for Pre-Treatment and Treatments 1-3. This result is in 
agreement with the parametric test performed in Table 6.21.
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6.4.13 Descriptive Analysis -  “Area under the Curve”
Figure 6.18 shows the histogram plots for the variable “Area under the Curve” by 
Pre-Treatment and Treatments 1, 2, and 3. We can infer from Figure 6.18 that the “Area 
under the Curve” for Pre-Treatment and Treatments 1, 2 and 3 each have a slightly 
skewed distribution.
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Figure 6.18: Histograms for “Area under the Curve” by Treatment, Pre-Treatment (upper
left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower right)
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6.4.14 Scatter “Area under the Curve” by Treatments
To determine if a relationship exists between the “Neurons” and “Area under the 
Curve,” a scatter diagram is explored to examine whether the data is scattered with a 
pattern. Figure 6.19 shows no correlation between the two variables observed, i.e the 
“effect (Treatment)” is not related to the “cause (Neurons)” in any way, but we see some 
outliers in Treatment groups 1, 2 and 3.
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Figure 6.19: Scatter Plots for “Area under the Curve” by Treatment, Pre-Treatment
(upper left), Treatment 1 (upper right), Treatment 2 (lower left), and Treatment 3 (lower
right)
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6.4.15 Area indices for culture without Ara-C
Table 6.25 shows a summary of the spike indices. Pre-Treatment has the lowest 
total “Area under the Curve” (5297.734) and lowest mean (69.70703). Treatment 3 has 
the highest total “Area under the Curve” (195393.93) and highest mean (2570.973). The 
standard deviation and standard errors are listed. Based on the standard errors, 95% 
confidence intervals (Cl) also are listed. For the Pre-Treatment, the 95% Cl is 
34.81413to 104.59993. This implies that if 100 similar samples were drawn, in 95 out of 
100 tests, the mean “Area under the Curve” would fall between 34.81 and 104.60.
Table 6.25 — Area indices for culture without Ara-C
95%
confidence 
interval 
for mean
Total 
Area 
under the 
Curve
Mean 
Area 
under the 
Curve
Standard
deviation
Standard
error
Lower
bound
Upper
bound
Pre-
Treatment
5297.734 69.70703 152.6976 17.51562 34.81413 104.59993
Treatment
1
68919.08 906.83 5413.957 621.0235 -330.3122 2143.9722
Treatment
2
129325.32 1701.649 13091.18 1501.661 -1289.814 4693.112
Treatment
3
195393.93 2570.973 20762.24 2381.592 -2173.402 7315.347
The box plots in Figure 6.20 show the “Area under the Curve” by Treatment 
groups. Pre-Treatment is from a population centered on 70 with standard deviation 153 
from a distribution with extremely short tails. Treatment 1 is from a population centered 
on 907 with standard deviation 5414 and from a distribution skewed to the right.
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Treatment 2 is from a population centered on 1702 with standard deviation 13091 from a 
distribution skewed to the right. Treatment 3 is from a population centered on 2571 with 
standard deviation 20762 from a distribution skewed to the right. We observe an 
increase with respect to the “Area under the Curve” once the Neurons are stimulated 
with 500nM glutamate concentration, suggesting a slower recovery to baseline, but 
subsequent addition of 250 and 750 nM also increases the “Area under the Curve.”
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Figure 6.20: Box plots for "Area under the Curve" by Treatments
The box plots in Figure 6.20 demonstrate that the middle 50% of the data exhibit 
a non-linear increasing trend. We observe an increase once Treatment 1 is applied. Also, 
we note possible outliers in Treatment groups 1, 2 and 3. We will redo the plot above 
without the outliers, for better interpretation.
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6.4.16 Five Number Summaries (“Area under the Curve”)
The five number summaries from Table 6.26 display the dispersion of the data, 
highlighting the minimum and maximum “Area under the Curve.” The lower (Ql) and 
upper (Q3) quartiles of the data show the middle 50% for the “Area under the Curve.” 
We observed that Treatment 3 has the highest “Area under the Curve” (181200.00) and 
the highest mean “Area under the Curve” (2571.00), Treatment 1 has the highest median 
“Area under the Curve” (215.9) and the highest upper quartile “Area under the Curve” 
(250.9).While Pre-Treatment has the lowest mean, lowest median, lowest lower and 
upper inter quartile range, as well at the lowest minimum “Area under the Curve.”
Table 6.26 -  Summary (“Area under the Curve”)
Min. 1st Qu. Median Mean 3rd Qu. Max.
8 . 0 2  61.12 156.30 1312.00 213.40 181200.00
Summarv (“Area under the Curve*” Treatment)
• Pre-Treatment
Min Is* Q. Median Mean 3rd Q. Max.
42.29 49.83 51.87 69.71 54.12 1383.00
• Treatment: 1
Min 1st Q. Median Mean 3rd Q. Max.
41.1 195.9 215.9 906.8 250.9 47450.0
« Treatment: 2
Min 1st Q. Median Mean 3rd Q. Max.
41.42 150.70 170.90 1702.00 213.10 114300.00
• Treatment: 3
Min 1st Q. Median Mean 3rd Q. Max.
8.02 98.22 136.80 2571.00 207.10 181200.00
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6.4.17 Model Assumptions 
Test for normality
Two-sample Kolmogorov-Smimov test 
Data: “Areas,” and Neurons 
D = 0.7336, p-value < 2.2e-16 
Alternative hypothesis: two-sided
Since the p-value (< 2.2e-16) is less than 0.05, we reject the null hypothesis and 
conclude that the data comes from a non-normal distribution.
Test for homogeneity of variance 
Bartlett test of homogeneity of variances 
Data: “Areas,” by Treatment
Bartlett's K-squared = 702.5589, df = 3, p-value < 2.2e-16
Also, since the p-value (< 2.2e-16) is less than 0.05, we conclude that the 
assumption of constant variance is not satisfied.
To further investigate our findings from the descriptive analysis, we seek to test 
the null hypothesis that all the mean “Area under the Curve” by treatment are equal and 
drawn from the same population, against the alternative hypothesis that not all the mean 
“Area under the Curve” are equal and drawn from a non-identical population.
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
The result from Table 6.27 indicates that the Treatment effect is not significant 
given the three degrees freedom test among the three group of treatment, our degree of 
freedom, DF = 3 (p-value =0.647), i.e. they all come from identical populations.
176
Table 6.27 -  ANOVA
Df Sum Sq Mean Sq F value Pr(>F)
| Treatment 3 2.618e+08 87255424 0.552 0.647
Residuals 300 4.738e+10 157945923
Signif. codes: 0 **♦*’ 0.001 0.01 **’ 0.05 V 0.1 ‘ ’ 1
Based on the ANOVA test in Table 6.27, and to improve model coefficients, a repeated 
measure design is explored.
6.4.18 Repeated Analysis Of Variance -  Hypothesis Test
The source of variability in this repeated measure analysis is “Treatments” and 
“Neurons.” We are interested in the effect of Treatment and this treatment effect is 
nested within each of the Neurons. The error term is “Neurons/Treatment,” read as 
“Treatment within Neurons.”
H0: we want to test the null hypothesis that the means of all “Area under the 
Curve” by treatment are equal (Identical population)
Against the alternative hypothesis that
Hj: Not all “Area under the Curve” means are equal (non-identical population)
Decision: Reject the null hypothesis if p-value < a; where a=0.05.
We observed in Table 6.28, once “Neurons” variability is parceled out, we do not 
have a significant “Treatment” main effect, (p-value -  0.0974) in the three degree 
freedom test. This implies that the glutamate effect is not significant on the Neurons.
Next, we consider a non-parametric version (Kruskal-Wallis and Friedman Test) 
of the one way ANOVA and repeated measures for comparison to previous analysis.
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Table 6.28 -  Repeated ANOVA
Error: Neurons
Df Sum Sq Mean Sq F value Pr(>F)
Residuals 1 1.186e+09 1.186e+09
Error: Neurons:Treatment
Df Sum Sq Mean Sq
Treatment 3 1425499 475166
Error: Within
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 9.785e+08 326172324 2.123 0.0974
Residuals 296 4.548e+10 153647838
Signif. codes: 0 ‘***’ 0.001 ‘**1’ 0.01 0.05 V 0.1 ‘ ’ 1
6.4.19 Kruskal-Wallis Rank Sum Test
Data: “Areas,” by Treatment
Kruskal-Wallis chi-squared = 174.2728, df = 3, p-value < 2.2e-16
Since p-value < 2.2e-16is less than 0.05, we observe a significant treatment 
effect, i.e. the mean “Area under the Curve” by Treatment differs. This result does not 
correspond with the analysis in Table 6.27.
6.4.20 Friedman Rank Sum Test 
Data: “Areas,” Treatment and Neurons
Friedman chi-squared = 188.2421, df = 3, p-value < 2.2e-16
The formula reads “Areas” as a function of Treatment given “Neurons” and in 
this analysis “Neurons” is treated as a blocking variable. Also, since the p-value (< 2.2e- 
16) is less than 0.05, the result indicates that the mean “Area under the Curve” differs
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significantly for Pre-Treatment and Treatments 1-3. This result does not correspond to 
the parametric test shown in Table 6.28.
6.4.21 Outliers Analysis
As noted in Figures 6.19 and 6.20, with respect to the outliers in the plots, we 
explore the plots of Cook distance and standard residuals versus the fitted in Figures
6.21 and 6.22, respectively, to check for outliers. From the plots we observe that data 
points corresponding to 77, 153 and 229 in Figure 6.21 are outliers, and they are deleted. 
We repeat the same outliers check analysis, and data point corresponding to 81, 95, 266 
and 267 are also deleted and the conditions are satisfied in Figures 6.23 and 6.24. We 
delete seven data points from a total of 304 observations in the original variable (“Area 
under the Curve”). We use the remaining 297 observations for the rest of the analyses in 
this section.
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Figure 6.21: Cook’s distance plot
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Figure 6.22: Standard residuals versus fitted
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Figure 6.23: Cook’s distance plot
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Next, we re-plot the box plot in Figure 6.20 without the outliers. From Figure 
6.25, we observe a decreasing trend in the plot after the application of Treatment 1. The 
middle 50% of the data drops in Treatments 2 and 3.
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Figure 6.25: Box plots for "Area under the Curve" by Treatments
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From Table 6.29, we observe a huge decrease in the Mean “Area under the 
Curve” in Treatments 1, 2 and 3 when compared to Table 6.25 with outliers.
Table 6.29 -  Randomized Area Indices without Outliers
95%
confiden
ce
interval 
for mean
Total Area 
under the 
Curve
Mean 
Area 
under the 
Curve
Standard
deviation
Standard
error
Lower
bound
Upper
bound
Pre-
Treatmen
t
3914.985766 52.19981 4.760606 0.5497075 51.10449 53.295
Treatmen 
1 1
19135.70586 262.133 149.8332 17.53665 227.1743 297.09
Treatmen 
1 2
15001.71994 200.0229 90.22181 10.41792 179.2648 220.78
Treatmen 
13
12312.56791 168.6653 111.6581 13.06859 142.6136 194.71
Next, we re-analyze the data without the outliers using one way ANOVA and the 
repeated measure design to see if Treatment effect is significant and to observe if model 
coefficients can be improved. The result is presented in Tables 6.30 and 6.32.
The result from Table 6.30 indicates that there is a statistically significant 
difference in the three degrees freedom test among the three groups of Treatments, our 
degree of freedom, DF = 3 (p-value <2e-16), i.e. they all come from non-identical 
populations.
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Table 6.30 -  ANOVA without Outliers
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 1728152 576051 53.95 <2 e - l 6  ***
Residuals 292 3118096 10678
Signif. codes: 0 ***♦’ 0.001 ***’ 0.01 0.05 V 0.1 ‘ ’ 1
To determine which pairs of treatment levels are significantly different from each 
other, we look at a Tukey HSD Pair-wise comparison test of all the treatment levels (TO 
-  Tl, TO -  T2, TO -  T3, T1 -  T2, T1 -  T3, T2 -  T3).
Table 6.31 shows the 95% Pair-wise comparison between the Treatment means. 
Differences between Treatment means are significant at five percent level if the 
confidence interval around the estimation of the difference does not contain zero and 
from the Table 6.31 Tl -  TO, T2 -  TO, T3 -  TO, T2 -  Tl and T3 -  Tl Treatment means 
are significantly different, because the intervals around the means do not contain zero. 
T3 -  T2 Treatment mean is not significant, because the intervals around their means 
contain zero. This can also be visualized by the plot in Figure 6.26.
Table 6.31 -  Treatment -  Tukey HSD Test
Diff lwr upr pad j
1 - 0 209.93315 166.03305 253.83324 0 . 0 0 0 0 0 0 0
2 - 0 147.82312 104.22066 191.42558 0 . 0 0 0 0 0 0 0o
1 116.46550 72.56541 160.36560 0 . 0 0 0 0 0 0 0
2 - 1 -62.11002 -106.01012 -  18.20993 0.0017217
3 -1 -  93.46764 -  137.66336 -49.27192 0.0000006
3 -2 -31.35762 -75.25771 12.54247 0.2541681
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Figure 6.26: Intervals that contain zero indicates that the Treatments are not significant
and significant for those without zero.
This result is not consistent with the ANOVA analysis in Table 6.27 (data set 
with outliers). Based on the ANOVA analysis in Table 6.30, and to improve model 
coefficient, a repeated measure design is considered.
6.4.22 Repeated Measure Analysis of Variance for “Area under the Curve”
The source of variability in this repeated measure analysis is “Treatments” and 
“Neurons.” We are interested in the effect of Treatment and this treatment effect is 
nested within each of the Neurons. The error term is “Neurons/Treatment,” read as 
“Treatment within Neurons.”
From Table 6.32, we observe once “Neurons” variability is parceled out, we have 
a significant “Treatment” main effect, (p-value <2e-l6) in the three degree freedom test. 
This result is not consistent with the analysis in Table 6.28, and we observe a reduced 
sum of square error (Treatment) in Table 6.32 when compared to Table 6.30.
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Table 6.32 -  Repeated ANOVA without outliers
Error: Neurons
Df Sum Sq Mean Sq F value Pr(>F)
Residuals 1 441628 441628
Error: Subject: Treatment
Df Sum Sq Mean Sq
Treatment 3 908875 302958
Error: Within
Df Sum Sq Mean Sq F value Pr(>F)
Treatment 3 972077 324026 36.98 <2e-16 ***
Residuals 288 2523668 8763
Signif. codes: 0 £***’ 0.001 ***’ 0.01 **’ 0.05 V 0.1 ‘ ’ 1
Next, we consider a non-parametric version of ANOV A (Kruskal- Wallis Test).
6.4.23 Kruskal-Wallis Rank Sum Test
Data: “Areas,” by Treatment
Kruskal-Wallis chi-squared = 181.4083, df = 3, p-value < 2.2e-16
Since p-value < 2.2e-16 is less than 0.05, we observe a significant treatment 
effect, i.e. the mean “Area under the Curve” by Treatment differs. This result is 
consistent with the parametric test performed in Table 6.28.
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6.5 Conclusions and Summaries/Comparison
Table 6.33 -  Variable: “Number of Spikes”
STATISTIC A 
L TESTS
SIMILARITIES (+Ara- 
C/-Ara-C)
DIFFERENCES
+Ara-C -Ara-C
Histogram
Plots
Both come from a slightly 
skewed distribution 
(Figures 6.1 and 6.14)
Much activity with 
4+ spikes. (Figure 
6 .1 )
Majority of the 
spikes are 
between 0  and 2  
(Figure 6.14)
Scatter Plots Neurons resting at 0 in 
Pre-Treatment. (Figures 
6 . 2  and 6.15)
Cells randomly 
scattered with 
respect to 
“Number of 
Spikes” except in 
TO (Figure 6.2)
Fewer spikes, 
cells resting at 0 . 
(Figure 6.15)
Spike Indices Maximum “Number of 
Spikes” and highest mean 
“Number of Spikes” 
observed in T3 for both 
cultures (Tables 6.1 and 
6.16)
More activity 
(Table 6.1)
Less activity 
(Table 6.16)
Box Plots Increasing trend in the 
median for TO and Tl, 
trend drops in T2 and 
increases in T3. Minimum 
“Number of Spikes” for 
all the Treatment groups 
equal 0, outliers in TO and 
Tl for both cultures 
(Figures 6.3 and 6.16)
Tl, T2 and T3 
from population 
with long tail. 
(Figure 6.3)
TO from a 
population with 
short tail. 
Outliers in T2 
and T3 (Figure 
6.16).
ANOVA Both analyses shows 
significant treatment 
effects (Tables 6.3 and 
6.19)
Sum of square 
error for Treatment 
is 725 (Table 6.3)
Sum of square 
error for 
Treatment is 
27.9 (Table 6.19)
Tukey HSD T2 -  T l, T3 -  Tl, T3 -  T2 
pairs were not significant, 
while Tl -  TO and T3- TO 
pairs significant for both 
cultures (Figures 6.4 and 
6.17)
Test reveals 3 
pairs as significant 
Tl -  TO, T2 -  TO 
and T3 -  TO 
(Figure 6.4)
Test reveals 2 
pairs as
significant T I ­
TO and T3 -  TO 
(Figure 6.17)
Repeated
ANOVA
Both analyses reveal 
significant treatment 
effect (Tables 6.5 and 
6 .2 1 )
Sum of square 
error Treatment is 
478.1 (Table 6.5)
Sum of square 
error Treatment 
is 35.7 (Table 
6 .2 1 )
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Table 6.33 continued.
Pair-wise T Consistently T1-T0, T2- 
TO, T3-T0 significant 
while T2-T1 and T3-T1 
pairs are not significant. 
(Tables 6 .6 , 6.22, 6.23 
and 6.24)
T3-T2 is not 
significant (Table 
6 .6 )
T3-T2 is 
significant 
(Tables 6.22, 6.23 
and 6.24)
Kruskal-Wallis Test reveals significant 
treatment effect
Kruskal-Wallis chi- 
squared is 84.5982
Kruskal-Wallis 
chi-squared is 
20.7939
Friedman Rank Test reveals significant 
treatment effect
Friedman chi- 
squared is 79.035
Friedman chi- 
squared is 
32.2355
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Table 6.34 -  Variable: “Area under the Curve”
STATISTICAL
TESTS
SIMILARITIES
(+Ara-C/-Ara-C)
DIFFERENCES 
+Ara-C -Ara-C
Histogram Plots Both plots slightly 
skewed to the right 
(Figures 6.5 and 6.18)
Wider Area under 
the Curve observed 
(Figure 6.5)
Smaller area 
under the Curve 
observed (Figure 
6.18)
Scatter Plots Both have neurons 
resting at 0 in TO, 
outliers in both plots, 
more activity in Tl for 
both cultures (Figures 
6 . 6  and 6.19)
Less activity in TO, 
T2 and T3 (Figure 
6 .6 )
More activity in 
Tl and T3 
(Figure 6.19)
Area Indices Pre-Treatment has the 
lowest mean, lowest 
total Area under the 
Curve, Tl has the 
maximum total Area 
under the Curve, and 
highest mean Area 
under the Curve for both 
cultures (Tables 6.9 and 
6.25)
N/A N/A
Box Plots We observe a nonlinear 
increasing trend in TO 
and Tl for both cultures 
and both plots have 
outliers in T2 and T3 
(Figures 6.7 and 6.20)
Trend drops as T2 
and T3 applied 
(Figure 6.7)
Trend drops as T2 
was applied and 
increased as T3 
applied (Figure 
6 .2 0 )
ANOVA Both analyses show 
Non- significant 
treatment effects (Tables 
6.11 and 6.27)
Treatment not 
Significant (Table 
6 .1 1 )
Treatment not 
Significant, 
(Table 6.27)
Tukey HSD N/A N/A N/A
Repeated
ANOVA
Treatment effect is not 
significant in both 
analyses (Tables 6 . 1 2  
and 6.28)
Sum of square error 
Treatment is 
9.583e+08 (Table 
6 .1 2 )
Sum of square 
error Treatment is 
9.785e+08 (Table 
6.28)
Pair-wise T N/A N/A N/A
Kruskal-Wallis Test reveals significant 
treatment effect
Kruskal-Wallis chi- 
squared is 180.313
Kruskal-Wallis 
chi-squared is 
174.2728
Friedman Rank Test reveals significant 
treatment effect
Friedman chi- 
squared is 185.9707
Friedman chi- 
squared is 
188.2421
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6.6 Conclusion on Outliers
One way ANOVA for the variable “Area under the Curve” without outliers 
shows a significant treatment effect for both cultures treated or not treated with Ara-C, 
(Tables 6.14 and 6.30). This result is not consistent with the analysis with outliers in 
Tables 6.11 and 6.27. The corresponding Tukey HSD test reveals ALL pairs as 
significant for culture with Ara-C excluding outliers, but five pairs as significant for 
culture without Ara-C once the outliers are deleted (Figures 6.13 and 6.26). Box plots for 
the variable “Area under the Curve” for both cultures, shows an increasing trend with 
outliers and a decreasing trend without outliers (Figures 6.7, 6.12, 6.20 and 6.25). 
However, the repeated ANOVA with outliers for both cultures is not significantly 
different with respect to Treatment effects (Tables 6.12 and 6.27). This result is not 
consistent to the analyses shown in Tables 6.15 and 6.30, excluding the outliers where 
we observe significant treatment effect. Finally both non-parametric tests for both 
cultures under this analysis are significant.
¥CHAPTER 7 
Conclusion and Future Directions
In this work, we have sought to mathematically represent a least squares model 
that best describes the fluctuations in calcium fluorescence intensity and statistically 
represent the “Number of Spikes” and the “Area under the Oscillatory Curve,” to predict 
brain cell network behavior to glutamate response. From the algebraic least squares fit, 
we observe that the seventh degree polynomial was effective in following the fluctuation 
in the data. The confidence interval plot revealed the bound with the biggest and smallest 
sizes to be Treatment 3 and Pre-Treatment, respectively. The smallest confidence bound 
showed that the cells are less active and behaving in a similar fashion due to Neuronal 
synchrony while the biggest confidence bound in Treatment 3 suggest that the cells are 
more active and behaving with greater variability. For all cultures depleted of glia, one 
way ANOVA showed significant treatment effect. For all cultures not depleted of glia, 
we observed some significant treatment effects, while others were not significant. We 
attribute these non-significant effects to the changing ratio of neurons to glia responding 
to the glutamate effect.
When glutamate addition pattern with unequal time step followed an ascending 
order i.e. 250-500-750nM, we observe that while each of the three successive stimuli
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continued to increase in glutamate concentration, unexpectedly, the most spiking activity 
was observed in Treatment 2, which was an intermediate 500nM glutamate 
concentration (Figure 4.3). We hypothesize that the highest concentration Treatment 3 
leads to fewer spikes due to synchrony of neuronal activity. This is supported by the 
“Area under the Curve” result, where indeed the highest glutamate concentration 
resulted in the largest calcium load (Figure 4.7).
For the randomized cultures, spiking activities followed a high -  low -  high 
pattern representing glutamate stimulus of 500-250-750nM (Figure 6.3).We 
hypothesize that if the Neurons are stimulated first with a higher concentration, we will 
observe more spiking activities and wider “Area under the Curve.” Subsequent lower or 
higher glutamate additions will result in lower or higher spiking activities, respectively. 
Furthermore, for the variable “Area under the Curve,” one way ANOVA with outliers 
for both cultures showed non-significant treatment effects and significant treatment 
effects without outliers. For both cultures depleted or not depleted of glia, excluding 
outliers, we may hypothesize, that the cell recovery to baseline after a double fold 
stimuli will be slow and subsequent stimuli will result in a faster recovery to baseline 
based on the plot from Figures 6.12 and 6.25. We conclude that the “Area under the 
Curve” is a best prediction of what the cell will do next. For example, a wider “Area 
under the Curve” suggests a longer recovery period for the Neurons and as such less 
spiking activities.
To further validate our findings with the randomized cultures, one future 
direction will involve more randomization orders of the glutamate stimulus presented in 
Table 7.1. Also, we will explore tracking the outlier regions of interest (ROIs) over time
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to determine their impact and exact calcium fluorescence intensity considered as outlier. 
Further, we will consider applying non-parametric Pair-wise Tests in our future analysis. 
Finally, since all the brain cells analyzed in this work are healthy cells, we will 
experiment with cancerous brain cells and analyze their behavior to glutamate stimulus.
Table 7.1 -  Future Direction on Randomized order sets.
Glutamate Stimulus Order (nM) Result
1 . 250- 500- 750 Analyzed
2 . 250- 750- 500 Future Direction
3. 500- 250- 750 Analyzed
4. 500- 750- 250 Future Direction
5. 750- 250- 500 Future Direction
6 . 750- 500- 250 Future Direction
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